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Guidance on the type of review and how to read this report 
 
Method 
This report presents an evidence and gap map derived from a systematic mapping review of existing systematic reviews. This systematic mapping review 
uses methods consistent with those used for systematic reviews for the identification and critical appraisal of systematic reviews relevant to the optimal 
prescribing of two groups of medications: 1) medications to prevent and treat cardiovascular disease and 2) drugs which may cause dependency and 
antidepressants. This systematic review evidence is then presented within an online, interactive, evidence and gap map, which is structured in a grid format 
where decision making points along the patient care pathway are presented for each medications of interest.  
The evidence and gap map summarises the quantity and quality of systematic review evidence which is available on the optimal prescribing of each type of 
medication of interest at each decision point on the patient care pathway. Systematic reviews are grouped together within each segment according to their 
quality. The reader can click on the segment of the map to view further information about the reviews which sit within each segment.  
Scope of the review 
This systematic mapping review was commissioned by the NIHR PRP Prpgramme following a request to the Department of Health and Social Care (DHSC) 
Research and Development Committee by NHS England NHS Improvement (NHSE-I) with a focus on optimising the prescribing of statins, antihypertensive 
medications, antidepressants, opioids, benzodiazepines, gabapentinoids and non-benzodiazepine hypnotics. As our definition of optimal prescribing 
encompassed both prescribing behaviour and behaviour related to taking medications, we were interested in the following types of quantitative and 
qualitative systematic review evidence: 
- The effectiveness or experiences of interventions intended to improve prescribing practices or patient adherence to prescribed regimens1;  
                                                          
1 We recognise that patient behaviour with regard to taking their medications as prescribed is the product of an initial decision making process between prescriber and 
patient, which is revised over time to consider factors such as effectiveness, side-effects and the extent to which medication taking can be incorporated into the patient’s 
- The effectiveness or experiences of interventions intended to improve implementation of interventions intended to improve prescribing practices 
or patient adherence;  
- Practitioner views or perceptions of making prescribing decisions;  
- Guidelines intended to inform prescribing practise. 
Due to the large quantity of existing evidence identified through our scoping work, this systematic mapping review focused on identifying and 
presenting systematic review evidence only, as the most reliable level of evidence. Any gaps within this systematic review evidence represent potential 
areas for further searches for primary evidence. Whilst the map presents a summary of the key characteristics of the available evidence, it does not 
provide an insight of the findings of each review beyond what is reported in the abstract for each review. It is beyond the scope of this document to 
bring together the reported findings of each of the reviews included in the evidence and gap map. 
Report structure 
This is a technical report structured to foreground the findings of the evidence and gap map. Thus, the reported is divided into three sections: 
1. Evidence summary: An executive summary providing an overview of the key findings. 
2. Part 1: This provides a background to the systematic mapping review, a brief methods section and a summary of the main findings of the evidence 
and gap map, grouped according to each of the research objectives and medications of interest. This section concludes with a discussion of the 
groups of evidence and gaps presented in the map, and the strengths and limitations of both the reviews included in the evidence and gap map and 
the systematic review processes used to identify this evidence. 
3. Part 2: In part two we provide the full methodological detail including the search strategy, inclusion criteria, data extraction and quality appraisal 
processes. This section also explains how the patient care pathway used as the basis for the evidence and gap map was developed and details the 
                                                          
daily routine. For convenience, we use the term “patient adherence” throughout this report to encapsulate this continual decision making process in which the patient can 
choose, and/or be enabled, to play an active role. 
input stakeholders, patients and members of the public had throughout the review process and how this influenced the final evidence and gap 
map. This section concludes with the appendices which contain further details of the search strategy, reviews excluded at full-text screening, 




What do we want to know? 
Evidence suggests the prescribing and taking of, or adherence to, certain types of medication is not at optimal levels. This review focuses on two areas of 
challenge. The first area of interest is under-prescribing and poor adherence to medications to prevent cardiovascular disease (CVD), specifically statins and 
antihypertensives. The second area of interest in this review concerns the over-prescribing of drugs that may cause dependency (DCD, which includes 
opioids, benzodiazepines, gabapentinoids and non-benzodiazepine hypnotics) and antidepressants. Scoping of the evidence base revealed an abundance of 
primary and secondary research across these two types of medication. We therefore aimed to identify, categorise and map the existing systematic review 
evidence, identifying both abundant and scarce areas of research.  
What did we find? 
Overview 
One hundred and thirty systematic reviews met the eligibility criteria for inclusion in the evidence-gap map. All reviews were first critically appraised using 
four criteria from the Collaboration for Environmental Evidence Synthesis Assessment Tool (CEESAT). Only the thirty-six reviews which scored positively on 
all four of these items were prioritised for full quality appraisal using the AMSTAR-2 tool. Fifteen of these reviews were of ‘High’ overall quality, 12 of 
‘Moderate’ overall quality, six of ‘Low’ overall quality and three of ‘Critically Low’ overall quality. Reviews with a negative score on one or more CEESAT item 
received a rating of ‘Critically Low’ overall quality. 
Summary of evidence and gaps 
The final evidence and gap map indicates areas where a significant body of systematic review research already exists. For example, with regard to the 
prescription of statins and antihypertensive medication, there are a number of reviews which synthesise qualitative evidence on patient and/or 
family/carer experience of adherence and/or taking this type of medication. There are also twelve reviews of predominantly ‘High’ and ‘Moderate’ overall 
quality which examine the effectiveness of interventions which aim to improve adherence to these two types of medication. These reviews were 
represented across the patient care-pathway for both types of medication, but particularly with regard to information and advice giving (n=8 statins, n=17 
antihypertensives), choosing a medication (n=8 statins, n=14 antihypertensives) and progress review (n=14 statins, 27 antihypertensives) although the 
reviews were predominantly of ‘Critically Low’ quality. 
Twenty-two systematic reviews synthesised evaluations of interventions to promote the deprescribing of medication which included DCD and 
antidepressants, although only six of these were of ‘High’ or ‘Moderate’ overall quality. Similarly, all DCD and antidepressant medications (aside from 
gabapentinoids) were included in at least one review focusing on evaluating interventions to optimise prescribing which was appraised using the AMSTAR-2 
tool, however the quality of this evidence was variable. 
Whilst there is a body of qualitative systematic review evidence which examines barriers and facilitators to the deprescribing of DCD and antidepressants, 
and of experiences of adhereing to/taking stain and antihypertensive medication, there were no systematic reviews which examined experiences or views 
of specific interventions to promote adherence or aid deprescribing. In addition, only two reviews of qualitative evidence scored positively on all four 
CEESAT criteria. The rest were deemed to be of ‘Critically Low’ overall quality.  
What are the implications? 
This evidence and gap map highlights the available quantitative and qualitative systematic review evidence to inform the optimal prescribing of DCD, 
antidepressants, statins and antihypertensive medication. The map summarises key characteristics of these systematic reviews and identifies areas where 
no, or low-quality systematic reviews have been conducted. These gaps highlight areas which may benefit from further searches to identify if any primary 
research exists, which could be combined within further evidence synthesis. Consultation with policy and commissioning stakeholders is required to confirm 
in which areas further evidence syntheses or primary research could best inform government policy. 
How did we get these results? 
Systematic reviews published since 2010 were sought from bibliographic databases, websites and author contact and included if they brought together 
quantitative and/or qualitive evidence on: 
- The effectiveness or experiences of interventions intended to improve prescribing practices or patient adherence;  
- The effectiveness or experiences of interventions intended to improve implementation of interventions intended to improve prescribing practices 
or patient adherence;  
- Practitioner views or perceptions of making prescribing decisions;  
- Guidelines intended to inform prescribing practise. 
Systematic reviews which met these criteria were organised within an evidence gap-map according to the medication of interest and the revelance to the 
patient care pathway. Key characteristics of each systematic review were extracted by two reviewers, with this information being used to filter the 
information displayed in the evidence and gap map.   
Part 1: Background, brief methods, findings and implications 
 
Background 
Guidance produced by the General Medical Council indicates that ‘prescribing’ is used to encompass several activities including not only the supply and 
prescription of ‘prescription only’ medications, devices and dressings, but also supporting activies such as the provision of information and advice to 
patients and negotiating an agreed treatment plan.1  The guidance recognises that optimal prescribing considers the wider system beyond the prescribing 
behaviour of an individual clinician, and requires knowledge of government laws, guidelines and policies and consideration of the individual views, 
experiences and needs of patients themselves. Thus, for the purposes of this report, we consider ‘optimal prescribing’ to encompass both the prescribing 
behaviour of the clinician and the taking of medications by the patient. 
The Exeter PRP Evidence Review Facility was commissioned by the NIHR PRP Programme following a request to the Department of Health and Social Care 
(DHSC) Research and Development Committee by NHS England and NHS Improvement (NHSE-I) to conduct a systematic review of evidence relating to the 
optimising of the prescribing of three different groups of medication: medications to treat cardiovascular disease (CVD), specifically statins and 
antihypertensives, and drugs that may lead to dependency ((DCD); including antidepressants, opioids, benzodiazepines, gabapentinoids and non-
benzodiazepine hypnotics). Issues relating to the prescribing for these two specific medication groups of interest are discussed separately below. 
Medications to prevent and treat cardiovascular disease 
The early detection of risk factors for CVD and initiation of preventative treatment is a key part of the NHS Long Term Plan.2 The prescribing of high 
intensity statins is recommended over the use of low intensity statins as an effective measure to prevent CVD.3  However evidence suggests that the 
prescribing of high-intensity statins, has not yet reached optimal levels, with one study indicating that over half of patients who had been prescribed statins 
for primary prevention of CVD had not achieved the required reduction in cholesterol levels.3 In addition, various patient factors can influence whether or 
not statin medication is taken as prescribed; with female gender, non-white race and low socio-economic status are being associated with non-adherence, 
although there are many other factors which may influence adherence.4, 5 
Hypertension is also linked with to an increased risk of CVD, including coronary disease, left ventricular hypertrophy and valvular heart diseases.6 
Antihypertensive medication can be used both alone and in combination with statins to reduce the occurrence of CVD.7  Whilst, the proportion of untreated 
hypertension in England has decreased between 2003 and 2018 for both men and women,8 there is some indication that awareness and treatment of 
hypertension within the whole of the UK may have decreased slightly over the last five years with trends in the prescription of antihypertensives within UK 
primary care currently under review.9, 10 Patient non-adherence to antihypertensives can also be high, with one study indicating that adherence decreases 
with the number of antihypertensive medications prescribed.11 To achieve optimal prescribing of statins and antihypertensive medication, it is essential that 
the factors influencing their prescription and patient adherence are are fully understood. 
Drugs that may cause dependency and antidepressants  
The medications of interest within these categories are used to treat mental and physical health conditions such as anxiety, insomnia, chronic pain and 
depression. Whilst it is recommended that these medications are prescribed for short-term use only, a recent review by Public Health England (PHE)(2019) 
indicates these medications are prescribed to 1 in 4 adults in the UK, with many patients taking them beyond the short periods for which they are 
licensed.12 This places individuals at increased risk of physical and/or psychological dependence, which can make it harder for them to stop taking the 
medicine. This has important long-term health implication for patients taking these over prolonged periods of time, including developing medication 
tolerance, and thus requiring increasing doses to maintain medication effects.13, 14 Patients may also experience unpleasant withdrawal symptoms or side-
effects which can negatively impact on their quality of life.14, 15 Prolonged prescribing of these types of medications can also have cost implications for the 
NHS. For example, in a situation likened to the USA opioid pandemic, opioid prescription within the UK has more than doubled between 1998 and 2018,16 
with 1.5 million people with muscuoskeletal pain being prescribed opioids, 45% of which are overprescribed – at a cost of £100 million per year.17 
The PHE (2019) review encouraged further research on the prevention and treatment of dependence on/withdrawal from these medications.12 It is 
essential to understand the factors which may influence the prescription, review and withdrawal of DCD from the perspective of both prescriber and 
patient to avoid an approach that may lead to blanket ‘deprescribing’ of these medications, which does not take into consideration the needs and 
circumstances of individual patients or the availability of alternative health/social care services.  
Existing evidence 
Scoping of the literature revealed an array of existing systematic reviews of qualitative and quantitative evidence relevant to achieving the optimal 
prescribing of DCD, antidepressants, statins and antihypertensives. Prior to conducting a further systematic review and synthesis of evidence to understand 
the factors that influence the prescription and/or taking of drugs to prevent CVD and DCD, there is a need to clarify the quantity, quality and type of 
systematic review evidence already available in this area. This can be achieved by the production of an evidence and gap map and will help identify research 
areas where a body of evidence on this topic already exist and gaps where further systematic reviews on more specific subject areas could be usefully 
undertaken. 
Aims and objectives of evidence and gap map 
To map the quantitative and qualitative systematic review evidence available to inform the optimal prescribing of statins, antihypertensives, 
antidepressants and DCD (benzodiazepines, opiates, non-benzodiazepine hypnotics, gabapentinoids) and the point at which this evidence could be used to 
inform decision making in the patient care pathway for each type of medication, thus identifying gaps in the review evidence.  
Specific research objectives were to map systematic reviews of quantitative and qualitative evidence published since 2010 regarding: 
- The effectiveness or experiences of interventions intended to improve prescribing practices or patient adherence;  
- The effectiveness or experiences of interventions intended to improve implementation of interventions intended to improve prescribing practices or 
patient adherence;  
- Practitioner views or perceptions of making prescribing decisions;  
- Guidelines intended to inform prescribing practise. 
  
Brief methods 
Our review protocol was prospectively registered on Open Science Framework and Open Respository Exeter.18  The methods used to create this evidence and 
gap map were consistent with the best practice approach for conduct of systematic reviews and development of evidence and gap maps.19, 20 Below, we 
summarise how we identified relevant systematic review evidence and developed the patient care pathways to use as the basis of our evidence and gap map. 
Full methods detail is provided in Part 2 of this report. 
Type of review  
We conducted a systematic mapping review, the product of which was an evidence and gap map. The early stages of a systematic mapping review are 
consistent with those of a traditional systematic review in that the methods used to identify relevant literature should be thorough, transparent and 
replicable.21 However, the research question of the systematic mapping review tends to be broader, and whilst some indication as to the quality of included 
studies is sometimes provided, a synthesis of their findings is not conducted. 22 Instead, a visual overview of the main characteristics of the included studies 
is mapped out; providing a summary of the type and quantity of evidence available with respect to the research question.22 The main stages in the 
development of the evidence and gap map are summarised below. 
Identification and selection of papers 
Potentially relevant studies were found through searching eight bibliographic databases with separate searches for medications related to CVD and DCD or 
antidepressants. Searches combined terms for optimising prescribing with terms for statins/antihypertensives and CVD or terms for relevant 
antidepressants and DCD. We also searched topically relevant websites and conducted backwards citation chasing for all reviews that met our inclusion 
criteria. Full details of our search strategy can be found in Appendix A: Search report.   
Inclusion criteria were applied to the title and abstract of each study independently by two reviewers (LS, MN), with disagreements resolved through 
discussion or referral to a third reviewer (SB) if requied. The full texts of each review were then screened in the same way. 
  
Data extraction and quality appraisal 
Table 1 illustrates data which were extracted from each included review. Data extraction was completed by one reviewer (LS, MN) and checked by a second 
(MN, LS), with consultation with a third reviewer to resolve any disagreements (SB). 
Table 1: Data extracted from included systematic reviews 
Data Description 
Focus/Aim of review The primary/secondary aims of each review which were 
relevant to the aims and objectives of the evidence and gap 
map 
Type of review For example, systematic, scoping, realist 
Type of studies included Did the review include quantitative or qualitative primary 
studies or a mixture of both? 
Synthesis methods The type of synthesis conducted in the systematic review e.g. 
narrative, meta-analysis, thematic 
Medication of interest The type of medication included in the review relevant to the 
aims/objectives of the evidence and gap map 
Medical condition for which 
medication of interest being taken 
Medical condition/s for which the medication/s of interest was 
prescribed 
Other medications included Indicates if other medications outside of the focus of the 
evidence and gap map were included in the individual review 
Eligible age of participants within 
studies included in the review 
Eligible age of participants as stated within review inclusion 
criteria 
Does review population inclusion 
criteria include any equity 
characteristics outlined by 
PROGRESS? 
PROGRESS Characteristics include: place of residence, 
race/ethnicity/culture/language, occupation, gender/sex, 
religion, education, socio-economic status, social capital 
Does review consider any 
PROGRESS characteristics within 
its synthesis strategy? 
See above 
Intervention name, aim and 
outcomes measured 
For quantitative studies evaluating the effectiveness of 
interventions aiming to improve adherence or deprescribing* 
Perspectives obtained in 
systematic reviews of qualitative 
studies 
The population whose perspectives were obtained within 
qualitative studies e.g. patient, family/carer, prescriber 





Within qualitative studies, what was the phenomenon about 
which views/experiences were being sought e.g. experiences 
of an intervention to enhance adherence 
Setting/context Where was primary research included in the review conducted 
e.g. primary care, hospital inpatient 
Relevance of systematic review to 
aim of evidence and gap map 
Each systematic review was awarded a score of ‘High’, 
‘Medium’ or ‘Low’ relevance, according to the degree the 
systematic review was consistent with the aims of the 
evidence and gap map. 
Reviews were judged to be of ‘High’ relevance if review 
focused on evaluating intervention/gathering experiences 
regarding medication of interest within health/social care 
services relevant to UK service setting, ‘Medium’ relevance: if 
review aim/inclusion criteria somewhat relevant to aim of 
systematic mapping review, but also includes other 
medications not of interest, or quantity of relevant information 
is limited, ‘Low’ relevance: if quantity of relevant information 
low and/or intervention being evaluated not relevant to UK 
health/social care setting 
Overall quality rating The overall quality rating as indicated by the AMSTAR-2. All of 
the studies appraised using just the 4 CEESAT items were given 
a ‘Critically low’ rating 
*These details were not included as a filter option within the evidence and gap map. 
In order to provide the map user with an indication of the methodological and reporting quality of the evidence, each of the included reviews was first 
appraised using four criteria from the Collaboration for Environmental Evidence Synthesis Assessment Tool (CEESAT)23, which we deemed likely to be 
indicative of fatal flaws in quality:  
1. Is approach to searching clearly defined, systematic and transparent? 
2. Is search comprehensive? 
3. Does the review critically appraise each study? 
4. During critical appraisal was an effort made to minimise subjectivity? 
A modified version of the AMSTAR-2 quality appraisal tool, which included additional items more suited to the appraisal of systematic reviews of qualitative 
evidence, was then applied to all the systematic reviews which scored positively on all four CEESAT criteria.24 According to AMSTAR-2, systematic reviews are 
categorised as being of ‘High’, ‘Moderate’, ‘Low’ or ‘Critically Low’ overall quality.   
Any flaws in the reporting and/or conduct of reviews identified with these four CEESAT criteria meant that reviews could not score higher than a rating of 
‘Critically Low’ with the AMSTAR-2 tool, thus they were awarded this quality rating accordingly. As with data extraction, critical appraisal was undertaken by 
one reviewer and checked by a second with disagreements resolved through discussion. 
Development of patient care pathways 
To inform the structure of our evidence and gap map to display the systematic review evidence identified through our systematic search strategy, we 
constructed a patient care pathway, encompassing from the decision to access care through to the decision to maintain or discontinue medication. This was 
with a view to identifying where clusters of systematic review evidence exist and the point at which this evidence could be used to inform decision making in 
the patient care pathway, for each type of medication. The process of developing the global patient care pathway used as the basis for our evidence and gap 
map is described below within Development of patient care pathways. Three patient care pathways were developed for 1) Statins and antihypertensives 2) 
DCD and 3) antidepressants. Initially, these care pathways were based on NICE guidance for prescribing of relevant medication of interest (statins, 
antihypertensives, antidepressants), as well as NICE guidelines for optimal prescribing and shared decision making. We also incorporated evidence from other 
publications and guidelines, particularly for DCD.12, 25-31. 
To capture how the patient experience may interact and influence these ‘best-practice’ care pathways, we included existing research which explored the 
patient experience of taking some of the medications of interest.31 We worked alongside clinical stakeholders and members of the public who had experience 
of taking and/or discontinuing one or more of the medications included in the evidence and gap map. The patient care pathways developed for each of the 
three types of medications of interests within this review can be seen below in Figures 1 to 3. 

Figure 1: Patient care pathway - Statins and antihypertensive medication 

Figure 2: Patient care pathway - Antidepressants 

Figure 3: Patient care pathway - Drugs which may cause dependency 
The decision points that were common across each of these three individual pathways were combined into one overall pathway. This pathway also included 
decision points which were unique to individual pathways. These decision points were revised iteratively throughout the data extraction process to ensure 
that the content of the included studies were accurately reflected in the patient pathway and to prevent unnecessary repetition of information. This overall 
pathway was used as the basis for the evidence and gap map (see Figure 4 below) 

Figure 4: Overall patient carepathway 
Presentation of the evidence: the evidence and gap map 
To identify evidence gaps, we mapped the existing systematic review evidence onto the patient care pathway shown in Figure 1, divided by each type of 
medication of interest.  
On opening the map all the included systematic reviews are displayed. Systematic reviews are grouped within different coloured bubbles according to their 
overall quality based on their AMSTAR-2 scores (navy blue=High, turquoise=Moderate, orange=Low, grey=Critically low). The size of the bubble indicates the 
number of systematic reviews available to inform that particular part of the care pathway. Systematic reviews which are relevant to more than one medication 
of interest, point on the patient care pathway or research objective, are represented in multiple places within the evidence and gap map.  
Clicking on each segment of the map lets you view more detail about each of the systematic reviews found at that part of the patient care pathway. You can 
read the title and abstract of each review contributing to that part of the map, and find a link from which you can access the full text. You can also group 
reviews within this window by “segment” i.e. overall study quality. 
When accessing the ‘Filters’ tab at the top of the evidence and gap map, you can select various options which will change the systematic review evidence 
displayed in the map. These filters are based upon the information highlighted in Table 1 above. Error! Reference source not found. illustrates the position 
of this tab within the evidence and gap map. 
 
Figure 5: Position of Filter heading within evidence and gap map 
One of these options is “Overall quality rating”. By changing the options selected here, you can change the quality of the evidence displayed in the map. For 
example, if you wished to only display high quality evidence, you would check the ‘High quality’ box and deselect the other options.  
The evidence shown within the evidence and gap map can also be filtered by other characteristics of the included reviews. These are listed in Error! 
Reference source not found., alongside a brief description. 
User involvement 
We worked alongside a group of stakeholders with a variety of expertise in the topic area throughout the production of this evidence and gap map. 
Stakeholders included representatives from NHSE-I, NICE, clinicians and people with experience of taking one or more of the medications of interest. Key 
stages at which stakeholders contributed during the project included: 
- Development of the protocol; 
- Developing thef bibliographic database search strategies and list of relevant topic websites to be searched; 
- Providing insight on list of Included studies and resolving queries regarding eligibility for inclusion; 
- Supporting the development of the patient care-pathway; 
- Providing feedback on the presentation of existing review evidence within the evidence and gap map; 
- Providing insight into the gaps in systematic review evidence within the evidence and gap map. 
  
Results 
In this section we present the results to our systematic mapping review. First we briefly describe the number of systematic reviews included in our evidence 
and gap map, alongside the PRISMA diagrams detailing how we identified this evidence. We then provide a link to the evidence and gap map, accompanied 
by a summary of the existing systematic review evidence and gaps idenfied.  
The Overview of reviews section then provides an overview of participant characteristics within the included reviews and a summary of the quality and focus 
of the systematic reviews. The final section summarises the key features of the systematic reviews according to the different categories of medications of 
interest; 1) statins and antihypertensives 2) DCD and antidepressants. Within each category, the review evidence is split according to the type of primary 
evidence included in the reviews and how this relates to the research objectives of this mapping review. This results in the following subheadings: guidelines, 
qualitative evidence, reviews evaluating interventions to promote deprescribing, reviews evaluating interventins to promote adherence and reviews 
evaluating interventions to optimise prescribing. This presentation of the content of the evidence and gap map is intended to support readers of this report 
to access the evidence most relevant to their needs. 
What is in the map? 
In total, 130 systematic reviews met the eligibility criteria for inclusion in the evidence and gap map. Figure 6 and Figure 7 below show the PRISMA diagrams 
detailing how these systematic reviews were identified. A total of 16 reviews included evidence that was relevant to both drugs that can cause dependency 
and statins or antihypertensives, hence the sum total number of included systematic reviews in Figure 3 and Figrue 4 is 146. For a list of number of reviews 
retrieved via each source and reasons for exclusion at full-text, please see Appendix B: List of excluded studies.List of excluded studies 
 
Figure 6: Drugs that can cause dependency and antidepressants PRISMA diagram 
 
 
Figure 7: Statins and antihypertensives PRISMA diagram 
Summary of evidence and gaps 
Please click here to view the evidence and gap map 
- There were 130 systematic reviews included in the evidence and gap map. Only 15 were rated as ‘High’ quality, and 12 of ‘Moderate’ quality, using 
the AMSTAR-2 appraisal tool. The rest were of ‘Low’ or ‘Critically Low’ quality.  
- Gabapentinoids were not reprepresented as a medication group. 
Systematic reviews conducting qualitative synthesis (n=18) 
- Whilst systematic reviews of qualitative evidence which explore barriers and enablers to deprescribing of hypnotics, opiates, antidepressants and 
benzodiazepines have been conducted, none of these focus on views or experiences of specific interventions to aid deprescribing. 
- We found little to no systematic review evidence which explores practitioner experiences of prescribing hypnotic medication or statins. 
- There is plenty of systematic review evidence which focuses on patient and/or family and carer experiences of adhering to or taking 
antihypertensives or statins.  
- Only two systematic reviews of qualitative evidence were of ‘Moderate’ or ‘High’ quality. 
Interventions to optimise prescribing (n=33) 
- All DCD and antidepressant medications were included in at least one review appraised using the modified AMSTAR-2 tool, aside from 
gabapentinoids.  
- There was a substantial body of evidence from ‘Low’ or ‘Critically Low’ systematic reviews, predominantly focused on opiate and antidepressant 
medication. 
- Three reviews appraised using the modified AMSTAR-2 tool focused on optimising prescribing of statins and/or antihypertensives, being of ‘Low’, 
‘Moderate’ and ‘High’ quality. Medications of interest in four other reviews included statins and/or antihypertensives alongside medications not of 
interest, but these reviews were not appraised using the AMSTAR-2 tool. 
- Eight reviews included a mix of medications of interest across DCD, antidepressants and/or medications to treat or prevent CVD. Only three of 
these were appraised using AMSTAR-2 and were of variable overall quality. 
Interventions to promote deprescribing (n=22) 
- Other medications of interest within the DCD and antidepressant category were included within six systematic reviews of ‘High’ or ‘Moderate’ 
overall quality. There were a further fourteen reviews which were of ‘Critically Low’ quality. 
- Three reviews of ’Low’ or ’Critically Low’ quality evaluated interventions where the medications of interest included a mix of DCD and 
antihypertensives and/or antidepressants. 
Interventions to promote adherence (n=58) 
- With regard to reviews where only DCD and/or antidepressants were the medications of interest, only two reviews were appraised using the 
AMSTAR-2 tool; there was one review of ‘High’ quality that included evidence evaluating interventions to promote adherence to antidepressants, 
and one of ‘Low’ quality. The rest were of ‘Critically Low’ quality.  
- Ten reviews appraised using the AMSTAR-2 tool included evidence where medications of interest were antihypertensives and/or statins. These 
reviews were predominantly of ‘High’ to ‘Moderate’ overall quality. A further thirty reviews with this aim were of ‘Low’ or ‘Critically Low’ quality.  
- Lower quality reviews focused on improving adherence to predominantly antidepressant (n=8), with one review focusing on interventions to 
promote adherence to benzodiazepines. 
- Seven reviews evaluated interventions to improve adherence to a mix of medications of interest, including DCD, antidepressants and 
statins/antihypertensives. Two of these were appraised using the AMSTAR-2 tool and were of ‘High’ and ‘Moderate’ quality. 
Systematic reviews of guidelines (n=6) 
- Systematic review evidence of Clinical Practice Guidelines/clinical recommendations predominantly focuses on the management of pain, where the 
medication of interest is prescription of opiates, excluding a range of important DCD and other drugs of focus in this review. 
Overview of reviews 
Details of participant characteristics of the 130 included reviews included in the evidence and gap map are summarised within the Review Overview table 
(Appendix C: Descriptive tables for included reviews). A summary of key population characteristics from the included reviews is provided below. 
Participant characteristics of included studies 
Participant age was not clearly reported as an eligibility criterion in 55 of the included reviews.4, 32-85 For the remaining reviews, eligible age for inclusion was 
aged 16 or over (n=2),86, 87 17 years or over(n=2),88, 89 18 years or over/adult not-specified (n=55),90-144 19 or over (n=1),145 65 years or over(n=6) 146-151 or a 
range of ages (n=9).152-160 Five reviews included studies focusing exclusively on older participants,107, 153, 155, 157, 158 whilst two reviews excluded studies with 
‘elderly people’.105, 106  
Medications of interest within included reviews included: antihypertensives (n=27),45, 47, 53, 60, 62, 66, 77, 84, 85, 88, 93, 95, 97, 99, 101, 109, 116, 120, 133-135, 138, 139, 142, 152, 156, 158 
opiates (n=23),34, 36, 43, 46, 49, 51, 54, 63, 81-83, 103, 104, 111, 115, 122, 125, 129, 136, 137, 141, 143, 144 statins and antihypertensives (n=18),4, 32, 35, 38, 40, 52, 57, 61, 90, 96, 98, 113, 114, 117, 118, 121, 130, 
148 antidepressants (n=17),37, 48, 50, 76, 80, 86, 89, 91, 96, 105, 106, 112, 123, 124, 126, 145, 154 antidepressants and DCD (n=7),58, 68, 94, 108, 147, 155, 157 antidepressants and medications 
to treat cardiovascular disease(CVD) and/or hypertension (n=6), 41, 55, 64, 69, 72, 159 benzodiazepines (n=6),44, 78, 87, 107, 128, 153 a mixture of DCD, antidepressants and 
CVD (n=7),39, 73, 74, 102, 110, 150, 160 a mixture of DCD and medications to treat CVD and/or hypertension (n=3),71, 149, 155 a mixture of DCD (n=8),65, 70, 79, 92, 119, 127, 131, 
151 statins (n=7) 56, 59, 67, 75, 100, 132, 140 and hypnotics (n=1).146 
Quality of the evidence 
 
CEESAT scores 
The ratings on the four CEESAT items for each of the 130 included reviews can be seen in Table 10, Appendix C. Thirty-six reviews scored positively on all 
four items, thus achieving a total score of 0, indicating that their search and quality appraisal strategy were conducted and reported to high quality.32, 47, 50, 
52, 56, 59, 60, 66, 69, 71, 74, 77, 86, 92, 98, 102, 103, 106, 107, 119, 120, 122-124, 126, 130, 134-136, 140, 143, 144, 146, 153, 155, 157 These studies were prioritised for quality appraisal using the 
AMSTAR-2 tool. 
Forty-three reviews scored negatively on one of the four CEESAT items.4, 34, 36, 37, 40-43, 46, 51, 55, 57, 64, 65, 67, 70, 72, 75, 76, 78, 83, 87, 89, 91, 95, 99, 104, 105, 111, 114-116, 118, 121, 127-129, 
133, 141, 145, 150, 151, 154 Nine reviews scored negatively on the first item (clearly defined, systematic and transparent search strategy),37, 40-42, 46, 91, 111, 129, 133 11 
reviews scored negatively on the second item (comprehensive search),4, 34, 43, 65, 67, 89, 99, 105, 127, 128, 154 14 reviews scored negatively on the third item (critical 
appraisal of each study)36, 51, 55, 64, 70, 72, 76, 78, 95, 104, 116, 141, 145, 150 and nine reviews scored negatively on the fourth item (minimising subjectivity during critical 
appraisal).57, 75, 83, 87, 114, 115, 118, 121, 151 Thirty-three reviews scored negatively on two out of the four CEESAT items.33, 35, 38, 44, 49, 54, 58, 61, 63, 68, 79-82, 85, 93, 94, 100, 108, 112, 
117, 132, 137-139, 142, 147, 149, 152, 156, 158-160 Four reviews scored negatively on the first item,82, 85, 100, 158 20 reviews scored negatively on the second item,33, 38, 54, 68, 79-81, 
93, 94, 100, 117, 132, 137, 139, 142, 147, 149, 152, 156, 159 26 reviews44, 49, 54, 58, 61, 63, 68, 79, 81, 82, 93, 94, 100, 108, 112, 117, 132, 137, 139, 142, 147, 149, 152, 158-160 scored negatively on the third CEESAT 
item and 16 reviews scored negatively on the fourth item.33, 35, 38, 44, 49, 58, 61, 63, 80, 93, 108, 112, 117, 138, 156, 160 Fourteen reviews scored negatively on three out of the 
four items.48, 62, 73, 84, 88, 90, 96, 97, 101, 109, 110, 113, 125, 131 Three reviews scored positively (a green rating) on the first item,62, 84, 96 five reviews scored positively on the 
second item,48, 97, 101, 125, 131 one review88 scored positively on the third item and five reviews scored positively on the fourth CEESAT item.73, 90, 109, 110, 113 Four 
reviews scored negatively on all four CEESAT items.39, 45, 53, 148 
One observation regarding reviews that scored poorly on item 3, is that whilst these usually provided an overall quality rating for each of their included 
studies, many of these reviews did not provide a breakdown of how each of these studies performed on each item of the quality appraisal tool used within 
that review. Negative scores on item 4 were often due to the poor reporting of methods which meant it was unclear as to whether two reviewers had 
independently critically appraised the included studies. 
AMSTAR-2 scores 
The thirty-six reviews which scored positively on all four CEESAT items were quality appraised using the AMSTAR-2 tool (Appendix C, Table 11). Fifteen 
reviews were of ‘High’ overall quality ,32, 50, 56, 59, 71, 74, 86, 92, 98, 103, 120, 130, 140, 143, 146 12 of ‘Moderate’ overall quality,52, 60, 69, 107, 122, 123, 126, 135, 136, 144, 153, 157 six of ‘Low’ 
overall quality66, 77, 102, 106, 119, 155 and three of ‘Critically-low’ overall quality.47, 124, 134   
AMSTAR-2 criteria on which reviews scored well included; clearly identified PICO components (n=34), having a protocol (n=28), duplicate study selection 
(n=36), duplicate data extraction (n=36), description of included studies (n=29) and discussion of risk of bias of results (n=33). However 26 of the 34 reviews 
where this item was applicable did not provide an explanation on why certain study designs were included, 20 reviews did not provide adequate detail of 
included studies, and 19 reviews did not report funding sources (see Appendix D, Table 11). 
Of the two qualitative reviews appraised using the AMSTAR-2, both scored positively on the majority of the additional qualitative quality appraisal items 
added to the tool.56, 123 Exceptions to this was the item requiring description of synthesis methodology and/or theoretical framework where both reviews 
received a ‘Partial Yes’ score, and the item requiring authors to reflect on their theoretical perspectives which may have influenced the review findings, on 
which both reviews scored negatively. 
  
Focus of included reviews 
The focus of the included reviews is summarised in Table 2 and described further within the accompanying text. 
Table 2: Focus of included reviews 
Type of evidence Number of 
reviews* 
Topic/type of evaluation Appraised using AMSTAR-2 Y/N: 
N (Overall Quality rating) 
Medication of interest 
Qualitative 18*1 Prescriber, patient, and/or family/carer 
views of issues relating to prescribing and/or 
adherence to medications of interest 
Y: 2                                  (High: 1, 
Moderate: 1) 
AD: 1  
Statins: 1  
N: 16 AD: 1  
AD+AH: 1 
AD+DCD: 3  
AH: 4  
Benzodiazepines: 1  
CVD Mix: 1 
DCD+CVD: 1  
DCD Mix: 1  
Opioids: 2  
Statins: 1  
Quantitative 33 Evaluating intervention to optimise 
prescribing 
Y: 11                                (High: 3, 
Moderate: 6, Low: 2, Critically 
low: 1) 
AD: 2 
AD+DCD: 1  
AH: 1 
CVD Mix: 1 
DCD Mix+CVD: 2 
Opioids: 3  
Statins: 1 
Type of evidence Number of 
reviews* 
Topic/type of evaluation Appraised using AMSTAR-2 Y/N: 
N (Overall Quality rating) 
Medication of interest 
N: 22 AD: 2  
AD+CVD: 1  
AH: 1  
CVD Mix: 2  
DCD+AD: 2 
DCD+AD+ CVD: 1  
DCD+CVD: 1 
DCD Mix: 1,  
Opioids: 10  
Statins: 1  
Quantitative 22 Evaluating intervention to deprescribe 
medication 
Y: 9                                           (High: 
3, Moderate: 3, Low: 2, Critically 
low: 1) 
AD: 1  
Benzodiazepines: 2  
DCD+AD+CVD: 1  
DCD Mix: 2  
Hypnotics/z-drugs: 1  
Opioids: 2  
N: 13 Benzodiazepines: 3  
DCD+AD+CVD: 2  
DCD Mix: 5  
Opioid:3  
Quantitative 58 Evaluating intervention to optimise patient 
adherence to a medication 
Y: 14 
(High: 7, Moderate: 3, Low: 2, 
Critically low: 2) 
AD: 2  
AD+AH: 1 
AH: 6  
DCD+AD+CVD: 1, 
Statins: 1  
Statins+AH: 3  
Type of evidence Number of 
reviews* 
Topic/type of evaluation Appraised using AMSTAR-2 Y/N: 
N (Overall Quality rating) 
Medication of interest 
N: 44 AD: 8  
AD+CVD: 4  
AH: 16  
Benzodiazepines: 1  
DCD+AD+CVD: 1  
Statins: 2  
Statins+AH: 12 
Guidelines 6 Recommendations/clinical practice 
guidelines regarding prescribing of opioids 
for pain (4 chronic, 2 acute following 
surgery) 
Y: 1                                (High 
quality) 
Opioids: 1 
N: 5 Opioids: 5 
*This N>130 due to some reviews having multiple aims; *15 reviews within qualitative category also synthesised quantitative data 4, 108, 156, 158, 160  AH=Antihypertensive; 
AD=Antidepressant; CVD=medication to treat Cardiovascular Disase; DCD=Drugs which may Cause Dependency 
 
Quality appraised using AMSTAR-2: Higher-quality evidence 
Two reviews appraised using the AMSTAR-2 tool synthesised qualitative evidence.56, 123 One explored patient and prescriber views of 
prescribing/deprescribing of antidepressants,123 whilst the other explored patient, carer and family member views of adherence to statins.56  
Eleven reviews quality appraised using the AMSTAR-2 tool focused on evaluating interventions where the primary or secondary aim was to optimise the 
prescribing of a medication.50, 52, 59, 71, 77, 122, 126, 136, 144, 155, 157 Medications of interest included: opiates (n=3),122, 136, 144 antidepressants (n=2),50, 126 mix of DCD 
and medications to treat CVD (n=2),71, 155 mixture of DCD and antidepressants (n=1),157 statins (n=1),59 statins and antihypertensives (n=1),52  antihypertensives 
(n=1).77 Five of these reviews included medications outside of the focus of this review.50, 71, 136, 155, 157 
Nine of the 36 reviews quality appraised using the AMSTAR-2 tool focused on evaluating interventions where the primary or secondary aim was to promote 
the deprescribing of a medication.92, 102, 103, 107, 119, 122, 124, 146, 153 Medications of interest within these reviews were benzodiazepines and hypnotics (n=2),92, 119 
benzodiazepines (n=2),107, 153 hypnotics (n=1),146 antidepressants (n=1),124 opiates(n=2) 103, 122 and a mix of DCD, antidepressants and medication to treat 
cardio-vascular disease (CVD).102 These medications of interest were included alongside other medications in three reviews.102, 146, 153 
Fourteen of the systematic reviews fully appraised using the AMSTAR-2 tool focused on evaluating interventions where the primary or secondary aim was to 
promote adherence.32, 47, 60, 66, 69, 74, 86, 98, 106, 120, 130, 134, 135, 140 Medications of interest included in these reviews included: antihypertensives (n=6),47, 60, 66, 120, 134, 
135 statins and antihypertensives (n=3),32, 98, 130 antidepressants (n=2),86, 106 a mixture of DCD, antidepressants and medication to treat CVD (n=1),74 
antidepressants and medications to treat CVD (n=1)69 and statins (n=1).140 Seven reviews also included medications outside of the focus of this evidence and 
gap map.32, 69, 74, 106, 130, 135, 140 
One systematic review synthesised Clinical Practice Guidelines (CPGs) regarding prescription of opioids within a hospital setting.143 
Quality appraised using CEESAT criteria: lower quality evidence 
Sixteen systematic reviews which scored poorly on one or more CEESAT items conducted synthesis of studies including qualitative data or performed 
qualitative synthesis.4, 33, 48, 54, 62, 78, 79, 101, 108, 132, 137, 147, 156, 158-160 Three reviews scored negatively on one CEESAT item4, 78, 156 and the remaining thirteen reviews 
were within the lowest scoring category, scoring negatively on between two to four CEESAT items.33, 48, 54, 62, 79, 101, 108, 132, 137, 147, 158-160 Medications of interest 
included: antihypertensives (n=4),62, 101, 156, 158 a mixture of DCD and antidepressants (n=3),33, 108, 147 opiates (n=2),54, 137 antidepressants (n=1),48 statins (n=1),132 
antidepressants and medication to treat CVD (n=1),159 mix of DCD, antidepressants and medication to treat CVD (n=1),160 a mixture of DCD (n=1),79 
benzodiazepines (n=1)78 and statins and antihypertensives (n=1).4 Seven reviews also included medications outside the focus of this evidence and gap map.4, 
33, 108, 132, 147, 159, 160 Perspectives obtained included patient (n=10),4, 62, 79, 101, 108, 132, 156, 158-160 carer and/or family member (n=3)132, 159, 160 and 
practitioner/prescriber (n=9).33, 48, 54, 78, 108, 137, 147, 156, 159 Phenomenon of interest included: reasons for adherence to medication (n=7),4, 62, 79, 101, 132, 156, 158 
experiences of an intervention to promote adherence (n=3),4, 156, 159 experiences of an intervention to promote deprescribing (n=4),33, 78, 79, 160 experiences of 
taking a medication (n=1) 159 and experiences of prescribing (n=8).33, 48, 54, 78, 108, 137, 147, 156  
Thirty eight systematic reviews of evidence evaluating a relevant intervention scored negatively on one of the four CEESAT items. Twenty-one reviews 
evaluated interventions with the primary or secondary aim to enhance adherence to one of the medications of interest.40-42, 55, 57, 64, 72, 75, 76, 89, 91, 95, 99, 105, 114, 116, 
118, 121, 133, 145, 154 Medications of interest were as follows: antidepressants (n=6),76, 89, 91, 105, 145, 154  a mixture of antidepressants and medication to treat CVD 
(n=4),41, 55, 64, 72 statins and antihypertensives (n=6),40, 42, 57, 114, 118, 121  antihypertensives (n=4)95, 99, 116, 133 and statins (n=1).75 Eight of these 38 reviews focused 
on evaluating interventions which aimed to deprescribe one or more medications.65, 70, 87, 104, 127, 128, 150, 151 Medications of interest included: mix of DCD (n=4),65, 
70, 127, 151 benzodiazepines (n=2),87, 128 opiates (n=1),104 and a mixture of DCD, antidepressants and medication to treat CVD (n=1).150 Eleven reviews evaluated 
interventions with the primary or secondary aim to optimise the prescribing of certain medications.34, 36, 37, 51, 55, 67, 82, 83, 115, 127, 141 Medications of interest 
included within these reviews were: opiates (n=7),34, 36, 51, 82, 83, 115, 141 antidepressants (n=1),37 statins (n=1),67 a mixture of DCD (n=1),127 mix of antidepressants 
and medication to treat CVD (n=1).55 Sixteen of the 38 reviews scoring 1 on the CEESAT included medications beyond the scope of this systematic mapping 
review.37, 40, 41, 55, 57, 64, 67, 70, 72, 82, 83, 105, 114, 118, 150, 154  
A further 35 reviews synthesising evidence evaluating an intervention scoring negatively on two to four items of the four CEESAT items. Five evaluated 
interventions with the primary or secondary aim to aid the deprescribing of a medication.44, 49, 63, 110, 131 Medications of interest included: opiates (n=2),49, 63 
mixture of DCD,131 mix of DCD, antidepressants and medication to treat CVD (n=1)110 and  benzodiazepines (n=1).44 Twenty-three reviews focused on 
interventions with the primary or secondary aim of enhancing adherence to one or more medications.35, 38, 44, 45, 53, 61, 73, 84, 85, 88, 90, 93, 96, 97, 100, 109, 112, 117, 138, 139, 142, 
148, 152 Medications of interest included: benzodiazepines (n=1),44 mixture of DCD, antidepressants and medication to treat CVD (n=1),73  statins and 
antihypertensives (n=6),35, 38, 61, 90, 117, 148 antidepressants (n=2),96, 112 antihypertensives (n=11),45, 53, 84, 88, 93, 97, 109, 138, 139, 142, 152 and statins (n=1).100 Eleven reviews 
evaluated interventions with the primary or secondary aim to optimise the prescribing of one or more medications.39, 49, 58, 63, 80, 81, 85, 94, 113, 117, 149 Medications 
of interest include: mixture of DCD and antidepressants (n=3),58, 68, 94 opiates (n=3),49, 63, 81 statins and antihypertensives (n=2),55, 117 mixture of DCD, 
antidepressants and medication to treat CVD (n=1),39 mixture of DCD and antihypertensives (n=1),149 antidepressants (n=1)80 and antihypertensives (n=1).85 
Twenty of the 35 reviews receiving a CEESAT score of between 2 and 4 also included medications not relevant to the aims of this evidence-gap map.35, 38, 39, 44, 
58, 61, 67, 73, 80, 84, 85, 90, 94, 100, 110, 113, 117, 148, 149, 152  
Five systematic reviews synthesised CPGs which made reference to the prescription of opioids.43, 46, 111, 125, 129, 143  Two of these reviews also made reference 
to other medications outside the focus of this review.43, 125 The majority of these guidelines scored negatively on one CEESAT criterion, although one review 
scored poorly on three out of the four items.125 
Summary of systematic review evidence: by medication of interest  
An overview of the type of interventions, qualitative evidence and CPGs evaluated within the reviews included in the evidence and gap map can be found in 
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Statin Tsioufis 2020138 Green Amber Green Red 2 
Statin Uhlig 2013139 Green Amber Amber Green 2 
Statin Yuan 201985 Amber Amber Green Green 2 
DCD Chong 201196 Green Amber Amber Red 3 
DCD Ford 201748 Amber Green Amber Red 3 
DCD Hart 2020110 Amber Amber Amber Green 3 
DCD Mayer 2010125} Amber Green Amber Red 3 
DCD Polinski 201173 Amber Amber Amber Green 3 
DCD Pollman 2015131 Amber Green Amber Red 3 
Statin Al Alshaikh 201690 Amber Amber Amber Green 3 
Statin Conn 201597 Amber Green Amber Red 3 
Statin Dhar 2017101  Amber Green Amber Red 3 
Statin Gupta 2010109 Amber Amber Amber Green 3 
Statin 
Guzman-
Tordecilla 202088 Amber Amber Green Red 3 
Statin Kang 2016113 Amber Amber Amber Green 3 
Statin Marshall 201262 Green Amber Amber Red 3 
Statin Xiong 201884 Green Amber Amber Red 3 
Statin Du 201945 Amber Amber Amber Red 4 
DCD Chhina 2013.39 Amber Amber Amber Red 4 
Statin Kawalec 201853 Amber Amber Amber Red 4 
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CL=Critically Low overall quality; H=High overall quality; Low overall quality; M=Moderate overall quality; N=No; NA=Not 
Applicable; NRSI=Non-Randomised Studies of healthcare Interventions; PICO=Population, Intervention, Comparator, 




Table 12 to 13 in Appendix C. Below, a summary of the information contained in these tables is 
presented according to the medication of interest, with reference to the quality of the systematic 
reviews contributing to each medication group. 
Drugs that can cause dependency (DCD) and antidepressants 
 
Reviews of qualitative evidence 
Reviews prioritised for quality appraisal using AMSTAR-2 
The review by Maund et al (2019) received a ‘Moderate’ overall quality rating on the AMSTAR-2. This 
review examined patient experience of deprescribing of antidepressants.123 
Reviews not prioritised for quality appraisal using AMSTAR-2 
Eight reviews synthesised qualitative data, or using qualitative synthesis techniques, pertaining to the 
prescription of or adherence to DCD and/or antidepressants.33, 48, 54, 78, 79, 108, 137, 147 The medications of 
interest in four reviews included more than one type of DCD/antidepressant,33, 79, 108, 147 however only 
the review by Sirdifield et al. focused exclusively on these medications of interest.79 Three reviews 
explored views of prescribing the medication of interest,33, 108, 147 with the review by Anderson et al. 
focusing on GPs’ experiences of stopping benzodiazepines in particular.33 One review explored 
patients’ experience of seeking and using benzodiazepines and z-drugs.79 All four reviews received the 
lowest CEESAT total score of between two and four and were thus of critically-low quality. 
Four reviews focused exclusively on one medication of interest, including; benzodiazepines (n=1),78 
opiates (n=2)54, 137 and antidepressants (n=1).48 One review explored prescriber experiences of an 
intervention (deprescribing)78 and three reviews included practitioner experiences of prescribing a 
medication.48, 54, 137 These reviews received CEESAT scores of 1 (n=1)78 or 2-4 (n=3).48, 54, 137  
Reviews evaluating interventions to optimise prescribing 
Reviews prioritised for quality appraisal using AMSTAR-2 
Six reviews evaluated interventions where the primary or secondary aim was to optimise 
prescribing.50, 122, 126, 136, 144, 157 Medications of interest were as follows: antidepressants (n=2),50, 126 a 
mixture of DCD and antidepressants (n=1),157 and opiates (n=3).122, 136, 144 Three of these also included 
other medications outside the focus of our systematic mapping review.50, 136, 157 Overall quality ratings 
were: High (n=1)50 and Moderate (n=4).126, 136, 144, 157. In addition, one ‘Moderate’ quality review 
evaluated the effectiveness of an intervention which aimed to optimise the prescribing of and/or 
deprescribing of opiates in patients with chronic non-cancer pain.122 
Reviews not prioritised for quality appraisal using AMSTAR-2 
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Nine reviews with a CEESAT total score of one synthesised interventions intended to optimise the 
prescribing of different DCDs. Medications of interest to this systematic mapping review included 
opiates (n=7),34, 36, 51, 82, 83, 115, 141 antidepressants (n=1)37 and benzodiazepines and hypnotics (n=1).127 
Two of these reviews included medications outside of the scope of this systematic mapping review.37, 
82 
Seven reviews with a CEESAT total score of between two and four, included medications of interest 
such as: opiates (n=3)49, 63, 81, DCD and antidepressants (n=3)58, 68, 94 and antidepressants (n=1).80 All of 
these reviews except those conducted by Wetzel et al81 and Furlan et al49 included medications beyond 
the scope of this mapping review. 
Reviews evaluating interventions to promote deprescribing  
Reviews prioritised for quality appraisal using AMSTAR-2 
Eight reviews focused on evaluating interventions where the primary or secondary aim was to 
promote the deprescribing of a medication, where medication of interest included hypnotics (n=1),146 
antidepressants (n=1),124 benzodiazepines and hypnotics (n=2),92, 119 benzodiazepines (n=2),107, 153 and 
opiates (n=2).103, 122 Two of these reviews also included medications not relevant to the aim of this 
systematic mapping review.146, 153 Based on scores on AMSTAR-2, the overall quality of these reviews 
were: High (n=3),92, 103, 146 Moderate (n=3),107, 153 Low(n=1)119 and Critically low (n=1).124 
Reviews not prioritised for quality appraisal using AMSTAR-2 
Seven reviews had one critical flaw in the conduct and/or reporting of search methods or quality 
appraisal items.65, 70, 87, 104, 127, 128, 151 Four focused on deprescribing a mix of DCD,65, 70, 127, 151 two on 
deprescribing benzodiazepines87, 128 and one on reducing long-term opiate use in chronic pain.104  
In addition, four reviews with a CEESAT total score between two and four evaluated interventions with 
the primary or secondary aim to aid the deprescribing of a medication.44, 49, 63, 131 Two of these reviews 
included evaluations of interventions with the secondary aim of optimising prescribing,49, 63 with both 
including studies evaluating effectiveness of substitution treatment for opiate addiction. Two reviews 
focused on deprescribing benzodiazepines and/or hypnotic medication,44, 131 one of which included 
medication outside of the focus of this review.44  
Reviews evaluating interventions to promote adherence 
Reviews prioritised for quality appraisal using AMSTAR-2 
Only two reviews with the primary or secondary aim to evaluate interventions to promote adherence 
to antidepressants were prioritised for quality appraisal using the AMSTAR-2. One received a ‘High’ 
overall quality rating86 and the other a ‘Low’ overall quality rating.105  
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Reviews not prioritised for quality appraisal using AMSTAR-2 
Six reviews with a CEESAT total score of one aimed to evaluating interventions intending to enhance 
adherence to antidepressants.76, 89, 91, 105, 145, 154 Two of these also included medications beyond the 
focus of this mapping review.105, 154 Three reviews with a CEESAT total score between two and four 
synthesised primary studies with the primary or secondary aim to improve adherence, with 
medications of interest including: antidepressants (n=2),96, 112 benzodiazepines (n=1),44 One review 
included other medications beyond the scope of this mapping review.44  
Reviews of guidelines 
Reviews prioritised for quality appraisal using AMSTAR-2 
Only one of the reviews was prioritised for quality appraisal, receiving a ‘High’ overall quality rating.143 
This review synthesised CPGs about the prescription of opioids for the management of acute pain in 
hospital inpatients. 
Reviews not prioritised for quality appraisal using AMSTAR-2 
Five systematic reviews43, 46, 111, 125, 129  synthesised CPGs or recommendations about the management 
of either acute (n=1) 111 or chronic (n=4) pain.43, 46, 125, 129 With regard to appropriate use of medication, 
the medication of interest was opiates for all five reviews, although two reviews did also make 
reference to other medications including non-steroidal anti-inflammatories, acetaminorphen, 
codeine, tramadol and/or muscle relaxants.43, 125 One of the guidelines were for reference with use for 
hospital inpatients,111 one for hospital outpatients,46 three for patients within primary health and/or 
social care,43, 46, 125 one secondary care125 and one did not report this information.129 Four of the 
reviews scored poorly on one CEESAT item,43, 46, 111, 129 indicating at least one critical flaw in the conduct 
and/or reporting of search methods or quality appraisal. One review received a CEESAT score of 3, 




Statins and antihypertensives 
Reviews of qualitative evidence 
Reviews prioritised for quality appraisal using AMSTAR-2 
The review by Kinnear et al was prioritised for full quality appraisal, receiving an overall quality score 
of ‘High’.56 This review explored issues relating to adherence to statins in adults and children with 
familial hypercholesterolemia. 
Reviews not prioritised for quality appraisal using AMSTAR-2 
Six reviews synthesised primary studies containing qualitative data and/or conducting qualitative 
analysis pertaining to the prescription of, or adherence to, statins and/or antihypertensive 
medication.4, 62, 101, 132, 156, 158 Four reviews focused exclusively on antihypertensive medication, all of 
which examined patient views of issues relating to adherence.62, 101, 156, 158 One of these reviews utilised 
a qualitative synthesis strategy with studies including quantitative/narrative data, on factors which 
are associated with medication adherence in older adults with high blood pressure.158  The systematic 
review conducted by Khatib et al156 included patient and provider perspectives on barriers to optimal 
hypertension awareness, treatment, or follow up with a health care provider. All of these reviews 
received a CEESAT score of between 2 and 4, aside from the reviews by Khatib et al156 and Ingersgaard 
et al,24 which received a CEESAT score of one. 
Two reviews focused on exploring issues relating to adherence to statins and/or antihypertensives 
and interventions intended to enhance adherence.4, 132 Both reviews included the perspective of the 
patient and one also included carers and/or family members.132 The reviews by Ingersgaard et al4 and 
Rashid et al132 received a CEESAT score of one and two respectively. 
Reviews evaluating interventions to optimise prescribing 
Reviews prioritised for quality appraisal using AMSTAR-2 
Three reviews aimed to evaluate interventions with the primary or secondary aim of optimising statins 
(n=1),59 antihypertensives (n=1)77 and statins and hypertensives (n=1).52 These reviews were given a 
‘High’,59 ‘Moderate’52 or ‘Low’77 quality rating, with one also including medication outside of the focus 
of this review.59 
Reviews not prioritised for quality appraisal using AMSTAR-2 
One review with a CEESAT total score of 1 intended to optimise the prescribing of statins alongside 
other medications outside of the focus of this systematic mapping review (n=1).67 
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Three reviews with a CEESAT total score of between 2 and 4 synthesised primary studies whether the 
primary or secondary aim was to optimise the prescribing of statins and antihypertensives (n=2)113, 117 
or antihypertensives (n=1),85 alongside other types of medication. 
Reviews evaluating interventions to promote adherence 
Reviews prioritised for quality appraisal using AMSTAR-2 
Ten reviews focused on evaluating interventions where the primary or secondary aim was to promote 
adherence to at least one type of medication of interest, including: antihypertensives (n=6),47, 60, 66, 120, 
134, 135 antihypertensive and statins (n=3),32, 98, 130 and statins (n=1).140 Five were of ‘High’ overall 
quality,32, 98, 120, 130, 140 two were of ‘Moderate’ overall quality,60, 135 one was of ‘Low’ quality66 and two 
were ‘Critically-low’ overall quality.47, 134 
One moderate-quality review evaluating interventions to improve shared decision making regarding 
antihypertensives also included a broad range of other medications in one review.135 
These medications of interest were included alongside other medications in three reviews. These 
medications included any lipid-lowering medications (n=1),140 anti-platelet medication (n=1),32 
medications for primary prevention of CVD (n=1).130 
Reviews not prioritised for quality appraisal using AMSTAR-2 
Eleven reviews with a CEESAT total score of 1 synthesised studies which evaluated interventions with 
the primary or secondary aim to increase adherence to statins and/or antihypertensives. Medications 
of interest in these reviews included antihypertensive medication (n=4),95, 99, 116, 133 statins (n=1)75 and 
both statins and antihypertensives (n=6).40, 42, 57, 114, 118, 121  Five of these reviews also included other 
medications beyond focus of systematic mapping review.40, 42, 57, 114, 118 
Nineteen reviews with a CEESAT total score between 2 and 4 synthesised primary studies with the 
primary or secondary aim to improve adherence, with medications of interest including: statins and 
antihypertensives (n=6),35, 38, 61, 90, 117, 148 antihypertensives (n=12)45, 53, 84, 85, 88, 93, 97, 109, 138, 139, 142, 152 and 
statins (n=1).100 Nine reviews also included other medications beyond the scope of this systematic 
mapping review.35, 38, 84, 85, 90, 100, 117, 148, 152 
Mix of medications 
Reviews of qualitative evidence 
Reviews not prioritised for quality appraisal using AMSTAR-2 
Two reviews synthesised qualitative evidence relating to a mix of medication.159, 160 In a review 
including patient and family member/carer perspectives on interventions to encourage deprescribing, 
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Reeve et al included any long term medication, including benzodiazepines, antidepressants and 
antihypertensives.160 The other review explored medication taking experiences of a variety of 
medications, including antidepressants and antihypertensives, and issues associated with adherence 
from the perspective of the practitioner, patient and carer/family members.159 Both reviews received 
a total CEESAT score of 2, and were thus of critically-low quality. 
Reviews evaluating interventions to optimise prescribing 
Five reviews synthesised primary studies with the primary or secondary aim of evaluating 
interventions to optimise the prescribing of one or more medications of interest. 
Reviews prioritised for appraisal using AMSTAR-2 
In two reviews prioritised for appraisal using the AMSTAR-2 medications of interest included DCD and 
those for the treatment of CVD (n=2).71, 155 These reviews were rated as ‘High’71 and ‘Low’ overall 
quality.155 
Reviews not prioritised for quality appraisal using AMSTAR-2 
Medications of interest within one review with scoring poorly one CEESAT item included both 
antidepressants and statins (n=1).55 In addition, two reviews scoring poorly on between 2 and 4 
CEESAT items included studies where the medication of interest were antidepressants, DCD and 
antihypertensives (n=1)39 or a mixture of hypnotics, benzodiazepines and antihypertensives (n=1).149 
All of these reviews included other types of medication beyond the focus of this systematic mapping 
review. 
Reviews evaluating interventions to promote deprescribing 
Reviews prioritised for appraisal using AMSTAR-2 
Only one review was prioritised for appraisal using the AMSTAR-2.102 The medications of interest in 
this low-quality review included a mixture of DCD medications and antihypertensives alongside 
medications not of interest. 
Reviews not prioritised for quality appraisal using AMSTAR-2 
One review which scored poorly on one CEESAT item included participants taking a mixture of DCD, 
antidepressants and medications to treat CVD.150 One review with a CEESAT total score between 2 and 
4 included participants taking a range of DCD, antidepressants and/or antihypertensives alongside 
other medications outside of the scope of this mapping review.110  
Reviews evaluating interventions to promote adherence 
Reviews prioritised for appraisal using AMSTAR-2 
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Two reviews appraised using the AMSTAR-2 included the primary or secondary aim to evaluate 
interventions to improve adherence to a range of DCD and/or antidepressants and medications to 
prevent CVD.69, 74 These reviews also included medications not of interest to the aim of this systematic 
mapping review. These reviews were of ‘High’74 and ‘Moderate’ overall quality.69 
Reviews not prioritised for quality appraisal using AMSTAR-2 
Four reviews with a CEESAT total score of 1 aimed to evaluate interventions to enhance adherence to 
antidepressants and medications to treat/prevent CVD alongside medication outside the focus of this 
mapping review. systematic mapping review.41, 64, 72 
One review with a CEESAT total score between 2 and 4 synthesised primary studies with the primary 
or secondary aim to improve adherence, with medications of interest including: antidepressants, 
benzodiazepines, hypnotics, and statins (n=1).73 
Discussion 
We were asked to identify the quantitative and qualitative systematic review evidence which could 
inform the optimal prescribing of DCD (benzodiazepines, non-benzodiazepine hypnotics/z-drugs, 
opioids and gabapentinoids), antidepressants, statins and antihypertensive medication. We 
conducted searches, screening and data extraction using methods consistent with systematic review 
guidelines and mapped the eligible systematic review evidence onto a patient care pathway 
developed through drawing on government guidelines, existing research and stakeholder expertise. 
The final evidence and gap map indicates areas where a significant body of systematic review 
research already exists. With regard to statins and antihypertensive medication, there are a number 
of reviews which synthesise qualitative evidence on patient and/or family/carer experience of 
adherence and/or taking this type of medication. There are also a large number of reviews which 
examine the effectiveness of interventions which aim to improve adherence to these two types of 
medication. These were predominantly of low overall quality, with ten being of ‘Moderate’ or ‘High’ 
quality. These reviews were represented across the patient care pathway for both types of 
medication, but particularly with regard to information and advice giving (n=8 statins, n=17 
antihypertensives), choosing a medication (n=8 statins, n=14 antihypertensives) and progress review 
(n=14 statins, 27 antihypertensives) although the reviews were predominantly of ‘Critically Low’ 
quality. 
Twenty-two systematic reviews synthesised evaluations of interventions to promote the 
deprescribing of medication which included DCD and antidepressants, although the majority of 
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these were of low overall quality. Similarly, all DCD and antidepressant medications (aside from 
gabapentinoids) were included in at least one review focusing on evaluating interventions to 
optimise prescribing which was appraised using the AMSTAR-2 tool, however the quality of this 
evidence was variable. 
There is a body of qualitative systematic review evidence which examines barriers and facilitators to 
the deprescribing of DCD and antidepressants, and of experiences of adhering to/taking statin and 
antihypertensive medication. However there was very little evidence which examined experiences or 
views of specific interventions to promote adherence or aid deprescribing. In general reviews of 
qualitative evidence were reported or conducted to a low standard, with only 2 rated as Moderate 
or High quality.  
Strengths and limitations 
 
Included systematic review evidence 
Overall the quality of the majority of the systematic review evidence included within the evidence 
and gap map was low, which may have implications for the confidence which can be placed in the 
findings of these reviews. This issue was particularly evident for reviews conducting qualitative 
synthesis, only two of which scored sufficiently well on the CEESAT criteria to be prioritised for full 
quality appraisal using the modified AMSTAR-2 tool. Five of the reviews conducting qualitative 
synthesis also included synthesised quantitative data, with the methods of synthesis methods being 
unclear in three of these reviews. 
Many of the systematic reviews included within the evidence and gap map had broad or multiple 
aims, with the outcomes of interest to this systematic mapping review being one of several within 
these reviews, meaning the focus of included reviews may not directly align with the objectives of 
the systematic mapping review. In addition, often medications of interest were included alongside 
other medications outside of the scope of this review, which may also impact on the relevance of 
the findings from individual reviews to the aim of this systematic mapping review. 
Methods used to produce the evidence and gap map 
This systematic mapping review incorporates a diverse set of evidence with a range of aims and 
medications of interest into one evidence and gap map. By arranging this evidence in accordance 
with a global patient care pathway, separated according to type of medication, we aimed to support 
the map users to find the evidence most suited to their requirements. Guidance from our clinical 
and patient stakeholders was invaluable when developing the patient pathways on which this 
evidence and gap map is based. The perspectives of different stakeholder groups complemented 
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each other well; the views of clinicians allowed us to incorporate details on how the pathway may 
work in practise, whilst the experiences of patients provided additional insight on how the ‘ideal’ 
pathway may not always be delivered and emphasised the importance of shared decision making, 
involvement of families and third-sector services. 
Due to the large volume of evidence available and broad remit for this systematic mapping review, 
this evidence and gap map includes only systematic review evidence. Systematic reviews which may 
have met the eligibility criteria for this review that were used to underpin NICE guidelines were not 
retrieved through our database searches. It was beyond our resources to search through individual 
guidelines to locate relevant reviews.  
Only reviews which scored positively on all four CEESAT critera were prioritised for full quality 
appraisal using the AMSTAR-2 tool. The reviews evaluated using only the CEESAT criteria were 
awarded a ‘Critically low’ AMSTAR-2 overall rating. Full appraisal using the AMSTAR-2 would have 
provided a more complete assessment of review quality. However, we feel that the overall score 
would not be affected for the majority of these reviews due to the nature of the limitations in 
reporting and conduct originally identified by the CEESAT criteria.  
Whilst the relevance of each systematic review to the research objectives of this systematic mapping 
review was agreed upon by two reviewers in line with criteria outlined at the start of the data 
extraction process, these ratings were given from a research perspective. It is possible that those 
from more clinical or public health backgrounds may have awarded different ratings. 
The extent to which the global patient care pathway used as the basis of the evidence and gap map 
could represent the individual nuances that should be considered by the prescriber for each of the 
medications of interest is, for pragmatic reasons, limited. Whilst the patient care pathway 
considered NICE guidelines and incorporated stakeholder views and experience for the prescribing 
of different medications, not all of this information could be included in one patient care pathway 
without affecting the pathway’s utility within this systematic mapping review. Instead, the pathway 
represents key decision points accross each of the medications of interest, allowing for systematic 
reviews relevant to different types of medications of interest to be included within one map. 
Implications for further work 
The evidence and gap map indicates several areas where further work may be beneficial. Potential 
areas for further work include: 
- Searching for primary studies where gaps in high quality systematic review evidence have 
been identified and may benefit from systematic review For example, qualitative evidence 
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regarding patient and/or prescriber experiences of specific interventions to aid 
deprescribing or practitioner experiences of prescribing statins or hypnotic medication; 
- Conducting further synthesis of existing systematic review evidence of the effectiveness of 
interventions to improve adherence and/or deprescribing of medications of interest; 
- Conducting further synthesis of existing systematic reviews of experiences of taking or 
adhering to statin and/or antihypertensive medication; 
- Exploring the extent to which the interventions identified within the evidence and gap map 
meet the definition of person-centred care and their perceived effectiveness. 
- Conducting a synthesis between and within the bodies of evidence for the two drug types, to 
draw out whether there are common themes that could inform prescribing policy 
Decisions regarding potential future work should be made following consultation with key policy 
stakeholders, to ensure that any systematic review or primary research work undertaken reflects a 
clearly defined policy need. 
Conclusions 
This evidence and gap map highlights the available quantitative and qualitative systematic review 
evidence to inform the optimal prescribing of DCD, antidepressants, statins and antihypertensive 
medication. The map summarises key characteristics of these systematic reviews and identifies areas 
where no, or low-qualiity systematic, have been conducted. These gaps highlight areas which may 
benefit from further searches to identify if any primary research exists, which could be combined 
within further evidence synthesis. Consultation with policy and commissioning stakeholders is 
required to confirm the areas in which further evidence syntheses or primary research could best 
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Part 2: Full description of methods 
The methods used to create this evidence and gap map were consistent with the best practice 
approach recommended by the University of York’s Centre for Reviews and Dissemination for the 
identification, screening and quality appraisal of scientific literature161 and informed by Campbell 
guidance for the development of evidence and gap maps.20 Full details of the methods used to identify 
the literature and create the evidenceand gap map can be found in our review protocol, registered on 
the Open Science Framework18 prior to commencing the review. Below, we summarise our methods 
consistent with relevant aspects of the PRISMA reporting guidance.162  
Identification of studies 
The bibliographic database search strategies were developed using MEDLINE (via Ovid) by an 
information specialist (SB) in consultation with the review team, key stakeholders and members of 
the public who had experience of being prescribed one or more of the medications of interest.  
Eight bibliographic databases were searched on 11th August 2020: 
• the Cochrane Database of Systematic Reviews (via the Cochrane Library)  
• CINAHL (via EBSCO) 
• EMBASE (via Ovid) 
• Health Management Information Consortium (HMIC) (via Ovid)  
• MEDLINE ALL (via Ovid)  
• PsycInfo (via Ovid)  
• Conference Proceedings Citation Index – Science (via Web of Science, Clarivate Analytics)  
• Science Citation Index (via Web of Science, Clarivate Analytics) 
The search strategy for evidence relating to statins and antihypertensives combined search terms for 
optimising prescribing with terms for statins/antihypertensives and terms for cardiovascular diseases. 
The search strategy for evidence relating to drugs which can cause dependency combined search 
terms for optimising prescribing with terms for relevant drugs (Benzodiazepines, z-drugs, opioids and 
antidepressants). The search strategies used both controlled headings (e.g. MeSH in MEDLINE) and 
free-text searching (i.e. title and abstract searching), were date limited from 2010 to date and used a 
systematic reviews study type search filter to limit the results to systematic reviews.  
We also searched the web-based systematic review database Epistemonikos (via 
https://www.epistemonikos.org/en/) and the preprints server medRxiv (via 
https://www.medrxiv.org/). The full search strategy is reported in Appendix A.  
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The results of the searches were exported to Endnote X8 (Clarivate Analytics, Philadelphia, PA, USA) 
and de-duplicated using the automated de-duplication feature and manual checking.  
Backwards citation chasing was undertaken for all of the systematic reviews that met our inclusion 
criteria. We also searched a selection of topically relevant websites identified through consultation 
with our stakeholders. Please contact the authors for a full report of the search strategies used for 
each website. The full list of websites searched is as follows: 
Websites searched 
• Royal Pharmaceutical Society  https://rpsgb.koha-ptfs.co.uk/  
• Royal College of Physicians  https://rcp.soutron.net/Portal/Default/en-
GB/Search/SimpleSearch  
• Royal College of Psychiatrists  https://rcpsych.soutron.net/Portal/Default/en-
GB/Search/SimpleSearch  
• Mind    https://www.mind.org.uk/ 
• Mental Health UK   https://mentalhealth-uk.org/ 
• Priory Group   https://www.priorygroup.com/ 
• Royal Pharmaceutical Society https://rpsgb.koha-ptfs.co.uk/  
• Royal College of Physicians  https://rcp.soutron.net/Portal/Default/en-
GB/Search/SimpleSearch      
• British Cardiovascular Society https://www.britishcardiovascularsociety.org/ 
• European Society of Cardiology https://www.escardio.org/ 
• British and Irish Hypertension Society   https://bihsoc.org/ 
• British Heart Foundation https://www.bhf.org.uk/ 
• Heart Research UK  https://heartresearch.org.uk/ 
Where conference abstracts and review protocols identified by the above search methods met our 
inclusion criteria, full texts for the completed systematic review were sought.  Efforts were made to 
contact the authors of relevant articles where full-texts could not be obtained. 
Inclusion criteria 
Inclusion and exclusion criteria are detailed below. Criteria for quantitative studies were structured 
according to the PICO format (Population, Intervention, Comparator and Outcome) and criteria for 
qualitative studies according to the PICo format (population, phenomenon of Interest, Context). 
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Adults (mean/median age ≥ 16 years) where a prescription for one or more of the following classes 









- Child/Paediatric populations (mean/median age  ≤ 15 years) 
- Patient groups where medication type not explicitly mentioned 
- Patients receiving services for use of illicit substances (e.g. heroin, cocaine) 
- Patients receiving treatment for cancer pain 




For systematic reviews of quantitative evidence, interventions must have aimed to improve one or 
more of the following: 
- Patient adherence to prescribed medication 
- Prescriber (e.g. Doctor, nurse, pharmacist) adherence to clinical guidance for prescribing 
- Prescriber practices  
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- Implementation of an intervention to enhance patient adherence or prescriber practices 
Where the above review aims were not made explicit, reviews were considered relevant if outcomes 
consistent with such aims were stated in the abstract, such as a measure of patient adherence. 
Interventions may have been conducted at a system-level or be targeted at the patient and/or 
prescriber. 
Comparator(s)/Control 
Any comparator was eligible for inclusion.  
Outcome   
All outcomes were of interest. 
Qualitative studies (PICo) 
Population 
Same as quantitative studies (see above). 
Phenomenon of interest  
With respect to systematic reviews of qualitative evidence, the focus was required to be on the 
views/perceptions/experiences of patients, carers or practitioners of any of the following: 
- Healthcare consultations to discuss initiation, reviewing or discontinuing a prescription 
- Interventions aiming to improve adherence/prescribing practice 
- Reasons for adherence or non-adherence to prescribed medication 
- Making prescribing decisions 
Context  
Any setting. 
Additional inclusion/exclusion criteria  
 
Study design: 
Only systematic reviews were eligible for inclusion, defined according to the criteria outlined by 
Martinic et al (2019), that each systematic review must: 
1) Have a clearly stated research question 




3) Define inclusion and exclusion criteria 
4) Clearly outline screening/study selection methods  
5) Critically appraise and report the quality/risk of bias of the included studies 
6) Provide information about data analysis and synthesis that allows the reproducibility of the 
results 
Include: 
- Systematic reviews of quantitative and/or qualitative literature 
- Systematic reviews of guidelines relating to prescribing of medications listed in ‘Population’ 
section above 
- Systematic review of reviews 
- Scoping reviews 
- Rapid reviews 
Exclude: 
- Reviews which did not meet the criteria outlined above 
- Primary studies 
Date limit 
Systematic reviews published from 2010 onwards. This date restriction was selected as systematic 
reviews outside of this period would be viewed as requiring an update to capture more recently 
published primary research. 





As an initial exercise to calibrate screening judgments and ensure the clarity of our inclusion and 
exclusion criteria, two reviewers (MN, LS) screened the same sample (n=100) of titles and abstracts 
identified by the bibliographic database searches.  Decisions were discussed in a group meeting to 
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ensure consistent application of criteria.  Where necessary, inclusion and exclusion criteria were 
revised to enable more consistent reviewer interpretation.   
The revised inclusion and exclusion criteria were then applied to the title and abstract of each 
identified citation independently by two reviewers (LS, MN), with disagreements resolved through 
discussion or referral to a third reviewer (SB) as required. The full text of each record was then 
retrieved and assessed for inclusion in the same way.  
Endnote X8 software was used to support study selection (Clarivate Analytics, Philadelphia, PA, USA). 
A PRISMA-style flowchart was produced to detail the study selection process and reason for exclusion 
of each record retrieved at full text, which can be viewed in Appendix C. 
Data extraction 
A standardised data extraction coding set was developed and piloted by the review team (LS, MN) 
on a five included studies to collect the following information from each included full text:  
Data extracted included: 
- Bibliographic information 
- Review focus/aim 
- Type of review 
- Type of studies included 
- Type of synthesis  
- Type of medication being prescribed 
- Medical condition(s) being treated 
- Age at which study participants eligible for inclusion (Deviation from protocol which stated: 
Mean age of population) 
- If review inclusion criteria and/or synthesis plan considered ethnicity of sample (Deviation 
from protocol which stated: Ethnicity of sample) 
- If review inclusion criteria and/or synthesis plan considered socio-economic status of sample 
(Deviation from protocol which stated: Socio-economic status of sample) 
- Intervention name and aim (Protocol only specified intervention name) 
- Perspectives obtained (Qualitative studies only) 
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- Experiences of which phenomenon (Qualitative studies only – additional information to that 
specified in protocol) 
- Service/part of care pathway (See Development of patient care pathways for further detail) 
- Setting/Context (Additional to that specified in protocol) 
- Outcomes evaluated  
Data extraction and quality appraisal was conducted using EPPI-Reviewer (v 4.11.5.2) and performed 
by one reviewer (MN, LS) and checked by a second (SB, LS, MN), with disagreements being settled 
through discussion, recruiting a third person as arbiter, if required.163  
Quality appraisal 
Protocol deviation 
During the study selection process, it was noted that the extent to which the included studies met the 
criteria for a systematic review as outlined by Krnic Martinic et al varied considerably, particularly with 
regard to two key aspects of systematic reviews: the reported search strategy and quality appraisal.164 
In order to identify the highest quality systematic reviews for inclusion in the evidence and gap map, 
two reviewers (LS, MN) independently applied four criteria from the Collaboration for Environmental 
Evidence Synthesis Assessment Tool (CEESAT) to each study eligible for inclusion in the review.23 These 
criteria were as follows: 
1. Search strategy: Is approach to searching clearly defined, systematic and transparent? 
2. Is search comprehensive? 
3. Does the review critically appraise each study? 
4. During critical appraisal was an effort made to minimise subjectivity? 
The reviewers identified items where each of the included reviews did not score at least a “Green”, 
with disagreements on any item resolved through discussion. The standards required to score a 
“Green” on each criteria are outlined in Table 3 below. A score lower than ‘Green’ indicates poor 







Table 3: Criteria required to score "Green" Rating on CEESAT items 
CEESAT criteria Standard necessary to achieve Green rating 
Search strategy: Is approach to searching clearly 
defined, systematic and transparent? 
 
All search terms, Boolean operators (‘AND’, ‘OR’ 
etc.) and wildcards are clearly stated so that the 
exact search is repeatable by a third party 
AND 
There is information about the sources 
searched, together with dates of search [but no 
limitations justified (e.g. language, or 
publication date, no grey literature searches) 
Is search comprehensive? 
 
Original: Sources of articles searched capture 
both conventionally published scientific 
literature and grey literature using a 
combination of databases, search engines and 
specialist websites (may also be informed by 
stakeholders) or limitations are fully justified. 
 
Modified: Require a minimum of 3 databases, 
AND at least one other source to avoid rating of 
amber. Specific searches for grey literature are 
NOT necessary 
Does the review critically appraise each study? 
 
Green: An effort is made to identify relevant 
sources of bias (threats to internal and 
external validity) 
AND 
Each type of bias or threat to internal and 
external validity is assessed individually for all 
included studies and reported on a critical 
appraisal sheet. 
During critical appraisal was an effort made to 
minimise subjectivity? 
 
Original: An effort is made to minimise 
subjectivity by predefining critical appraisal 




At least two people critically appraised each 
study but not independently (e.g. second person 
aware of first person’s decision) OR a subset of 
studies was appraised by at least two people 
independently and disagreements and process 
of resolution reported. 
 
Modified: do not need to check protocol; do 
NOT need mention of process for resolving 
disagreements to avoid Amber, AS LONG AS it is 
clearly stated that two reviewers performed 
appraisal independently 
 
Content reproduced from Collaboration for Environmental Evidence 2018 
As indicated in Table 3 above, the reviewers amended the original CEESAT criteria on two of the items.  
The requirement for review authors to search grey literature was relaxed due to the reasonable 
assumption that relevant studies would not be likely to be identified via such methods. However we 
required a selection of databases and at least one non-database source to be searched for 
comprehensiveness. Furthermore a pragmatic approach regarding checking of protocols was taken to 
expedite the process. We also decided not to downgrade reviews if explicit mention of the 
disagreement process was not made, as long as independent reviewers performed the review tasks. 
We assumed that independent reviewers would inevitably have such conversations over 
disagreements. 
This process enabled us to quickly assess the rigour and transparency of the methods used for 
searching and critical appraisal in the review; two of the fundamental components of systematic 
reviews which we found to be commonly flawed. Only studies which scored a “Green” on all four items 
(a CEESAT total score of zero) were prioritised for full quality appraisal using the AMSTAR-2 quality 
appraisal tool.24 By definition, all remaining studies would have been defined by the AMSTAR-2 tool 
as, at best, of ‘Low’ quality. For the purposes of clarifying how they were included in the map, these 
studies were awarded a ‘Critically Low’ rating. Please note that reviews subjected to full quality 




We adapted the AMSTAR-2 by adding items from the reporting standards for qualitative evidence 
synthesis to enhance the tools applicability to reviews of qualitative evidence.165 These items were as 
follows: 
1. Is synthesis methodology and/or theoretical framework clearly described and justified? 
2. Was the description and rationale for any sampling described? 
3. Was the process of data extraction clearly described? 
4. Was the process for coding of data clearly described? 
5. Was the process of developing themes clearly described? 
6. Do the authors reflect on how their theoretical or ideological perspectives may have 
influenced their review findings? 
7. Was use of any software clearly described? 
Quality appraisal was conducted in EPPI-reviewer software, using the same approach as for data 
extraction. 
Data analysis and presentation 
Details of the studies included within the evidence and gap map were tabulated and included within 
the main body of the report. Characteristics of included reviews provided within the study overview 
table include author, date of publication, focus of review, type of studies included, study designs 
included, review synthesis methods, eligible age of participants, medication of interest and relevance 
to the aim of the systematic mapping review. Within the table describing details of reviews evaluating 
effectiveness of interventions, the following details were included: first author, date of publication, 
indicator of study quality (where applicable), medications included, intervention name and aim, 
outcomes evaluated, setting/context and relevant parts of patient care pathway. This information was 
also tabulated for systematic reviews of qualitative evidence and clinical practice guidelines (CPGs), 
with the exception that intervention details were substituted with details of the perspectives of 
participants obtained and the phenomenon of interest or CPG aim and description respectively. 
Development of patient care pathways 
The medications of interest were divided into three groups, 1) Statins and antihypertensives, 2) 
Antidepressants and 3) Drugs which can cause dependency (encapsulating opioids, benzodiazepines, 
Z-drugs/hypnotics). Care pathways were developed for each of these groups by drawing upon the 
relevant NICE guidelines/care pathways for each of our medications of interest as well as NICE 
guidance/care pathways for optimising prescribing and shared decision making.25-29 Where necessary, 
other publications and guidelines were sought, particularly for the pathway pertaining to drugs which 
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can cause dependency.12, 30 We asked clinicians with relevant topic expertise to comment on how well 
each pathway reflected their experience and knowledge of working within the area. 
Whilst the care pathways based upon this information could be viewed as representing best practice, 
we also wanted to capture how patients and their family/carers could interact with, and potentially 
alter the course of, these pathways. To do this we drew upon an existing systematic review of 
qualitative evidence which explored patient experiences of taking medications, some of which were 
relevant to those of interest to our review.31 We also consulted with patients and carers with 
experience of taking one or more of these medications to check to what extent the pathways reflected 
their experience of accessing, being prescribed, adhering to and discontinuing their medication. 
Once the individual pathway for each type of medication of interest to our review had been agreed 
(see Development of patient care pathways), we developed one single pathway based upon common 
decision points across all of the pathways. This informed the development of both our data extraction 
codes and the structure of our final evidence and gap map. We ensured that this summary pathway 
also captured parts of the care pathways which may be unique to particular medications of interest. 
The pathway was also revised in an iterative manner during data extraction and development of the 
evidence and gap map to ensure the summary pathway best reflected the content of the studies 
included within the review. 
Development of evidence and gap map 
We used EPPI-Mapper software to organise the systematic reviews identified as relevant to the aims 
of this evidence and gap map (see: Aims and objectives of evidence and gap map).166 In order to 
provide an accessible structure, the systematic review evidence is mapped according to the 
medication of interest it relates to and how each review may be used within the patient care pathway, 
which covers from initial help-seeking and patient consultation through to medication adherence and 
review. Included systematic reviews could occur in multiple places within the evidence map if they 
were applicable to more than one point in the patient care pathway. 
The systematic review evidence displayed on the map can also be filtered according to the various 
categories used during data extraction, including: Aim/focus of the review, type of review, type of 
studies included, synthesis methods, medications of interest, medical condition, Eligible age of 
participants included, PROGRESS criteria, perspectives obtained, experiences, setting/context and 
relevance of review to the overall aim of our evidence and gap map. 
Within each segment of the grid, systematic review evidence is presented in bubbles according to the 
AMSTAR-2 ‘Overall Quality’ rating. The colour and size of the bubble indicates the quality rating (from 




We worked alongside a variety of stakeholders and advisors including clinicians, researchers, 
commissioners and policy makers to ensure our evidence and gap map reflects the needs of 
individuals who will use it. The list of stakeholders who supported this work is listed below and 
details of how their contributions influenced the evidence and gap map are provided in Table 4 . 
List of stakeholders: 
• Nisha Rajendran (Senior Analytical Lead/Epidemiologist, NHS England) 
• Bhavana Reddy (Specialist Pharmacist Adviser, NHS England)  
• David Glover (Medicines Analysis, NHS England and NHS Improvement) 
• Brian Mackenna (Pharmacist, NHS England Medicines and Diagnostics Policy Unit) 
• Jonathan Underhill (Associate Director Medicines Evidence, National Institute of Health and 
Care Excellence) 
• Fizz Annand (Programme Manager, Health Improvement, Alcohol, Drugs, Tobacco & Justice 
Division, Public Health England) 
• Elizabeth Hughes (Deputy Medical Director, Health Education England) 
• Sarah Pontefract (Lecturer in Clinical Pharmacy and Therapeutics, Editorial Lead SCRIPT 
eLearning programme, University of Birmingham) 
• Jamie Coleman (Professor of Clinical Pharmacology and Medical Education, Principle 
Investigator SCRIPT eLearning programme, University of Birmingham) 
Clinical advisor to systematic mapping review: Philip Evans (GP and Associate Professor of General 
Practice and Primary Care, University of Exeter) 
 
 
Table 4: Stakeholder engagement and impact on development of evidence and gap map 
Stage of 
review 
Stakeholder, mode of 
contact 





- Defining our research question 
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- Developing the project protocol, specifically 
enabling us to identify key populations and 
outcome categories to include within our map 
- Finalising search terms for bibliographic 
database searches 
Screening NR, email 
 
- Providing clarification on review inclusion 
criteria 











- Developing the patient care pathway, which 
highlights the key decision making 
opportunities, for patients who are prescribed 





PE, teleconference - Checking what level of information will be 
useful to the intended users of our evidence 
map 
- Ensuring our map of available evidence is 
accessible to our intended audience 
- Checking evidence placed correctly in evidence 
and gap map 
- Providing feedback on preliminary findings. 
Dissemination  - Identifying opportunities for dissemination of 
findings. 
DG=David Glover, FA=Fizz Annand NR=Nisha Rajendran, PE=Philip Evans, SP=Sarah Pontefract 
We also worked alongside people with experience of being prescribed statins, antihypertensives, 
antidepressants and/or DCD. Three 1-1.5 hour meetings were held over Zoom between June 2020 
and December 2020, each with between 3-5 participants. The group were consulted at key points 
during the project’s development, with their feedback incorporated into the following areas of the 
review:  
- Refining and sense checking research questions, 
- Developing our inclusion criteria, 
- Providing insight on how patients may interact with an ‘ideal’ patient care pathway 
based on existing guidelines and/or research for statins, antihypertensives and DCD, 
- Ensuring the information contained in our evidence map is accessible to patients and 
members of the public. 
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Activities which supported the involvement of people with lived experience within this systematic 
mapping review included: 
- A presentation which introduced the background, aims and objectives of this review and 
explained the methods that would be used. This provided the opportunity for the 
research team to ask questions on the extent to which our research questions made 
sense and to listen to people’s experience of taking one or more medications of interest. 
These narratives informed the development of our inclusion criteria and care pathway. 
- Sharing a draft version of the global patient pathway and talking through it, step by step. 
People with lived experience were given the opportunity to ask questions, highlight 
parts of the pathway which didn’t agree with care they had received and identify parts 
of the pathway which were not clear and needed more explanation; 
- Sharing a draft version of the evidence and gap map and requesting feedback regarding 




Appendix A: Search report 
 
Bibliographic database searches 
Drugs that cause dependency 
Database: Cochrane Database of Systematic Reviews 
Host:  Cochrane Library 
Issue:  Issue 8 of 12, August 2020 
Date Searched:  11/8/2020 
Searcher: SB  
Hits: 111 
Strategy:  
#1 (((appropriate* or discontinu* or enhance* or inappropriate* or incorrect* or "in correct*" 
or optim* or safe or suboptim* or "sub optim*" or tapering or withdrawal) NEAR/4 (drug* or 
medicine* or medication* or prescri*))):ti,ab,kw 
#2 MeSH descriptor: [Inappropriate Prescribing] this term only  
#3 MeSH descriptor: [Drug Prescriptions] explode all trees  
#4 (((drug* or guideline* or guidance or medicine* or medication* or patient* or prescri*) 
NEAR/4 (adhere* or compliance or concordance))):ti,ab,kw  
#5 MeSH descriptor: [Patient Compliance] explode all trees  
#6 ((shared or sharing or informed) near/2 (decision* or choice*)):ti,ab,kw  
#7 ((decision near/2 (aid* or support*))):ti,ab,kw  
#8 MeSH descriptor: [Decision Making] this term only 
#9 MeSH descriptor: [Decision Support Techniques] this term only 
#10 (((consumer* or patient*) near/3 (involv* or participat*))):ti,ab,kw 
#11 MeSH descriptor: [Patient Participation] this term only 
#12 ((patient NEXT cent* near/2 (approach* or care or decision* or intervention* or 
treatment*))):ti,ab,kw 
#13 MeSH descriptor: [Patient-Centered Care] this term only 
#14 ((behavi* near/2 chang*)):ti,ab,kw 
#15 ((restriction near/2 (policy or policies))):ti,ab,kw  
#16 {or #1-#15} 
#17 (benzodiazepine*):ti,ab,kw 
#18 ((alprazolam or flunitrazepam or chlordiazepoxide or clobazam or clonazepam or diazepam 
or lorazepam or midazolam or nitrazepam or oxazepam or prazepam or temazepam)):ti,ab,kw 
#19 MeSH descriptor: [Benzodiazepines] explode all trees 
#20 ((antidepres* or "anti depres*")):ti,ab,kw 
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#21 ((serotonin or norepinephrine or noradrenaline or neurotransmitter* or dopamin* or SSRI* 
or SNRI* or NARI* or SARI* or NDRI* or tricyclic* or tetracyclic*)):ti,ab,kw  
#22 MeSH descriptor: [Antidepressive Agents] explode all trees 
#23 ((opioid* or opiate*)):ti,ab,kw 
#24 ((morphine or hydromorphone or levorphanol or meperidine or methadone or 
propoxyphene of codeine or pentazocine or hydrocodone or oxycodone or fentanyl or 
tramadol)):ti,ab,kw 
#25 MeSH descriptor: [Analgesics, Opioid] explode all trees  
#26 ("z drug*"):ti,ab,kw 
#27 ((zopiclone or zolpidem or zaleplon or eszopiclone)):ti,ab,kw 
#28 MeSH descriptor: [Hypnotics and Sedatives] explode all trees 
#29 ((gabapentin* or mirogabalin or phenibut or pregabalin)):ti,ab,kw 
#30 MeSH descriptor: [Gabapentin] this term only 
#31 {or #17-#30} 
#32 #16 AND #31 in Cochrane Reviews [Drugs that cause dependency search results] 
#33 (statin*):ti,ab,kw 
#34 (("reductase inhibitors" or "HMGCR inhibitors")):ti,ab,kw 
#35 MeSH descriptor: [Hydroxymethylglutaryl-CoA Reductase Inhibitors] explode all trees  
#36 ((atorvastatin or Lipitor or Torvast)):ti,ab,kw 
#37 ((fluvastatin or Lescol)):ti,ab,kw  
#38 ((lovastatin or Mevacor or Altocor or Altoprev)):ti,ab,kw  
#39 ((pitavastatin or Livalo or Pitava)):ti,ab,kw 
#40 ((pravastatin or Pravachol or Selektine or Lipostat)):ti,ab,kw  
#41 ((rosuvastatin or Crestor)):ti,ab,kw  
#42 ((simvastatin or Zocor or Lipex)):ti,ab,kw  
#43 (antihypertensive*):ti,ab,kw  
#44 MeSH descriptor: [Antihypertensive Agents] explode all trees 
#45 ((ACE NEXT inhibitor* or antagonist or "angiotensin II receptor" or beta NEXT blocker* or 
calcium NEXT channel NEXT blocker* or thiazide NEXT diuretic*)):ti,ab,kw 
#46 ((acebutolol or adrenomedullin or alprenolol or amlodipine or atenolol or 
bendroflumethiazide or bepridil or betaxolol or bethanidine or bimatoprost or bisoprolol or 
bosentan or "bretylium tosylate" or brimonidine tartrate or bupranolol or captopril or carteolol or 
carvedilol or celiprolol or chlorisondamine or chlorothiazide or chlorthalidone or cilazapril or 
clonidine or cromakalim or cyclopenthiazide or debrisoquin or diazoxide or dihydralazine or 
dihydroalprenolol or diltiazem or doxazosin or enalapril or enalaprilat or eplerenone or epoprostenol 
or felodipine or fenoldopam or fosinopril or guanabenz or guanethidine or guanfacine or 
hexamethonium or "hexamethonium compound*" or hydralazine or hydrochlorothiazide or 
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hydroflumethiazide or indapamide or indoramin or irbesartan or isradipine or kallidin or ketanserin 
or labetalol or latanoprost or lisinopril or losartan or mecamylamine or methyldopa or metipranolol 
or metolazone or metoprolol or mibefradil or minoxidil or muzolimine or nadolol or nebivolol or 
nicardipine or nicorandil or nimodipine or nisoldipine or nitrendipine or nitroprusside or olmesartan 
medoxomil or oxprenolol or pargyline or pempidine or penbutolol or "pentolinium tartrate" or 
perindopril or phenoxybenzamine or phentolamine or pinacidil or pindolol or piperoxan or 
polythiazide or prazosin or propranolol or protoveratrines or quinapril or ramipril or reserpine or 
rilmenidine or telmisartan or teprotide or terlipressin or ticrynafen or timolol or todralazine or 
tolazoline or torsemide or travoprost or trichlormethiazide or trimethaphan or valsartan or 
"veratrum alkaloid*" or vincamine or xipamide)):ti,ab,kw 
#47 (103-#46) 
#48 (cardiovascular):ti,ab,kw 
#49 MeSH descriptor: [Cardiovascular Diseases] explode all trees 
#50 (((cardiac or coronary or heart) near/3 (arrest* or attack* or disease* or failure*))):ti,ab,kw 
#51 ((heart or myocard* or transient) near/3 (infarc* or ischaemi* or ischemi*)):ti,ab,kw  
#52 (angina*):ti,ab,kw 
#53 MeSH descriptor: [Angina Pectoris] this term only 
#54 (stroke*):ti,ab,kw 
#55 MeSH descriptor: [Stroke] explode all trees 
#56 {or #48-#55} 
#57 #16 and #47 and #56 in Cochrane Reviews  [Statins search results] 





Date Searched:  11/8/2020 
Searcher: SB  
Hits:  372 
Strategy 
1. TI ( (appropriate* or discontinu* or enhance* or inappropriate* or incorrect* or "in 
correct*" or optim* or safe or suboptim* or "sub optim*" or tapering or withdrawal) N3 
(drug* or medicine* or medication* or prescri*) ) OR AB ( (appropriate* or discontinu* or 
enhance* or inappropriate* or incorrect* or "in correct*" or optim* or safe or suboptim* or 
"sub optim*" or tapering or withdrawal) N3 (drug* or medicine* or medication* or prescri*) 
) 
2. (MH "Inappropriate Prescribing")  
3. (MM "Prescriptions, Drug+")  
4. TI ( (drug* or guideline* or guidance or medicine* or medication* or patient* or prescri*) N3 
(adhere* or compliance or concordance) ) OR AB ( (drug* or guideline* or guidance or 
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medicine* or medication* or patient* or prescri*) N3 (adhere* or compliance or 
concordance) )  
5. (MM "Patient Compliance+")  
6. TI ( (shared or sharing or informed) N1 (decision* or choice*) ) OR AB ( (shared or sharing or 
informed) N1 (decision* or choice*) )  
7. TI ( decision N1 (aid* or support*) ) OR AB ( decision N1 (aid* or support*) )  
8. (MM "Decision Making")  
9. (MM "Decision Support Techniques")  
10. TI ( (consumer* or patient*) N2 (involv* or participat*) ) OR AB ( (consumer* or patient*) N2 
(involv* or participat*) )  
11. (MM "Consumer Participation")  
12. TI ( "patient cent*" N1 (approach* or care or decision* or intervention* or treatment*) ) OR 
AB ( "patient cent*" N1 (approach* or care or decision* or intervention* or treatment*) )  
13. (MH "Patient Centered Care")  
14. TI (behavi* N1 chang*) OR AB (behavi* N1 chang*)  
15. TI ( restriction N1 (policy or policies) ) OR AB ( restriction N1 (policy or policies) )  
16. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 
OR S15  
17. TI benzodiazepine* OR AB benzodiazepine*  
18. TI ( alprazolam or flunitrazepam or chlordiazepoxide or clobazam or clonazepam or 
diazepam or lorazepam or midazolam or nitrazepam or oxazepam or prazepam or 
temazepam ) OR AB ( alprazolam or flunitrazepam or chlordiazepoxide or clobazam or 
clonazepam or diazepam or lorazepam or midazolam or nitrazepam or oxazepam or 
prazepam or temazepam )  
19. (MH "Antianxiety Agents, Benzodiazepine+")  
20. TI ( antidepres* or "anti depres*" ) OR AB ( antidepres* or "anti depres*" )  
21. TI ( (serotonin or norepinephrine or noradrenaline or neurotransmitter* or dopamin* or 
SSRI* or SNRI* or NARI* or SARI* or NDRI* or tricyclic* or tetracyclic*) ) OR AB ( (serotonin 
or norepinephrine or noradrenaline or neurotransmitter* or dopamin* or SSRI* or SNRI* or 
NARI* or SARI* or NDRI* or tricyclic* or tetracyclic*) )  
22. (MH "Antidepressive Agents+")  
23. TI ( (opioid* or opiate*) ) OR AB ( (opioid* or opiate*) )  
24. TI ( (morphine or hydromorphone or levorphanol or meperidine or methadone or 
propoxyphene of codeine or pentazocine or hydrocodone or oxycodone or fentanyl or 
tramadol) ) OR AB ( (morphine or hydromorphone or levorphanol or meperidine or 
methadone or propoxyphene of codeine or pentazocine or hydrocodone or oxycodone or 
fentanyl or tramadol) )  
25. (MH "Analgesics, Opioid+")  
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26. TI "z drug*" OR AB "z drug*"  
27. TI ( (zopiclone or zolpidem or zaleplon or eszopiclone) ) OR AB ( (zopiclone or zolpidem or 
zaleplon or eszopiclone) )  
28. (MH "Hypnotics and Sedatives")  
29. TI ( (gabapentin* or mirogabalin or phenibut or pregabalin) ) OR AB ( (gabapentin* or 
mirogabalin or phenibut or pregabalin) )  
30. (MH "Gabapentin")  
31. S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR 
S29 OR S30  
32. S16 AND S31   
33. TI statin* OR AB statin*  
34. TI ( "HMG-CoA reductase inhibitor*" or "3-hydroxy-3-methyl-glutaryl-CoA reductase 
inhibitor*" or "3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor*" or "HMGCR 
inhibitor*" or "Hydroxymethylglutaryl-CoA Reductase Inhibitor*" ) OR AB ( "HMG-CoA 
reductase inhibitor*" or "3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor*" or "3-
hydroxy-3-methylglutaryl coenzyme A reductase inhibitor*" or "HMGCR inhibitor*" or 
"Hydroxymethylglutaryl-CoA Reductase Inhibitor*" )  
35. (MH "Statins+")  
36. TI ( atorvastatin or Lipitor or Torvast ) OR AB ( atorvastatin or Lipitor or Torvast )  
37. TI ( fluvastatin or Lescol ) OR AB ( fluvastatin or Lescol )  
38. TI ( lovastatin or Mevacor or Altocor or Altoprev ) OR AB ( lovastatin or Mevacor or Altocor 
or Altoprev )  
39. TI ( pitavastatin or Livalo or Pitava ) OR AB ( pitavastatin or Livalo or Pitava )  
40. TI ( pravastatin or Pravachol or Selektine or Lipostat ) OR AB ( pravastatin or Pravachol or 
Selektine or Lipostat )  
41. TI ( rosuvastatin or Crestor ) OR AB ( rosuvastatin or Crestor )  
42. TI ( simvastatin or Zocor or Lipex ) OR AB ( simvastatin or Zocor or Lipex )  
43. TI antihypertensive* OR AB antihypertensive*  
44. (MH "Antihypertensive Agents+")  
45. TI ( "ACE inhibitor*" or antagonist or "angiotensin II receptor" or "beta blocker*" or "calcium 
channel blocker*" or "thiazide diuretic*" ) OR AB ( "ACE inhibitor*" or antagonist or 
"angiotensin II receptor" or "beta blocker*" or "calcium channel blocker*" or "thiazide 
diuretic*" )  
46. TI ( acebutolol or adrenomedullin or alprenolol or amlodipine or atenolol or 
bendroflumethiazide or bepridil or betaxolol or bethanidine or bimatoprost or bisoprolol or 
bosentan or "bretylium tosylate" or brimonidine tartrate or bupranolol or captopril or 
carteolol or carvedilol or celiprolol or chlorisondamine or chlorothiazide or chlorthalidone or 
cilazapril or clonidine or cromakalim or cyclopenthiazide or debrisoquin or diazoxide or 
dihydralazine or dihydroalprenolol or diltiazem or doxazosin or enalapril or enalaprilat or 
eplerenone or epoprostenol or felodipine or fenoldopam or fosinopril or guanabenz or 
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guanethidine or guanfacine or hexamethonium or "hexamethonium compound*" or 
hydralazine or hydrochlorothiazide or hydroflumethiazide or indapamide or indoramin or 
irbesartan or isradipine or kallidin or ketanserin or labetalol or latanoprost or lisinopril or 
losartan or mecamylamine or methyldopa or metipranolol or metolazone or metoprolol or 
mibefradil or minoxidil or muzolimine or nadolol or nebivolol or nicardipine or nicorandil or 
nimodipine or nisoldipine or nitrendipine or nitroprusside or olmesartan medoxomil or 
oxprenolol or pargyline or pempidine or penbutolol or "pentolinium tartrate" or perindopril 
or phenoxybenzamine or phentolamine or pinacidil or pindolol or piperoxan or polythiazide 
or prazosin or propranolol or protoveratrines or quinapril or ramipril or reserpine or 
rilmenidine or telmisartan or teprotide or terlipressin or ticrynafen or timolol or todralazine 
or tolazoline or torsemide or travoprost or trichlormethiazide or trimethaphan or valsartan 
or "veratrum alkaloid*" or vincamine or xipamide ) OR AB ( acebutolol or adrenomedullin or 
alprenolol or amlodipine or atenolol or bendroflumethiazide or bepridil or betaxolol or 
bethanidine or bimatoprost or bisoprolol or bosentan or "bretylium tosylate" or brimonidine 
tartrate or bupranolol or captopril or carteolol or carvedilol or celiprolol or chlorisondamine 
or chlorothiazide or chlorthalidone or cilazapril or clonidine or cromakalim or 
cyclopenthiazide or debrisoquin or diazoxide or dihydralazine or dihydroalprenolol or 
diltiazem or doxazosin or enalapril or enalaprilat or eplerenone or epoprostenol or 
felodipine or fenoldopam or fosinopril or guanabenz or guanethidine or guanfacine or 
hexamethonium or "hexamethonium compound*" or hydralazine or hydrochlorothiazide or 
hydroflumethiazide or indapamide or indoramin or irbesartan or isradipine or kallidin or 
ketanserin or labetalol or latanoprost or lisinopril or losartan or mecamylamine or 
methyldopa or metipranolol or metolazone or metoprolol or mibefradil or minoxidil or 
muzolimine or nadolol or nebivolol or nicardipine or nicorandil or nimodipine or nisoldipine 
or nitrendipine or nitroprusside or olmesartan medoxomil or oxprenolol or pargyline or 
pempidine or penbutolol or "pentolinium tartrate" or perindopril or phenoxybenzamine or 
phentolamine or pinacidil or pindolol or piperoxan or polythiazide or prazosin or propranolol 
or protoveratrines or quinapril or ramipril or reserpine or rilmenidine or telmisartan or 
teprotide or terlipressin or ticrynafen or timolol or todralazine or tolazoline or torsemide or 
travoprost or trichlormethiazide or trimethaphan or valsartan or "veratrum alkaloid*" or 
vincamine or xipamide ) 
47. S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR 
S45 OR S46  
48. TI cardiovascular OR AB cardiovascular  
49. (MH "Cardiovascular Diseases+")  
50. TI ( (cardiac or coronary or heart) N2 (arrest* or attack* or disease* or failure*) ) OR AB ( 
(cardiac or coronary or heart) N2 (arrest* or attack* or disease* or failure*) )  
51. TI ( (heart or myocard* or transient) N2 (infarc* or ischaemi* or ischemi*) ) OR AB ( (heart or 
myocard* or transient) N2 (infarc* or ischaemi* or ischemi*) )  
52. TI angina* OR AB angina*  
53. (MH "Angina Pectoris")  
54. TI stroke* OR AB stroke*  
55. (MH "Stroke+")  
56. S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55  
57. S16 AND S47 AND S56  
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58. TI ( (effectiveness or implementation or literature or map or mapping or qualitative or rapid 
or realist or systematic or scoping or "state of the art" or umbrella) N1 (assessment* or 
overview* or review* or synthes*) ) OR AB ( (effectiveness or implementation or literature 
or map or mapping or qualitative or rapid or realist or systematic or scoping or "state of the 
art" or umbrella) N1 (assessment* or overview* or review* or synthes*) )  
59. TI ( "meta analy*" or metaanaly* or metasynthe* or "meta synthe*" ) OR AB ( "meta analy*" 
or metaanaly* or metasynthe* or "meta synthe*" )  
60. TI ( (systematic or evidence) N0 assess* ) OR AB ( (systematic or evidence) N0 assess* )  
61. TI ( qualitative N1 (evidence or synthes*) ) OR AB ( qualitative N1 (evidence or synthes*) )  
62. TI overarching N1 model OR AB overarching N1 model  
63. TI "review* of reviews" OR AB "review* of reviews"  
64. S58 OR S59 OR S60 OR S61 OR S62 OR S63  
65. S32 AND S64  [Drugs that cause dependency search results] 
66. S57 AND S64 [Statins search results] 
Notes: Date limited 2010 to date of search. 
 
Database: Epistemonikos   
Host: https://www.epistemonikos.org/en/ 
Issue:  n/a 
Date Searched: 12/8/2020 
Searcher: SB  
Hits: 56 
Strategy 
1. title:(prescription* OR prescribing OR prescribe*) OR abstract:(prescription* OR prescribing 
OR prescribe*)  
2. title:(optimi* OR inappropriat* OR enhance*) OR abstract:(optimi* OR inappropriat* OR 
enhance*)  
3. title:(benzodiazepine*) OR abstract:(benzodiazepine*) OR title:(antidepres* OR "anti 
depres*") OR abstract:(antidepres* OR "anti depres*") OR title:(opioid* OR opiate*) OR 
abstract:(opioid* OR opiate*) OR title:("z drug*") OR abstract:("z drug*") OR 
title:(gabapentin*) OR abstract:(gabapentin*) 
4. 1 AND 2 AND 3 
Notes: Date limited 2010 to 2020. 
 
Database:  medRxiv 
Host: 12/8/2020 
Issue: n/a 
Date Searched:  





optimi* and prescri* and benzodiazepine * 5 hits 
optimi* and prescri* and antidepres*  5 hits 
optimi* and prescri* and opioid*  11 hits 
optimi* and prescri* and "z drug*  66 hits 




Issue: 1974 to 2020 August 10 
Date Searched: 11/8/2020 
Searcher: SB  
Hits: 1776 
Strategy: 
1. ((appropriate* or discontinu* or enhance* or inappropriate* or incorrect* or "in correct*" 
or optim* or safe or suboptim* or "sub optim*" or tapering or withdrawal) adj4 (drug* or 
medicine* or medication* or prescri*)).tw. 
2. exp *inappropriate prescribing/ 
3. *prescription/ 
4. ((drug* or guideline* or guidance or medicine* or medication* or patient* or prescri*) adj4 
(adhere* or compliance or concordance)).tw. 
5. exp *patient compliance/ 
6. medication compliance/ 
7. ((shared or sharing or informed) adj2 (decision* or choice*)).tw. 
8. (decision adj2 (aid* or support*)).tw. 
9. exp *decision making/ 
10. exp *decision support system/ 
11. ((consumer* or patient*) adj3 (involv* or participat*)).tw. 
12. *patient participation/ 
13. ("patient cent*" adj2 (approach* or care or decision* or intervention* or treatment*)).tw. 
14. *patient care/ 
15. (behavi* adj2 chang*).tw. 
16. *behavior change/ 
17. (restriction adj2 (policy or policies)).tw. 
18. or/1-17 
19. benzodiazepine*.tw. 
20. (alprazolam or flunitrazepam or chlordiazepoxide or clobazam or clonazepam or diazepam 
or lorazepam or midazolam or nitrazepam or oxazepam or prazepam or temazepam).tw. 
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21. exp benzodiazepine derivative/ 
22. (antidepres* or "anti depres*").tw. 
23. (serotonin or norepinephrine or noradrenaline or neurotransmitter* or dopamin* or SSRI* 
or SNRI* or NARI* or SARI* or NDRI* or tricyclic* or tetracyclic*).tw. 
24. exp antidepressant agent/ 
25. (opioid* or opiate*).tw. 
26. (morphine or hydromorphone or levorphanol or meperidine or methadone or propoxyphene 
of codeine or pentazocine or hydrocodone or oxycodone or fentanyl or tramadol).tw. 
27. exp opiate/ 
28. "z drug*".tw. 
29. (zopiclone or zolpidem or zaleplon or eszopiclone).tw. 
30. hypnotic agent/ 
31. sedative agent/ 
32. (gabapentin* or mirogabalin or phenibut or pregabalin).tw. 
33. gabapentin/ 
34. or/19-33 
35. 18 and 34 
36. statin*.tw. 
37. ("HMG-CoA reductase inhibitor*" or "3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor*" 
or "3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor*" or "HMGCR inhibitor*" or 
"Hydroxymethylglutaryl-CoA Reductase Inhibitor*").tw. 
38. "statin (protein)"/ 
39. (atorvastatin or Lipitor or Torvast).tw. 
40. (fluvastatin or Lescol).tw. 
41. (lovastatin or Mevacor or Altocor or Altoprev).tw. 
42. (pitavastatin or Livalo or Pitava).tw. 
43. (pravastatin or Pravachol or Selektine or Lipostat).tw. 
44. (rosuvastatin or Crestor).tw. 
45. (simvastatin or Zocor or Lipex).tw. 
46. antihypertensive*.tw. 
47. exp antihypertensive agent/ 
48. ("ACE inhibitor*" or antagonist or "angiotensin II receptor" or "beta blocker*" or "calcium 
channel blocker*" or "thiazide diuretic*").tw. 
49. (acebutolol or adrenomedullin or alprenolol or amlodipine or atenolol or 
bendroflumethiazide or bepridil or betaxolol or bethanidine or bimatoprost or bisoprolol or 
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bosentan or "bretylium tosylate" or brimonidine tartrate or bupranolol or captopril or 
carteolol or carvedilol or celiprolol or chlorisondamine or chlorothiazide or chlorthalidone or 
cilazapril or clonidine or cromakalim or cyclopenthiazide or debrisoquin or diazoxide or 
dihydralazine or dihydroalprenolol or diltiazem or doxazosin or enalapril or enalaprilat or 
eplerenone or epoprostenol or felodipine or fenoldopam or fosinopril or guanabenz or 
guanethidine or guanfacine or hexamethonium or "hexamethonium compound*" or 
hydralazine or hydrochlorothiazide or hydroflumethiazide or indapamide or indoramin or 
irbesartan or isradipine or kallidin or ketanserin or labetalol or latanoprost or lisinopril or 
losartan or mecamylamine or methyldopa or metipranolol or metolazone or metoprolol or 
mibefradil or minoxidil or muzolimine or nadolol or nebivolol or nicardipine or nicorandil or 
nimodipine or nisoldipine or nitrendipine or nitroprusside or olmesartan medoxomil or 
oxprenolol or pargyline or pempidine or penbutolol or "pentolinium tartrate" or perindopril 
or phenoxybenzamine or phentolamine or pinacidil or pindolol or piperoxan or polythiazide 
or prazosin or propranolol or protoveratrines or quinapril or ramipril or reserpine or 
rilmenidine or telmisartan or teprotide or terlipressin or ticrynafen or timolol or todralazine 
or tolazoline or torsemide or travoprost or trichlormethiazide or trimethaphan or valsartan 
or "veratrum alkaloid*" or vincamine or xipamide).tw. 
50. or/36-49 
51. cardiovascular.tw. 
52. exp cardiovascular disease/ 
53. ((cardiac or coronary or heart) adj3 (arrest* or attack* or disease* or failure*)).tw. 
54. ((heart or myocard* or transient) adj3 (infarc* or ischaemi* or ischemi*)).tw. 
55. angina*.tw. 
56. Angina Pectoris/ 
57. stroke*.tw. 
58. exp cerebrovascular accident/ 
59. or/51-58 
60. 18 and 50 and 59 
61. ((effectiveness or implementation or literature or map or mapping or qualitative or rapid or 
realist or systematic or scoping or "state of the art" or umbrella) adj2 (assessment* or 
overview* or review* or synthes*)).tw. 
62. ("meta analy*" or metaanaly* or metasynthe* or "meta synthe*").tw. 
63. ((systematic or evidence) adj1 assess*).tw. 
64. (qualitative adj2 (evidence or synthes*)).tw. 
65. (overarching adj2 model).tw. 
66. "review* of reviews".tw. 
67. or/61-66 
68. 35 and 67 [Drugs that cause dependency search results] 
69. 60 and 67 [Statins search results] 
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Notes: Date limited 2010 to date of search. 
 
Database: Health Management Information Consortium 
Host: Ovid 
Issue:  1979 to July 2020 
Date Searched: 11/8/2020 
Searcher: SB  
Hits: 10 




Issue: 1946 to August 10, 2020 
Date Searched: 11/8/2020  
Searcher: SB  
Hits: 875 
Strategy: 
1. ((appropriate* or discontinu* or enhance* or inappropriate* or incorrect* or "in correct*" 
or optim* or safe or suboptim* or "sub optim*" or tapering or withdrawal) adj4 (drug* or 
medicine* or medication* or prescri*)).tw. 
2. Inappropriate Prescribing/ 
3. exp *Drug Prescriptions/ 
4. ((drug* or guideline* or guidance or medicine* or medication* or patient* or prescri*) adj4 
(adhere* or compliance or concordance)).tw. 
5. exp *Patient Compliance/ 
6. ((shared or sharing or informed) adj2 (decision* or choice*)).tw. 
7. (decision adj2 (aid* or support*)).tw. 
8. *Decision Making/ 
9. *decision support techniques/ 
10. ((consumer* or patient*) adj3 (involv* or participat*)).tw. 
11. *patient participation/ 
12. ("patient cent*" adj2 (approach* or care or decision* or intervention* or treatment*)).tw. 
13. Patient-Centered Care/ 
14. (behavi* adj2 chang*).tw. 
15. (restriction adj2 (policy or policies)).tw. 
16. or/1-15 
17. benzodiazepine*.tw. 
18. (alprazolam or flunitrazepam or chlordiazepoxide or clobazam or clonazepam or diazepam 
or lorazepam or midazolam or nitrazepam or oxazepam or prazepam or temazepam).tw. 
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19. exp Benzodiazepines/ 
20. (antidepres* or "anti depres*").tw. 
21. (serotonin or norepinephrine or noradrenaline or neurotransmitter* or dopamin* or SSRI* 
or SNRI* or NARI* or SARI* or NDRI* or tricyclic* or tetracyclic*).tw. 
22. exp Antidepressive Agents/ 
23. (opioid* or opiate*).tw. 
24. (morphine or hydromorphone or levorphanol or meperidine or methadone or propoxyphene 
of codeine or pentazocine or hydrocodone or oxycodone or fentanyl or tramadol).tw. 
25. exp Analgesics, Opioid/ 
26. "z drug*".tw. 
27. (zopiclone or zolpidem or zaleplon or eszopiclone).tw. 
28. exp "hypnotics and sedatives"/ 
29. (gabapentin* or mirogabalin or phenibut or pregabalin).tw. 
30. Gabapentin/ 
31. or/17-30 
32. 16 and 31 
33. statin*.tw. 
34. ("HMG-CoA reductase inhibitor*" or "3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor*" 
or "3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor*" or "HMGCR inhibitor*" or 
"Hydroxymethylglutaryl-CoA Reductase Inhibitor*").tw. 
35. exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/ 
36. (atorvastatin or Lipitor or Torvast).tw. 
37. (fluvastatin or Lescol).tw. 
38. (lovastatin or Mevacor or Altocor or Altoprev).tw. 
39. (pitavastatin or Livalo or Pitava).tw. 
40. (pravastatin or Pravachol or Selektine or Lipostat).tw. 
41. (rosuvastatin or Crestor).tw. 
42. (simvastatin or Zocor or Lipex).tw. 
43. antihypertensive*.tw. 
44. exp Antihypertensive Agents/ 
45. ("ACE inhibitor*" or antagonist or "angiotensin II receptor" or "beta blocker*" or "calcium 
channel blocker*" or "thiazide diuretic*").tw. 
46. (acebutolol or adrenomedullin or alprenolol or amlodipine or atenolol or 
bendroflumethiazide or bepridil or betaxolol or bethanidine or bimatoprost or bisoprolol or 
bosentan or "bretylium tosylate" or brimonidine tartrate or bupranolol or captopril or 
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carteolol or carvedilol or celiprolol or chlorisondamine or chlorothiazide or chlorthalidone or 
cilazapril or clonidine or cromakalim or cyclopenthiazide or debrisoquin or diazoxide or 
dihydralazine or dihydroalprenolol or diltiazem or doxazosin or enalapril or enalaprilat or 
eplerenone or epoprostenol or felodipine or fenoldopam or fosinopril or guanabenz or 
guanethidine or guanfacine or hexamethonium or "hexamethonium compound*" or 
hydralazine or hydrochlorothiazide or hydroflumethiazide or indapamide or indoramin or 
irbesartan or isradipine or kallidin or ketanserin or labetalol or latanoprost or lisinopril or 
losartan or mecamylamine or methyldopa or metipranolol or metolazone or metoprolol or 
mibefradil or minoxidil or muzolimine or nadolol or nebivolol or nicardipine or nicorandil or 
nimodipine or nisoldipine or nitrendipine or nitroprusside or olmesartan medoxomil or 
oxprenolol or pargyline or pempidine or penbutolol or "pentolinium tartrate" or perindopril 
or phenoxybenzamine or phentolamine or pinacidil or pindolol or piperoxan or polythiazide 
or prazosin or propranolol or protoveratrines or quinapril or ramipril or reserpine or 
rilmenidine or telmisartan or teprotide or terlipressin or ticrynafen or timolol or todralazine 
or tolazoline or torsemide or travoprost or trichlormethiazide or trimethaphan or valsartan 
or "veratrum alkaloid*" or vincamine or xipamide).tw. 
47. or/33-46 
48. cardiovascular.tw. 
49. exp Cardiovascular Diseases/ 
50. ((cardiac or coronary or heart) adj3 (arrest* or attack* or disease* or failure*)).tw. 
51. ((heart or myocard* or transient) adj3 (infarc* or ischaemi* or ischemi*)).tw. 
52. angina*.tw. 
53. Angina Pectoris/ 
54. stroke*.tw. 
55. exp Stroke/ 
56. or/48-55 
57. 16 and 47 and 56 
58. ((effectiveness or implementation or literature or map or mapping or qualitative or rapid or 
realist or systematic or scoping or "state of the art" or umbrella) adj2 (assessment* or 
overview* or review* or synthes*)).tw. 
59. ("meta analy*" or metaanaly* or metasynthe* or "meta synthe*").tw. 
60. ((systematic or evidence) adj1 assess*).tw. 
61. (qualitative adj2 (evidence or synthes*)).tw. 
62. (overarching adj2 model).tw. 
63. "review* of reviews".tw. 
64. systematic review.pt. 
65. meta-analysis.pt. 
66. or/58-65 
67. 32 and 66 [Drugs that cause dependency search results] 
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68. 57 and 66 [Statins search results] 




Issue:  1806 to August Week 1 2020 
Date Searched: 11/8/2020 
Searcher: SB  
Hits: 297  
Strategy 
1. ((appropriate* or discontinu* or enhance* or inappropriate* or incorrect* or "in correct*" 
or optim* or safe or suboptim* or "sub optim*" or tapering or withdrawal) adj4 (drug* or 
medicine* or medication* or prescri*)).tw. 
2. prescription drug misuse/ 
3. exp "prescribing (drugs)"/ 
4. ((drug* or guideline* or guidance or medicine* or medication* or patient* or prescri*) adj4 
(adhere* or compliance or concordance)).tw. 
5. *treatment compliance/ 
6. ((shared or sharing or informed) adj2 (decision* or choice*)).tw. 
7. (decision adj2 (aid* or support*)).tw. 
8. Decision Making/ 
9. ((consumer* or patient*) adj3 (involv* or participat*)).tw. 
10. patient participation/ 
11. ("patient cent*" adj2 (approach* or care or decision* or intervention* or treatment*)).tw. 
12. (behavi* adj2 chang*).ti,ab. 
13. exp behavior change/ 
14. (restriction adj2 (policy or policies)).tw. 
15. or/1-14 
16. benzodiazepine*.tw. 
17. (alprazolam or flunitrazepam or chlordiazepoxide or clobazam or clonazepam or diazepam 
or lorazepam or midazolam or nitrazepam or oxazepam or prazepam or temazepam).tw. 
18. exp Benzodiazepines/ 
19. (antidepres* or "anti depres*").tw. 
20. (serotonin or norepinephrine or noradrenaline or neurotransmitter* or dopamin* or SSRI* 
or SNRI* or NARI* or SARI* or NDRI* or tricyclic* or tetracyclic*).tw. 
21. exp antidepressant drugs/ 
22. (opioid* or opiate*).tw. 
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23. (morphine or hydromorphone or levorphanol or meperidine or methadone or propoxyphene 
of codeine or pentazocine or hydrocodone or oxycodone or fentanyl or tramadol).tw. 
24. exp opiates/ 
25. "z drug*".tw. 
26. (zopiclone or zolpidem or zaleplon or eszopiclone).tw. 
27. exp hypnotic drugs/ 
28. exp sedatives/ 
29. (gabapentin* or mirogabalin or phenibut or pregabalin).tw. 
30. Gabapentin/ 
31. or/16-30 
32. 15 and 31 
33. statin*.tw. 
34. ("HMG-CoA reductase inhibitor*" or "3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor*" 
or "3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor*" or "HMGCR inhibitor*" or 
"Hydroxymethylglutaryl-CoA Reductase Inhibitor*").tw. 
35. statins/ 
36. (atorvastatin or Lipitor or Torvast).tw. 
37. (fluvastatin or Lescol).tw. 
38. (lovastatin or Mevacor or Altocor or Altoprev).tw. 
39. (pitavastatin or Livalo or Pitava).tw. 
40. (pravastatin or Pravachol or Selektine or Lipostat).tw. 
41. (rosuvastatin or Crestor).tw. 
42. (simvastatin or Zocor or Lipex).tw. 
43. antihypertensive*.tw. 
44. exp antihypertensive drugs/ 
45. ("ACE inhibitor*" or antagonist or "angiotensin II receptor" or "beta blocker*" or "calcium 
channel blocker*" or "thiazide diuretic*").tw. 
46. (acebutolol or adrenomedullin or alprenolol or amlodipine or atenolol or 
bendroflumethiazide or bepridil or betaxolol or bethanidine or bimatoprost or bisoprolol or 
bosentan or "bretylium tosylate" or brimonidine tartrate or bupranolol or captopril or 
carteolol or carvedilol or celiprolol or chlorisondamine or chlorothiazide or chlorthalidone or 
cilazapril or clonidine or cromakalim or cyclopenthiazide or debrisoquin or diazoxide or 
dihydralazine or dihydroalprenolol or diltiazem or doxazosin or enalapril or enalaprilat or 
eplerenone or epoprostenol or felodipine or fenoldopam or fosinopril or guanabenz or 
guanethidine or guanfacine or hexamethonium or "hexamethonium compound*" or 
hydralazine or hydrochlorothiazide or hydroflumethiazide or indapamide or indoramin or 
irbesartan or isradipine or kallidin or ketanserin or labetalol or latanoprost or lisinopril or 
losartan or mecamylamine or methyldopa or metipranolol or metolazone or metoprolol or 
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mibefradil or minoxidil or muzolimine or nadolol or nebivolol or nicardipine or nicorandil or 
nimodipine or nisoldipine or nitrendipine or nitroprusside or olmesartan medoxomil or 
oxprenolol or pargyline or pempidine or penbutolol or "pentolinium tartrate" or perindopril 
or phenoxybenzamine or phentolamine or pinacidil or pindolol or piperoxan or polythiazide 
or prazosin or propranolol or protoveratrines or quinapril or ramipril or reserpine or 
rilmenidine or telmisartan or teprotide or terlipressin or ticrynafen or timolol or todralazine 
or tolazoline or torsemide or travoprost or trichlormethiazide or trimethaphan or valsartan 
or "veratrum alkaloid*" or vincamine or xipamide).tw. 
47. or/33-46 
48. cardiovascular.tw. 
49. exp cardiovascular disorders/ 
50. ((cardiac or coronary or heart) adj3 (arrest* or attack* or disease* or failure*)).tw. 
51. ((heart or myocard* or transient) adj3 (infarc* or ischaemi* or ischemi*)).tw. 
52. angina*.tw. 
53. Angina Pectoris/ 
54. stroke*.tw. 
55. exp cerebral ischemia/ 
56. or/48-55 
57. 15 and 47 and 56 
58. ((effectiveness or implementation or literature or map or mapping or qualitative or rapid or 
realist or systematic or scoping or "state of the art" or umbrella) adj2 (assessment* or 
overview* or review* or synthes*)).tw. 
59. ("meta analy*" or metaanaly* or metasynthe* or "meta synthe*").tw. 
60. ((systematic or evidence) adj1 assess*).tw. 
61. (qualitative adj2 (evidence or synthes*)).tw. 
62. (overarching adj2 model).tw. 
63. "review* of reviews".tw. 
64. systematic review.pt. 
65. meta-analysis.pt. 
66. or/58-65 
67. 32 and 66 [Drugs that cause dependency search results] 
68. 57 and 66 [Statins search results] 
Notes: Date limited 2010 to date of search. 
Database: Conference Proceedings Citation Index – Science (CPCI-S); Science Citation Index (SCI) 
Host: Web of Science via Clarivate Analytics 
Issue:  n/a 
Date Searched: 11/8/2020  
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Searcher: SB  
Hits: 1030 
Strategy: 
1. TOPIC =((appropriate* or  discontinu*  or  enhance*  or  inappropriate*  or  incorrect*  or  
"in  correct*"  or  optim*  or  safe  or  suboptim*  or  "sub  optim*"  or  tapering  or  
withdrawal)  near/3  (drug* or medicine* or medication* or prescri*) )  
2. TOPIC =((drug* or  guideline*  or  guidance  or  medicine*  or  medication*  or  patient*  or  
prescri*)  near/3  (adhere* or compliance or concordance) )  
3. TOPIC =((shared or  sharing  or  informed)  near/1  (decision* or choice*) )  
4. TOPIC =((consumer* or  patient*)  near/2  (involv* or participat*) )  
5. TOPIC =("patient cent*"  near/1  (approach* or care or decision* or intervention* or 
treatment*) )  
6. TOPIC =(decision near/1  (aid* or support*) )  
7. TOPIC =(behavi* near/1  chang*)  
8. TOPIC =(restriction near/1  (policy or policies) )  
9. #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1  
10. TOPIC:  (benzodiazepine*)  
11. TOPIC:  ((alprazolam or flunitrazepam or chlordiazepoxide or clobazam or clonazepam or 
diazepam or lorazepam or midazolam or nitrazepam or oxazepam or prazepam or 
temazepam) )  
12. TOPIC:  ((antidepres* or "anti depres*") )  
13. TOPIC:  ((serotonin or norepinephrine or noradrenaline or neurotransmitter* or dopamin* 
or SSRI* or SNRI* or NARI* or SARI* or NDRI* or tricyclic* or tetracyclic*) )  
14. TOPIC:  ((opioid* or opiate*) )  
15. TOPIC:  ((morphine or hydromorphone or levorphanol or meperidine or methadone or 
propoxyphene of codeine or pentazocine or hydrocodone or oxycodone or fentanyl or 
tramadol) )  
16. TOPIC:  ("z drug*")  
17. TOPIC:  ((zopiclone or zolpidem or zaleplon or eszopiclone) )  
18. TOPIC:  ((gabapentin* or mirogabalin or phenibut or pregabalin) ) 
19. #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10  
20. #19 AND #9  
21. TOPIC:  (statin*)  
22. TOPIC:  ("HMG-CoA reductase inhibitor*" or "3-hydroxy-3-methyl-glutaryl-CoA reductase 
inhibitor*" or "3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor*" or "HMGCR 
inhibitor*" or "Hydroxymethylglutaryl-CoA Reductase Inhibitor*")  
23. TOPIC:  (atorvastatin or Lipitor or Torvast)  
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24. TOPIC:  (fluvastatin or Lescol)  
25. TOPIC:  (lovastatin or Mevacor or Altocor or Altoprev)  
26. TOPIC:  (pitavastatin or Livalo or Pitava)  
27. TOPIC:  (pravastatin or Pravachol or Selektine or Lipostat)  
28. TOPIC:  (rosuvastatin or Crestor)  
29. TOPIC:  (simvastatin or Zocor or Lipex)  
30. TOPIC:  (antihypertensive*)  
31. TOPIC:  ("ACE inhibitor*" or antagonist or "angiotensin II receptor" or "beta blocker*" or 
"calcium channel blocker*" or "thiazide diuretic*")  
32. TOPIC:  (acebutolol or adrenomedullin or alprenolol or amlodipine or atenolol or 
bendroflumethiazide or bepridil or betaxolol or bethanidine or bimatoprost or bisoprolol or 
bosentan or "bretylium tosylate" or brimonidine tartrate or bupranolol or captopril or 
carteolol or carvedilol or celiprolol or chlorisondamine or chlorothiazide or chlorthalidone or 
cilazapril or clonidine or cromakalim or cyclopenthiazide or debrisoquin or diazoxide or 
dihydralazine or dihydroalprenolol or diltiazem or doxazosin or enalapril or enalaprilat or 
eplerenone or epoprostenol or felodipine or fenoldopam or fosinopril or guanabenz or 
guanethidine or guanfacine or hexamethonium or "hexamethonium compound*" or 
hydralazine or hydrochlorothiazide or hydroflumethiazide or indapamide or indoramin or 
irbesartan or isradipine or kallidin or ketanserin or labetalol or latanoprost or lisinopril or 
losartan or mecamylamine or methyldopa or metipranolol or metolazone or metoprolol or 
mibefradil or minoxidil or muzolimine or nadolol or nebivolol or nicardipine or nicorandil or 
nimodipine or nisoldipine or nitrendipine or nitroprusside or olmesartan medoxomil or 
oxprenolol or pargyline or pempidine or penbutolol or "pentolinium tartrate" or perindopril 
or phenoxybenzamine or phentolamine or pinacidil or pindolol or piperoxan or polythiazide 
or prazosin or propranolol or protoveratrines or quinapril or ramipril or reserpine or 
rilmenidine or telmisartan or teprotide or terlipressin or ticrynafen or timolol or todralazine 
or tolazoline or torsemide or travoprost or trichlormethiazide or trimethaphan or valsartan 
or "veratrum alkaloid*" or vincamine or xipamide)  
33. #32 OR #31 OR #30 OR #29 OR #28 OR #27 OR #26 OR #25 OR #24 OR #23 OR #22 OR #21  
34. TOPIC =((cardiac or  coronary  or  heart)  near/2  (arrest* or attack* or disease* or failure*) ) 
35. TOPIC:  (cardiovascular)  
36. TS=((heart or  myocard* or transient)  near/2  (infarc* or ischaemi* or ischemi*) )  
37. TOPIC =angina*  
38. TOPIC =stroke*  
39. #38 OR #37 OR #36 OR #35 OR #34 
40. TOPIC =((effectiveness or  implementation  or  literature  or  map  or  mapping  or  
qualitative  or  rapid  or  realist  or  systematic  or  scoping  or  "state  of  the  art"  or  
umbrella)  near/1  (assessment* or overview* or review* or synthes*) )  
41. TOPIC =("meta analy*"  or  metaanaly*  or  metasynthe*  or  "meta  synthe*")  
42. TOPIC =((systematic or evidence)  near/0  assess*)  
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43. TOPIC =(qualitative near/1 (evidence or synthes*) )  
44. TOPIC =(overarching near/1  model)  
45. TOPIC ="review* of reviews"  
46. #45 OR #44 OR #43 OR #42 OR #41 OR #40 
47. #46 AND #20    [Drugs that cause dependency search results] 
48. #46 AND #39 AND #33 AND #9 [Statins search results] 
 
Table 5: Drugs that can cause dependency and antidepressant search results 
Database Hits 








Web of Science (CPCI-S/SCI) 1030 
TOTAL RECORDS 4614 
DUPLICATE RECORDS 1898 
UNIQUE RECORDS 2716 
 
Statins 
Database: Cochrane Database of Systematic Reviews 
Host:  Cochrane Library 
Issue: Issue 8 of 12, August 2020 
Date Searched: 10/8/2020 
Searcher: SB  
Hits: 33 
Strategy: see line 57 of Cochrane Database search above. 
Notes: date limited 2010 to date of search. 
Database: CINAHL 
Host: EBSCO 
Issue:  n/a 
Date Searched: 10/8/2020 




Strategy: see line 66 of CINAHL search above. 
Notes: Date limited 2010 to date of search. 
Database: Epistemonikos   
Host: https://www.epistemonikos.org/en/ 
Issue: n/a 
Date Searched:  10/8/2020 
Searcher: SB  
Hits: 16 
Strategy: 
1. title:(prescription* OR prescribing OR prescribe*) OR abstract:(prescription* OR prescribing 
OR prescribe*)  
2. title:(optimi* OR inappropriat* OR enhance*) OR abstract:(optimi* OR inappropriat* OR 
enhance*)  
3. title:(statin*) OR abstract:(statin*) OR title:(antihypertensive*) OR 
abstract:(antihypertensive*) 
4. 1 AND 2 AND 3 [Statins search results] 
Notes: Date limited 2010 to 2020 and limited to systematic reviews publication type. 
Database:  medRxiv 
Host: https://www.medrxiv.org/ 
Issue: n/a 
Date Searched: 10/8/2020 




optimi* and prescri* and statin*  7 hits 
optimi* and prescri* and antihypertensive* 1 hit 




Issue: 1974 to 2020 August 07 
Date Searched: 10/8/2020 
Searcher: SB  
Hits: 903 
Strategy: see line 69 of Embase search above. 
Notes: Date limited 2010 to date of search. 
Database: HMIC 
Host: Ovid 
Issue: 1979 to May 2020 
Date Searched: 10/8/2020 
Searcher: SB  
Hits: 0 
Strategy: see line 68 of MEDLINE search strategy above. 
Notes: Date limited 2010 to date of search. 
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Database: MEDLINE ALL 
Host: Ovid 
Issue: 1946 to August 07, 2020 
Date Searched: 10/8/2020 
Searcher: SB  
Hits: 371 
Strategy: see line 68 of MEDLINE search strategy above. 
Notes: Date limited 2010 to date of search. 
Database: PsycInfo 
Host: Ovid 
Issue: 1806 to August Week 1 2020 
Date Searched: 10/8/2020 
Searcher: SB  
Hits: 17  
Strategy: see line 68 of PsycInfo search strategy above. 
Notes: Date limited 2010 to date of search. 
Database: Conference Proceedings Citation Index – Science (CPCI-S); Science Citation Index (SCI) 
Host: Web of Science via Clarivate Analytics 
Issue:  n/a 
Date Searched: 10/8/2020  
Searcher: SB  
Hits: 638 
Strategy: see line 48 of CPCI-S/SCI search strategy above. 
 
Table 6: Statin search results 
Database Hits 








Web of Science (CPCI-S/SCI) 638 
TOTAL RECORDS 2159 
DUPLICATE RECORDS 714 






Website: Royal Pharmaceutical Society Library Catalogue   
URL: https://rpsgb.koha-ptfs.co.uk/  
Date Searched: 21/10/2020  
Searcher: SB 
Hits: 73 hits 
Strategy:  
Advanced search setting. 
Keyword:  opioid*   OR 
Keyword:  benzodiazepine*  OR 
Keyword:  antidepressant*   OR 
Keyword:  gabapentinoid* 
 
Website: Royal College of Physicians Library Catalogue  
URL: https://rcp.soutron.net/Portal/Default/en-GB/Search/SimpleSearch  
Date Searched: 21/10/2020 
Searcher: SB  
Hits: 6 
Strategy:  
All fields: opioid OR opioids OR benzodiazepine OR benzodiazepines OR antidepressant OR 
antidepressants OR gabapentinoid OR gabapentinoids 
 
Website: Royal College of Psychiatrists Library Catalogue   
URL: https://rcpsych.soutron.net/Portal/Default/en-GB/Search/SimpleSearch  
Date Searched: 21/10/2020 
Searcher: SB  
Hits: 20 
Strategy:  




Date Searched: 21/10/2020 
Searcher: SB 
Hits: 0 
Strategy:  Browsed website for relevant studies 
 
Website: Mental Health UK    
URL: https://mentalhealth-uk.org/ 
Date Searched: 21/10/2020 
Searcher: SB  
Hits: 0 




Website: Priory Group 
URL: https://www.priorygroup.com/ 
Date Searched: 21/10/2020 
Searcher: SB 
Hits: 0 
Strategy:  Browsed website for relevant studies 
 
Statins 
Website: Royal Pharmaceutical Society Library Catalogue   
URL: https://rpsgb.koha-ptfs.co.uk/  




Advanced search setting. 
Keyword:  statin*    OR  
Keyword:  “ace inhibitor*”  OR  
Keyword:  antihypertensive* 
 
Website: Royal College of Physicians Library Catalogue  
URL: https://rcp.soutron.net/Portal/Default/en-GB/Search/SimpleSearch      




All fields: statin OR statins OR "ace inhibitor" OR "ace inhibitors" OR antihypertensive OR 
antihypertensives 
 
Website: British Cardiovascular Society   
URL: https://www.britishcardiovascularsociety.org/ 
Date Searched: 21/10/2020  
Searcher: SB 
Hits: 0 
Strategy:  Browsed website for relevant studies.  
 
Website: European Society of Cardiology   
URL: https://www.escardio.org/ 
Date Searched: 21/10/2020  
Searcher: SB  
Hits: 0 




Website: British and Irish Hypertension Society    
URL: https://bihsoc.org/ 
Date Searched: 21/10/2020 
Searcher: SB  
Hits: 0 
Strategy:  Browsed website for relevant studies 
 
Website: British Heart Foundation   
URL: https://www.bhf.org.uk/ 
Date Searched: 21/10/2020 
Searcher: SB  
Hits: 31 (sum total of each keyword search) 
Strategy: Searched for keywords “statin”, “ace inhibitor” or “antihypertensive” (one term per 
search) and viewed the publications and research tabs. 
 
Website: Heart Research UK    
URL: https://heartresearch.org.uk/ 
Date Searched: 21/10/2020 
Searcher: SB 
Hits: 0 



















Appendix B: List of excluded studies 
The bibliographic database searches for studies on drugs that cause dependency identified 4614 
records. This reduced to 2729 unique records following the de-duplication process, including 13 
relevant studies that were uniquely identified from supplementary searching. At title and abstract 
screening, 2494 records were excluded leaving 235 studies to screen at full-text. Of these, 75 were 
included in the review and 160 were excluded. There were also 3 studies identified via the statins 
and antihypertensives searches which were eligible for inclusion in the drugs that can cause 
dependency review resulting in 78 included studies in total. The bibliographic database searches for 
studies on statins and antihypertensives identified 2159 records. This reduced to 1454 unique 
records following the de-duplication process, including 9 relevant studies that were uniquely 
identified from supplementary searching. At title and abstract screening, 1287 records were 
excluded leaving 167 studies to screen at full-text. Of these, 54 were included in the review and 113 
were excluded. There were also 14 studies identified via the drugs that can cause dependency 
searches which were eligible for inclusion in the statins and antihypertensives review resulting in 68 
included studies in total. 
Table 7: Studies excluded at full-text screening: Drugs that can cause dependency and antidepressants 
 Reference Reason for 
exclusion 
1. Abstracts from Professional Poster Presentations at AMCP's 2010 Educational 
Conference. Journal of Managed Care Pharmacy 2010;16. 
Abstract 
proceedings 
2. Abstracts of Papers Presented at the Health Services Research and Pharmacy Practice 
Conference, HSRPP 2016. International Journal of Pharmacy Practice 2016;24. 
Abstract 
proceedings 
3. Abstracts from the EGPRN Conference: 'Reducing the Risk of Chronic Diseases in General 
Practice/Family Medicine' 2017. European Journal of General Practice 2017;23. 
Abstract 
proceedings 
4. Prescribing and Research in Medicines Management (UK and Ireland) Annual Conference 
2018. Pharmacoepidemiology and Drug Safety 2018;27. 
Abstract 
proceedings 
5. Abstracts of Papers Presented at the Health Services Research and Pharmacy Practice 
Conference 2018. International Journal of Pharmacy Practice 2018;26. 
Abstract 
proceedings 
6. 46th ESAO Congress 3-7 September 2019 Hannover, Germany Abstracts. International 
Journal of Artificial Organs 2019;42:386-474. 
Abstract 
proceedings 
7. Abstracts of the XXVIth World Congress of Psychiatric Genetics (WCPG), 11 - 15 October 
2018, Glasgow, Scotland. European Neuropsychopharmacology 2019;29:S1021-S342. 
Abstract 
proceedings 





9. 30th Annual Meeting and Scientific Symposium of the American Academy of Addiction 
Psychiatry. American Journal on Addictions 2019;28. 
Abstract 
proceedings 





11. General Practice and the Community: Research on health service, quality improvements 
and training. Selected abstracts from the EGPRN Meeting in Vigo, Spain, 17-20 October 
2019. European Journal of General Practice 2020;26:42-50. 
Abstract 
proceedings 
12. Aguiluz J, Alvarez M, Pimentel E, Abarca C, Moore P. How to face a patient with 
benzodiazepine dependence in primary health care? Strategies for withdrawal. 
Medwave 2018;18:e7159. https://doi.org/10.5867/medwave.2018.01.7159 
Not SR 
13. Al Shemeili S, Stewart D. Use of the Drug Burden Index to identify and reduce potentially 




institutionalized care: A systematic review protocol. JBI Database of Systematic Reviews 
and Implementation Reports 2014;12:48-59. https://doi.org/10.11124/jbisrir-2014-809 
14. Alenezi A, Paudyal V, Yahyouche A. Interventions to improve adherence to medications 
for chronic non-malignant pain. International Journal of Pharmacy Practice 2019;27:35. 
https://doi.org/10.1111/ijpp.12533 
Abstract 
15. Alenezi A, Yahyouche A, Paudyal V. Interventions to optimize prescribed medicines and 
reduce their misuse in chronic non-malignant pain: a systematic review. Eur J Clin 
Pharmacol 2020; 10.1007/s00228-020-03026-4. https://doi.org/10.1007/s00228-020-
03026-4 
Duplicate  
16. Alford DP. Chronic back pain with possible prescription opioid misuse. JAMA 
2013;309:919-25. https://doi.org/10.1001/jama.2013.522 
Not SR 
17. Aljumah K, Donyai P. The impact of pharmacist intervention on patients' adherence to 
antidepressant medication and patient-reported outcomes. Value in Health 
2010;13:A243. 
Abstract 
18. Anderson C, Kirkpatrick S, Ridge D, Kokanovic R, Tanner C. Starting antidepressant use: a 
qualitative synthesis of UK and Australian data. BMJ Open 2015;5:e008636. 
https://doi.org/10.1136/bmjopen-2015-008636 
Not SR 
19. Anonymous. Abstracts of Papers Presented at the Health Services Research and 
Pharmacy Practice Conference, HSRPP 2016. International Journal of Pharmacy Practice 
2016;24. 
Duplicate 
20. Anonymous. Abstracts from the EGPRN Conference: 'Reducing the Risk of Chronic 
Diseases in General Practice/Family Medicine' 2017. European Journal of General 
Practice 2017;23. 
Duplicate 
21. Ansari B, Tote KM, Rosenberg ES, Martin EG. A Rapid Review of the Impact of Systems-
Level Policies and Interventions on Population-Level Outcomes Related to the Opioid 
Epidemic, United States and Canada, 2014-2018. Public Health Rep 2020;135:100S-27S. 
https://doi.org/10.1177/0033354920922975 
Drug not relevant 
22. Arandjelovic K, Eyre HA, Lenze E, Singh AB, Berk M, Bousman C. The role of depression 
pharmacogenetic decision support tools in shared decision making. J Neural Transm 
(Vienna) 2019;126:87-94. https://doi.org/10.1007/s00702-017-1806-8 
Not SR 
23. Argoff C, Wilson L, Kahan M, Sellers E. Systematic review: Managing aberrant drug 
behavior in primary care. Journal of Pain 2013;14:S76. 
https://doi.org/10.1016/j.jpain.2013.01.640 
Abstract 
24. Argoff CE, Kahan M, Sellers EM. Preventing and managing aberrant drug-related 
behavior in primary care: systematic review of outcomes evidence. J Opioid Manag 
2014;10:119-34. https://doi.org/10.5055/jom.2014.0201 
Not SR 
25. Atkinson TJ, Pisansky AJB, Miller KL, Jason Yong R. Common elements in opioid use 
disorder guidelines for buprenorphine prescribing. American Journal of Managed Care 
2019;25:E88-E97. 
Not SR 
26. Bauer M, Severus E, Kohler S, Whybrow PC, Angst J, Moller HJ, et al. World Federation of 
Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar 
depressive disorders. part 2: maintenance treatment of major depressive disorder-
update 2015. World J Biol Psychiatry 2015;16:76-95. 
https://doi.org/10.3109/15622975.2014.1001786 
Not SR 
27. Berna C, Kulich RJ, Rathmell JP. Tapering Long-term Opioid Therapy in Chronic 
Noncancer Pain: Evidence and Recommendations for Everyday Practice. Mayo Clin Proc 
2015;90:828-42. https://doi.org/10.1016/j.mayocp.2015.04.003 
Not SR 
28. Bicket MC, Brat GA, Hutfless S, Wu CL, Nesbit SA, Alexander GC. Optimizing opioid 
prescribing and pain treatment for surgery: Review and conceptual framework. Am J 
Health Syst Pharm 2019;76:1403-12. https://doi.org/10.1093/ajhp/zxz146 
Not SR 
29. Bi-Mohammed Z, Wright NM, Hearty P, King N, Gavin H. Prescription opioid abuse in 
prison settings: A systematic review of prevalence, practice and treatment responses. 
Drug Alcohol Depend 2017;171:122-31. 
https://doi.org/10.1016/j.drugalcdep.2016.11.032 
Drug not relevant 
30. Blanchard J, Hunter SB, Osilla KC, Stewart W, Walters J, Pacula RL. A Systematic Review 
of the Prevention and Treatment of Prescription Drug Misuse. Mil Med 2016;181:410-23. 
https://doi.org/10.7205/MILMED-D-15-00009 
Not SR 
31. Bourcier E, Savoldelli V, Fernandez C, Hindlet P. Regulatory and educational strategies 
for reducing the burden associated with prescriptions of sedative-hypnotics. Pharmacy 
Education 2016;16:166. 
Abstract 
32. Bousman C, Arandjelovic K, Mancuso S, Eyre H, Boadie D. SA110PHARMACOGENETIC 




PROSPECTIVE RANDOMIZED CONTROLLED TRIALS IN MAJOR DEPRESSIVE DISORDER. 
European Neuropsychopharmacology 2019;29:S1249. 
https://doi.org/10.1016/j.euroneuro.2018.08.332 
33. Bowers HM, Kendrick T, Glowacka M, Williams S, Leydon G, May C, et al. Supporting 
antidepressant discontinuation: the development and optimisation of a digital 
intervention for patients in UK primary care using a theory, evidence and person-based 
approach. BMJ Open 2020;10:e032312. https://doi.org/10.1136/bmjopen-2019-032312 
Not SR 
34. Chebli JL, Blaszczynski A, Gainsbury SM. Internet-Based Interventions for Addictive 
Behaviours: A Systematic Review. J Gambl Stud 2016;32:1279-304. 
https://doi.org/10.1007/s10899-016-9599-5 
Drug 
35. Checchi KD, Huybrechts KF, Avorn J, Kesselheim AS. Electronic medication packaging 
devices and medication adherence: a systematic review. JAMA 2014;312:1237-47. 
https://doi.org/10.1001/jama.2014.10059 
Drug 
36. Cheung JM, Bartlett DJ, Armour CL, Saini B. Treating Insomnia: A Review of Patient 
Perceptions Toward Treatment. Behav Sleep Med 2016;14:235-66. 
https://doi.org/10.1080/15402002.2014.981818 
Not SR 
37. Christo PJ, Manchikanti L, Ruan X, Bottros M, Hansen H, Solanki DR, et al. Urine drug 
testing in chronic pain. Pain Physician 2011;14:123-43. 
Not SR 
38. Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-
based guidelines for treating depressive disorders with antidepressants: A revision of the 
2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 
2015;29:459-525. https://doi.org/10.1177/0269881115581093 
Not SR 
39. Dann-Reed E, Wright D. Evaluating pharmacy interventions targeted to people affected 
by dementia: A systematic review of identified interventions to inform the development 
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42 
Not SR 
51. Jamshidnezhad A, Kabootarizadeh L, Hoseini SM. The Effects of Smartphone Applications 
on Patients Self-care with Hypertension: A Systematic Review Study. Acta Inform Med 
2019;27:263-7. https://doi.org/10.5455/aim.2019.27.263-267 
Not SR 
52. Jones LK, Gionfriddo MR, Tilberry S, Frisbie L, Gregor C, Gidding S, et al. Implementation 
strategies to improve statin utilization in individuals with hypercholesterolemia: A 
systematic review. JACCP Journal of the American College of Clinical Pharmacy 
2020;3:365. http://dx.doi.org/10.1002/jac5.1204 
Abstract 
53. Jornten-Karlsson M, Pintat S, Molloy-Bland M, Berg S, Ahlqvist M. Patient-Centered 
Interventions to Improve Adherence to Statins: A Narrative Synthesis of Systematically 
Identified Studies. Drugs 2016;76:1447-65. https://doi.org/10.1007/s40265-016-0640-x 
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type of surgery High 1   
Green highlighted text=High overall quality as appraised by AMSTAR-2, Turquoise highlighted text=Medium overall quality as appraised by AMSTAR-2, Orange highlighted text=Low overall 
quality as appraised by AMSTAR-2, Red highlighted text=Critically-low quality as appraised by the AMSTAR-2. *CEESAT Set: 1=prioritised for full quality appraisal using AMSTAR-2, CEESAT Set 
2=Scored poorly on 1 out of 4 items on CEESAT, CEESAT Set 3=Scored poorly on 2-4 items on CEESAT. BA=Before and After, BPD=Borderline Personality Disorder, CBA=Controlled Before and 
After, CPG=Clinical Practice Guidelines, CVD=Cardiovascular Disease, CT=Controlled-Trials, FH=Familial Hypercholesterolemia, HBP=High Blood Pressure, ITS=Interrupted Time Series, MA=Meta-
analysis, MMT=Methadone Maintenance Treatment, NR=Not Reported, OUD=Opioid Use Disorder, PPI=Proton Pump Inhibitors, PTSD=Post-Traumatic Stress Disorder, RCT=Randomized 
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Pharmacological interventions to 
facilitate benzodiazepine 
withdrawal or to switch from 




withdrawal symptoms, SAEs, 
Benzodiazepine mean dose,  
insomnia, anxiety, comorbid 
substance abuse, non-SAEs, 
relapse to benzodiazepine use, 













to adhere to 
deprescribing 
plan          





































supervised gradual withdrawal, 
supervised abrupt withdrawal, both 
gradual and abrupt withdrawal, 
gradual withdrawal with a 
prescribing intervention, 









Odds ratio in relation to not using 
benzodiazepines, at the level of 
patients or prescriptions 
Primary/ 
























































CV drugs, levodopa, 
nitrate 
Deprescription: reduce medication 
burden, and enhance control of 
chronic medical and mental health 
conditions commonly managed by 
primary care physicians, compared 
with standard care in the non-




Primary outcome: successful 
deprescription, Secondary 
outcome: AE related to drug or 
underlying chronic condition as a 























































2017103 Opiates NA 
Pharmacological, physiological, 
psychological or spiritual 
interventions to reduce/cease 
prescribed opioid use for the 
management of chronic non-cancer 
pain in adults: e.g. opioid 
antagonist treatment, dose 
tapering, or opioid replacement, 
physical therapy, massage, 
disability management, 
complementary therapies, or 
psychological approaches (CBT, 
counselling, and coping techniques) 
 
Primary outcomes: prescribed 
opioid use in adults, AE related to 
opioid reduction, Secondary 
outcomes: pain 
intensity/severity, psychological 
functioning, physical functioning NR 









































Interventions to reduce 
antipsychotic and/or 
benzodiazepine use in nursing 
homes. Interventions included: 
education (meetings, distribution 
of educational materials, 
educational outreach), referral of 
patients to psychiatric support 
service, development of specific 
care plans, multicomponent 
interventions (all incorporated 
educational outreach for care staff) 
 
 
Change in antipsychotic and/or 
benzodiazepine use, impact on 
clinical and/or economic 
outcomes Care home 
Progress review 







































Interventions to change patient’s 
long-term BZRA use. 
All interventions advocated GDR to 
patients. Included: written letters 
signed by patients, prescribers or a 
clinical pharmacist, short 
consultations provided by health-
care professionals [general 
practitioners (GPs), practice 
pharmacists, practice nurses] 
recommending 
reduction/discontinuation of the 
 
Primary outcome: BZRA use 
(complete discontinuation or 
reduction by 25%) Secondary 
outcomes: health-related QOL; 
withdrawal symptoms; anxiety; 
sleep quality; depression; and 
health-care utilization (i.e. GP 





and/or advice           
Decision to stop 
treatment: 
supported 


















medications, empowerment-based  
personalized educational booklet 






























2019124   Antidepressants NA 
Interventions to facilitate 
discontinuation of antidepressants: 
guided review of patients by 
primary care clinicians, abrupt 
discontinuation, tapering, 
psychological therapies, and 
pharmacologic approaches 
 
e.g. mindfulness-based cognitive 
therapy, mindfulness-based 
cognitive therapy+tapering 
support, CBT, Guided primary care 
clinician review, patient-specific 
letters to primary care clinician 
recommending to discontinue 
antidepressant and provide 
tapering advice, CBT+ tapering, 
MBCT+tapering, gradual 





QOL, antidepressant reduction, 
sexual function; other outcomes 
(e.g., social and occupational 









































(2015)146 Hypnotics/Z-drugs Anticholinergic 
Drug Burden Index to identify 
potentially inappropriate 
prescribing of anticholinergic and 
sedative agents in elderly patients 
in institutionalised care 
 
Prescribing of anticholinergic and 
sedative agents (e.g. cessation of 
therapy, prescribing altered to 
other agents, reduction in 
adverse drug reactions), DBI 
scores, physical and mental 
functioning; adverse effects of 






















medicines, changes to therapy 


































201986 Antidepressants NA 
Pharmacy-based management 
interventions to improve 
depression outcomes 
 
Depression symptom level, 
Acceptability of the intervention, 
diagnosis of depression, non-
adherence to medication, 
frequency of primary care 




























































Interventions to increase 
medication adherence, including: 
psychosis compliance therapy, 
collaborative care, compliance 
enhancing intervention, pharmacy-
































































2017135  Antihypertensives 








treatment for thyroid 
cancer, antibiotic use for 
upper respiratory 
infections, chemotherapy 
for cancer, medications 
for diabetes, hormone 
therapy, "breast cancer 
prevention medication, 
bisphosphonates, thyroid 
cancer radioactive iodine 
treatment 
Decision aids for people facing 
health treatment or screening 
decisions. 
Aim: help people make specific and 
deliberated choices among options, 
by making the decision explicit/by 
providing information on the 
options and outcomes relevant to 
person's health status as well as 
implicit methods to clarify values 
 
Attributes of choice made: does 
patient decision aid improve 
match between chosen option 
and features that matter most to 
informed patient (demonstrated 




Attributes of decision-making 
process: does patient decision aid 
help patients to recognize 
decision needs to be made, feel 
informed about options and their 
features, be clear about option 
features that matter most, 
discuss values with their clinician, 
and become involved in decision 
making? Other decision-making 
process variables: Decisional 
conflict, Patient-clinician 
communication, participation in 
decision making, proportion 
undecided, satisfaction with the 
choice/process of decision 
making/preparation for decision 
making. Secondary outcomes: 
Choice (the actual choice 
implemented; if not reported, 
the participants preferred 
option), adherence to chosen 
option, health status and quality 
of life (generic and condition-
specific), anxiety, depression, 
emotional distress, regret, 















































































prescription drugs taken 
without prescription or 
more than prescribed, 












treatment, bone active 
medication, non-
hormonal oral agents 
Automated telephone 
communication systems for 
preventing disease and managing 
long-term conditions 
 
Health behaviour and clinical 
outcomes, changes in health-
enhancing behaviour, risk-taking 
behaviour, physiological 
measures, blood biochemistry. 
Process outcomes: change in 
acceptability of service (e.g. 
consumer accessibility/usability 
of interventions to apply 
information/support supplied), 
satisfaction (e.g. patient/carer) 
the intervention), cost-
effectiveness. Cognitive 
outcomes: changes in knowledge 
(i.e. accurate risk knowledge and 
perception), attitude and 
intention to change, self-efficacy. 
Patient-centred outcomes: 
quality of life, adverse outcomes, 




























































Antihypertensives Antiplatelet  
Mobile phone text messaging to 
enhance adherence to 
recommended medication in 
patients with established arterial 
occlusive events 
 
Adherence to treatment, 
fatal/non-fatal cardiovascular 
events, combined CVD event, 
Surrogate outcomes according to 
the different interventions 
recommended for secondary 
prevention including: low-density 
lipoprotein-cholesterol, blood 
pressure, heart rate, urinary 11-

























































(2015)47  Antihypertensives NA 
Self-monitoring of blood pressure: 
improve medication adherence, 
medication persistence, and 





adherence and persistence, 
dietary outcomes, alcohol 
consumption and physical 
activity. Secondary outcomes: BP, 
BP control, and adherence to 













































(2017)66  Antihypertensives NA 
Interventions to enhance 
medication adherence and blood 
pressure control in hypertension 





















































disease, CVD/CV risk, 
diabetes, antibiotics, 






cancer, hepatitis, iron 
supplementation during 
pregnancy, liver 
transplant, malaria, oral 
contraceptives, 
Interventions to affect adherence 
with prescribed, self-administered 
medications 





































































dose aspirin, non-aspirin 
antiplatelet drugs) 
Mobile phone-based interventions 
to improve adherence to 
medication prescribed for the 
primary prevention of 
cardiovascular disease in adults 
 
Objective measures of adherence 
to treatment, combined CVD 
events, AE, indirect measures of 
adherence to treatment, health-
related quality of life, cognitive 
outcomes (satisfaction with 
treatment, medication-taking 
self-efficacy, autonomy related to 
medication, attitudes (e.g. 
concerns about medicine AEs)), 
costs, process measures: extent 
of intervention received and 









Progress review      
Patient 






































Interventions to improve 
adherence to lipid-lowering drugs: 
1. Simplification of drug regimen; 2. 
Patient education and information; 
3. Intensified patient care; 4. 
Complex behavioural approaches; 
5. Decision support systems; 6. 
Administrative improvements; and 
7. Pharmacy-led interventions 
Indirect measures of adherence, 
subjective measures of 
adherence, direct measures of 
adherence, physiological 
indicators, health outcome 
indications (e.g. quality of life, 
morbidity, mortality), AEs, 
implications for costs (impact of 
intervention on economic 





























































(2011)134  Antihypertensives NA 
ACEIs to treat essential 
hypertension 
Blood pressure control, mortality, 
morbidity, safety, specific 
adverse events, 
persistence/adherence, rate of 
use of a single antihypertensive 
medication for blood pressure 
control, lipid levels, rates of 
progression to type 2 diabetes, 
carbohydrate 
metabolism/diabetes control, left 









Other              
Setting of studies 
not restricted  
Choosing a 
medication 
Progress review       
Patient 



































(2016)120  Antihypertensives NA 
Free versus fixed drug combination. 
Aim: to increase adherence,  
increase overall BP-lowering 
efficacy 
Mortality, morbidity 
(cardiovascular outcomes such as 
coronary events, stroke, 
progression of peripheral 
vascular disease and kidney 
disease), mean systolic BP, AE, 























































(2014)98   
Statins 
Antihypertensives NA 
A fixed-dose combination therapy, 
a combination of several active 
components into a single pill, 
including at least one statin and 
one antihypertensive agent. Aim: 
to optimise CVD risk and reduce 
CVD fatal and non-fatal events 
Mortality, non-fatal CVD 
endpoints, AEs (overall rates of 
discontinuation, proportion of 
participants experiencing specific 
symptoms or results and rates of 
discontinuation by specific 
symptoms). Secondary 
outcomes: Systolic and diastolic 
blood pressure, total and LDL 
cholesterol, adherence, health-












































(2013)60   Antihypertensives NA 
National or regional health system 
arrangements on HT awareness, 
treatment, control, and 
antihypertensive medication 
adherence 
HT awareness (persons with 
clinically measured HT diagnosed 
by a health care professional as 
hypertensive), HT treatment (use 
of at least one antihypertensive 
medication in an individual with 
known HT), antihypertensive 




















































































Computerized advice on drug 
dosage to improve prescribing 
practice computerized advice on 




Proportion of participants/time: 
plasma drug concentrations 
within therapeutic range, studied 
physiological parameter within 
the target range. "Time to 
achieve therapeutic control, 
proportion of participants: with 
toxic drug levels, with clinical 
improvement, with adverse 
effects of drug therapy. 


























































Any tool (dementia-specific or non-





Prevalence of polypharmacy, 
prevalence of PIP, most common 
























































Antidepressants Antipsychotics, NSAID 
Interventions to change the care 
practices of staff for the benefit of 
the residents. Categorized 
interventions via their components: 
educational material (written 
material or a DVD/video or online 
website), training: delivered in 
person to staff, reminders (e.g. 
postcards, posters) designed to 






Change in staff behaviour, 
change in other staff outcomes 
(e.g. staff turnover, absenteeism, 
stress), change in resident clinical 
outcomes (not just satisfaction 
with care). Hygiene and infection 
control, nutrition, nursing home 
acquired pneumonia, depression, 
appropriate prescribing, physical 
restraint reduction, management 





















g of staff in teams or individually), 
champions responsible for driving 
change, 
consensus/multidisciplinary team 
meetings to discuss issues relating 
to practice, policy/procedure, 
change to staff responsibilities of 
staff or care organisation 
symptoms of dementia, falls 
reduction/prevention, quality 
improvement, philosophy of care, 
advance care directive, pain 
management, assault reduction, 
resident to resident 
mistreatment, pressure ulcer 


































2017136 Opiates NSAID 
Non-pharmacological interventions 
to improve pain management after 




Postoperative pain relief, 
opioid/other analgesic 
consumption, time to first 
request for analgesia Hospital (inpatient) 
Choosing a 
medication 





































2020144 Opiates NA 
 
Behavioural interventions and/or 
implementation strategies targeted 
at healthcare workers to change 
their behaviour, such as audit and 
feedback, educational meetings, 
local consensus processes, public 
release of performance data to 




Primary outcome: amount of 
opioid prescribed at hospital 
discharge after surgery. 
Secondary outcomes: 
postoperative pain control, 
overall satisfaction with pain 






























































Interventions to promote 
treatment initiation. Interventions 
included: 
Cultural tailoring, motivation, 
treatment preference matching, 
case management, education, 
collaborative or integrated care, 
shared or clinical decision-making 
 
Depression treatment initiation, 
treatment retention, mean 



































































antibiotic therapy, NSAID, 
nicotine gum, ezetimibe,  
thromboprophylaxis 
Manual paper reminders to 
improve compliance with 
preventive guidelines and disease 
management guidelines 
Patient-important endpoints: 
death, development of a 
pulmonary embolism , surrogate 
or intermediate endpoints: 
achievement of target blood 
pressure or serum cholesterol 
level, markers of disease/health 
status, adverse effects, resource 
use, changes in professional 

















































(2010)59  Statins Not clear 
Interventions for improving the 
adoption of shared decision making 
by healthcare professionals 
Healthcare professionals' 





































































Interventions to improve 
adherence to CVD guidelines and 
patient outcomes: education, audit 
and feedback, academic detailing, 
comprehensive interventions that 
included education, audit and 
feedback and an academic detailing 
component 






















































(2018)77  Antihypertensives NA 
Implementation interventions 
classified at the provider, 
organisational or health system 
levels. Aim: increasing physician 
adherence to the specified HF 
guideline recommendations 
 
Patient-level outcomes. Primary 
outcomes: process indicators 
(assessing guideline-consistent 
activities undertaken by a 
provider, proportion of patients 
who were: prescribed a 
guideline-recommended 
pharmacological treatment, 
referred for implantable 
cardioverter defibrillator, CRT 
consideration, provided self-care 
education at discharge, LVEF. 
























































































(2020)122 Opiates NA 
 
 
Interventions to reduce/cease 
prescription/ use of opioid 
analgesics in patients with chronic 
non-cancer pain: e.g. Dose 
reduction protocols, Opioid 
replacement with buprenorphine, 
mindfulness, Therapeutic 
Interactive Voice Response 





decision tools to improve guideline 
adherence and decrease opioid 
misuse risk, online education of 
patient simulation+case-based 
learning for safer prescribing 
Daily dose, opioid analgesic 
prescriptions, proportion 
participants who ceased/reduced 
opioid use, SAE/AE, pain 


















to adhere to 
deprescribing 
plan 
*A secondary aim or one of multiple aims of review. Green highlighted text=High Overall Quality AMSTAR-2, Turquoise highlighted text=Medium Overall Quality AMSTAR-2, Orange 
highlighted text=Low Overall Quality AMSTAR-2, Red highlighted text=Critically-low Overall Quality AMSTAR-2. ACEI= Angiotensin-Converting Enzyme Inhibitors, AE=Adverse Events, AIDS= 
Acquired Immunodeficiency Syndrome, BEZRA=Benzodiazepines/Zdrugs, BP=Blood Pressure, CBT=Cognitive Behavioural Therapy, CPM=Continuous Passive Motion, CRT= Cardiac 
Resynchronisation Therapy, CV=Cardiovascular, CVD=Cardiovascular Disease, DBI=Drug Burden Index, ED=Emergency Department, GDR=Gradual Dose Reduction, GP=General Practitioner, 
HF=Heart Failure, HIV= Human Immunodeficiency Virus, HT=Hypertension, LDL= Low-Density Lipoprotein, LOS=Hospital Length of Stay, NA=Not Applicable, NR=Not Reported, QOL=Quality Of 
Life, LVEF= Left Ventricular Ejection Fraction, MBCBT=Mindfulness Based Cognitive Behavioural Therapy, NSAID=Non-Steroidal Anti-Inflammatories, PIP=Potentially Inappropriately 














Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 






























201587  Benzodiazepines NA 
Interventions to reduce BZ use:  
Psychosocial intervention, contingency 
management, community 
reinforcement approaches, CBTs, 
relapse prevention, couples based 
interventions, family- based 
interventions, psychodynamic 
therapies, drug abuse counselling, BIs, 
coping skills training, supportive 
expressive therapy, social skills 
training, stress management, 
relaxation therapy, relapse prevention, 
DBT, MI/motivational enhancement 
therapies 
Successful discontinuation or 
reduction of BZ use by > 50%, 
metabolites, use of BZs, degree of 
effective dose reduction, abstinence 







Hospital (inpatient)                 
Hospital (outpatient) 
Working with 
other health or 
social care 
services/charitie
s Referral to 
specialist care 






































Strategies to reduce or discontinue 
long term opioid  therapy among adults 
prescribed LTOT for chronic pain: 
Interdisciplinary pain programs, 
buprenorphine-assisted dose 
reduction, behavioural interventions, 
other outpatient programs, other 
interventional programs, 
detoxification, ketamine-assisted dose 
reduction, acupuncture 
Reduction/discontinuation LTOT. 
Patient outcomes: pain, pain-related 
function, quality of life, opioid 
withdrawal symptoms, new-onset 
substance use, adverse events, 












































2011128 Benzodiazepines NA 
Minimal intervention (letter, self-help 
information, short consultation with a 
GP): reduce the long-term use of BZs in 
primary care 
BZ use, general health status, 
adverse effects of withdrawal, other 





and/or advice       















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 









































Interventions to stop pre-existing 
prescribing in situations where 
continued prescribing may no longer 
be clinically warranted: patient 
mediated interventions, manual 
reminders to prescribers, educational 
materials given to patients, face-to-
face intervention with individual 
prescribers, regulatory intervention, 
Audit and feedback, electronic 
reminders, educational materials sent 
to prescribers, educational meetings 








and/or advice      
Progress review 














Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 

























































Deprescribing by a health care 
professional of one or more regular 
prescription medications:  
Mortality, adverse drug withdrawal 
events, physical health, cognitive 
function and psychological health, 
quality of life 












































Interventions to deprescribe 
benzodiazepines and other hypnotics 
among older people: GP-targeted 
intervention, pharmacological 
substitution, mixed interventions 
including temporary pharmacological 
substitution + psychological support, 
tapering with psychological support, 
tapering with patient education 
Positive and negative (e.g. adverse 
drug withdrawal reactions) clinical 








Decision to stop 
treatment: 















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 

































Benzodiazepines      
Hypnotics/Z-drug NA 
Melatonin and melatonin agonists as 
treatments for benzodiazepines and 
hypnotics withdrawal in patients with 
primary insomnia Detoxification at end of treatment NR 
Progress review            





































201291 Antidepressants NA 
Pharmacist interventions: enhance 
patients adherence to antidepressant 
medication 
Adherence, patient satisfaction, 
psychological dimensions 


















































Interventions to improve medication 
adherence in mental health: 
Psychosis compliance therapy, 
multifaceted, stepped, collaborative 
care intervention, compliance-
enhancing programme, pharmacy-
based intervention, treatment 
supported by pharmacogenetics test, 
value-based benefit design policy: 
waived co-payments for medications, 
mental health counselling, promotion 
of a management programme for 
depression, financial incentive 






























Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 






















































Medicare Part D: increase drug 
utilization and lower Medicare and 
Medicaid participants out- of-pocket 
prescription drug costs, thereby 












































201889 Antidepressants NA 
Pharmacist education and counselling 
interventions: improving 
antidepressant medication adherence 











































201176 Antidepressants NA 
Pharmacist interventions to improve 
adherence to antidepressant 
medication among outpatients with 
depressive disorder: educational 
messages and counselling, monitoring 
and medication dosage adjustment and 























Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 















































Packaging interventions to improve 
adherence:  blister packs, unit-
packaging, unit-of-use systems, unit-of-
dose packaging, 


















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 







































































Health care provider targeted 
interventions to improve medication 
adherence: Research staff trained 
providers, integration of care across 
providers, increased providers, 
communication skills, monitor patients 
adherence behaviour, Provider- patient 
medication concordance, Increased 
provider time with patients, reduce the 
geographical distance between 
providers and patients, increase 




























Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 
















































chronic illnesses,  
osteoarthritis, 








Medication Adherence Interventions: 
Intervention content could include:  
prompts/cues to administer 
medications, self-monitoring of 
medication administration, self-
monitoring of disease symptoms, 
written instructions, rewards for 
increased adherence, increased 
communication between providers and 
patients, providing feedback to 
participants about their adherence, 
goal setting about adherence, habit 
assessment/modification, and problem 














































201399 Antihypertensives NA 
 
 
Interventions to improve adherence to 
antihypertensive medications: 
education,  lifestyle, verbal 
information/advice on disease and 
secondary-prevention drug treatment, 
goal setting, supply of printed 
information/advice material, screening 
for depression, personalized 
instructions, and integrated care 

















































Antihypertensives Yes, NR 
Automated telecommunication 
systems, including voice messaging and 
text messaging: promote adherence to 






















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 














































Value-based health insurance designs 
including: VBID vs usual medication 
coverage VBID+education vs usual 
medication coverage, VBID+education 
vs usual medication 
coverage+education 
 
Aim: increase patients understanding 
of importance of high-value 
medications,  increase number of 
adherent patients without increasing 









































2011116 Antihypertensives NA 
 
Drug Class: improve adherence to 












































Multimodal behavioural interventions 
for secondary stroke prevention:  
addresses: 1) medication education 
and/or medication compliance 
education, 2) education or active 
information provision e.g. about 
stroke, stroke (lifestyle) risk factors, 
and 3) one or more of four specified 
lifestyle behaviours i.e. smoking, diet, 
physical inactivity, and alcohol 
consumption, and/or behaviours 
associated with amelioration of 
lifestyle risk factors i.e. medication 
compliance and management of 
perceived psychosocial stress 
Primary outcomes of interest: 
physiological outcomes e.g. blood 
pressure, blood lipids, and lifestyle 
behaviour change. Secondary 
outcomes: psychosocial outcomes 
e.g. anxiety, learning e.g. knowledge 
of lifestyle risk factors for stroke, 






















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 





































Drug Insurance Cost Sharing Strategies:  
lower expenditures for prescription 
drug insurance plans 
Adherence, clinical events 
(myocardial infarction, stroke, 
death), QOL, healthcare utilization, 
or cost NR 
Accessing care 
































































                                                                                                                             
Community pharmacist interventions:                                                                                          
improve adherence, improve clinical 
outcomes. 
 
Behavioural outcome: adherence, 
self-efficacy. Clinical outcome: 
clinical biomarkers (e.g. blood 
pressure, glycosylated haemoglobin, 
LDL), hospitalisation rates, mortality, 
emergency room visits, markers of 
disease progress. Economic 
outcome: cost effectiveness analysis, 
or other relevant analysis. 
Humanistic outcome: patient quality 
of life, knowledge, or satisfaction 
Primary/health/soci





Decision to start 
agreed 















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 


































Rash, 201675 Statins NA 
Interventions targeting medication 
adherence:  
Prescription cost coverage, 
simplification of drug regimen, 
reminders, education-based, multi-
faceted interventions (including one or 
more of following: education, 
counselling, behavioural interventions, 
follow-up, medication review,  risk-
factor and adherence education, 
personalized health reports, bi-monthly 























































2020133 Antihypertensives NA 
Pharmacist-led interventions to 
improve medication adherence and BP 













































2014145 Antidepressants NA 
Extended-release antidepressants for 
medical management of MDD:  
improve adherence and a lower risk of 
adverse events 
Comparative efficacy, risk of harms,  
adherence, response, remission, 

















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 





































201495 Antihypertensives NA 
Interventions to improve management 
of BP: Pharmacological: education on 
drug treatment of BP, advice to 
patients to improve medication 
adherence, identifying drug adverse 
effects and drug prescribing issues, 
liaising with prescribers about concerns 
of drug treatment. 
Nonpharmacological: education about 
hypertension.  education about 
lifestyle (advice to patients on diet, 
weight management, alcohol 
consumption, smoking cessation) 
 
Systolic and diastolic BP, adherence, 
identification and management of 
drug-related problems, 
cardiovascular risk factors, i.e. 
























































Collaborative care including: multi-
professional patient care, structured 
management plan, scheduled patient 
follow up, enhanced inter-professional 
communication 
 
Aim: improve depression and diabetes 
outcomes in patients with both 
depression and diabetes 
Depression treatment response, 
depression remission, haemoglobin 
A1c (HbA1c) control, adherence to 
medication (including adherence of 





adherence             
Working with 






































202034 Opiates NA 
Stewardship Interventions, including:  
forcing functions and educational 
interventions (treatment algorithm 
forces the user into certain pathways 
to guide decision-making), prior 
authorization policies, order 
restrictions, education for both 
prescribers and patients. All 
interventions performed at a system 
level. Aim: optimise the prescribing of 
extended-release opioids for patients 
with acute pain  





















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 






































enhance patient awareness and 
education by providing legitimate 
information about conditions and 
treatment options  
Patient requests for advertised 
medication, physician prescribing in 















































201951 Opiates NA 
Prescriber education interventions to 
optimize opioid prescribing in acute 
care: stand-alone education, face-to-
face education within multifaceted 
interventions, incorporating other 
responsible prescribing strategies 
including new guidelines or consensus 
recommendations, continuous auditing 
and individualized feedback, and 
changes to computerized provider 
order entry (CPOE) systems 
 















































Standardised Patient training: 
Undergraduate medical training 
 
Improve medical proficiency, of 
relevance optimised opioid 






















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 



































201983  Opiates Methadone 
Prescription monitoring programs to 
reducing opioid prescribing, dispensing, 
and use: monitors outpatient 
prescription dispensing of opioids (or 
other drugs) by health care providers 
Change in overall volume of opioids 
prescribed/dispensed or proportion 
of specific opioids (e.g., oxycodone, 
hydrocodone) prescribed/dispensed, 
change in rates of multiple provider 
use, change in rates of inappropriate 
prescribing or dispensing practices, 
change in rates of nonmedical 







Progress review,                        












































Organisational or professional 
interventions to enhance prescribing of 
guideline-recommended medications. 
Interventions included: Distribution of 
educational materials, educational 
outreach visits, audit and feedback and 
reminders, continuity of care, 
communication and case discussions 
between distant healthcare 
professionals, distribution of 
published/printed recommendations 
for clinical care, including clinical 
practice guidelines 
Proportion of patients receiving 
guideline-recommended 
medications. Secondary outcomes: 
proportion of patients achieving 
target blood pressure and target LDL, 



























Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 

































































Patient-centred treatments to reduce 
BZ use and/or prescription: 
predominantly educational or 





































































201636 Opiates NA 
                                                                                                                                                                                                
Policies/guidelines aimed at Prescriber 
practices to guide opioid prescribing                                 
 
Prescriber level: Opioid prescribing 
(as proportion of patient visits and of 
all prescriptions; total number of 
prescriptions; average quantity 
prescribed; total opioid prescriptions 
exceeding upper daily limit in 
guidelines). Patient level: negative 
health outcomes related to opioid





























Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 




































2019115 Opiates NA 
Real-time electronic notifications, 
including predictive analytics and 
decision support applications: reduce 
ED recidivism 
Healthcare utilization outcomes: 
inpatient and outpatient visits, 30-
day hospital readmissions, ED or 
hospital length of stay, use of and 
prescription of opioids, use of 
diagnostic imaging and laboratory 
tests, healthcare cost, organizational 
financial performance, access to 
medical insurance, primary care, and 
safe housing access, 















































2020141 Opiates NA 
 
ED-based interventions:  
four common intervention 
components: electronic medical record 
(EMR) alerts, primary care contact and 
referral, individualized care plans or 
care pathways, and departmental 
opioid restriction policies.  
Intervention aim:  
improve ED visit frequency as well as 
other patient-, physician-, and system-
important outcomes 
Frequency of ED visits. Secondary 
outcomes: amount and type of 
opioids administered in ED, amount 
and type of opioids pre- scribed at 
ED discharge, total care-associated 
costs (e.g., physician, pharmacy, 





















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 






































































































Longer-duration (2–4 months) versus 
shorter-duration (28-day)prescriptions 
to improve patient outcomes 
Health outcomes, adverse events, 
medication adherence, medication 
wastage, professional administration 
time, pharmacists time and/or costs, 




















*Secondary aim or outcome within the review. AE=Adverse Events, BI=Behavioural Interventions, BP=Blood Pressure, BZ=Benzodiazepine, CBT=Cognitive Behavioural Therapy, 
COPD=Coronary Obstructive Pulmonary Disease, DBT=Dialectical Behavioural Therapy, ED=Emergency Department, GP=General Practitioner, HIV= Human Immunodeficiency Virus, 
IBD=Irritable Bowel Disease, LDL= Low-Density Lipoprotein, LTOT=Long-Term Opioid Therapy, MDD=Major Depressive Disorder, MI=Motivational Interviewing, NA=Not Applicable, NR=Not 













Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 



































Interventions to discontinue 
benzodiazepines and sedative 
hypnotics in community-dwelling 
individuals: pharmacologic 
therapy, psychological therapy, 
mixed, other, gradual dose 
reduction 
 
Direction of effect of 
endpoints related to 




















































































Interventions to improve or 
ensure appropriate use of 
opioids:  education, 
implementation of 
recommendations from clinical 
practice guidelines, using a tool 
to improve opioid prescribing, 
implementing urine drug tests, 
using disease management 
programs, reversal of overdose 
with naloxone, opioid 
substitution therapies, take-back 
program, prescription monitoring 
or review programs, regulations 
and policies, community or public 
health campaigns, collaborative 
strategies 
Unintended consequences of  
implemented strategy, adverse 
consequences to participants 
or society,  
inappropriate use, misuse, 

















Decision to stop 
treatment: 
supported 




to adhere to 
deprescribing 












Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 










































Diuretics, Beta Blockers, 
Hypoglycemics, Beta 







Interventions to reduce falls or 
use of FRIDs: Face-to-face 
medication consultations with 
community pharmacy resident, 
fall-related assessment 
performed by research physician, 
geriatrician assessment of falls 
risk and systematic medication 
review, consideration of potential 

















review in acute 































































Mauri, 202063 Opiates NA 
State opioid policies as a 
legislative or administrative 
action, such as a law or 
regulation, that directly targeted 
opioid misuse  
Opioid prescribing and 






























Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 











































Multimodal Interventions to 
improve adherence: categories 
included 
educational+motivational, 
simplification of drug regimen, 
environmental cues or 
reminders+reducing concerns 
and misbeliefs regarding 
medications, combined 
interventions to enhance risk 
factor management after stroke, 
prescribed 
medications+educated about 































































Polypill to improve medication 























Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 



































201993 Antihypertensives NA 
Medical Assistance Scheme to 
increase adherence to treatment: 
Examples include 
special packaging of medications, 
amount of prescribed 
medications,  interventions to 
improve communication with 
patients (more frequent visits, 
motivational interviewing, 
patient education, home BP 
monitoring, and provision of 
written instructions), duration 
















































Various HAARTs,  
luticasone propionate, 
travoprost, pilocarpine,  








Electronic medication packaging 
devices to promote medication 
adherence 
Adherence, health outcomes, 




















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 


































Conn (2015)97 Antihypertensives NA 
Interventions to increase 
adherence among adults with 















































resins or bile acid 
sequestrants, Niacin or 
nicotinic acid, combined 
medication regimen 
 
Interventions to increase 
adherence to self-administered 
lipid-lowering medication: Drug 
regimen simplification, patient 
education and information, 
intensified patient care with 
reminders via mail, telephone, 
and hand-held pill devices, 
complex behavioural approaches, 





Adherence to lipid-lowering 
medical therapy. Secondary 
outcomes: physiologic 
indicators (e.g., total 
cholesterol), health outcome 
indications (e.g., QOL, 
morbidity, mortality), adverse 












































Du, 201845 Antihypertensives NA 
Fixed-dose combination versus 
free-equivalent combination 
therapies on adherence to 









































Gupta, 2010109 Antihypertensives NA 
Fixed-Dose Combinations of 
Antihypertensive agents. Aim: to 
achieve better BP control by 
improving compliance  
Compliance (or adherence), 
persistence, BP-lowering 
















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 




































202088 Antihypertensives NA 
Interventions to enhance 
adherence and control of arterial 
hypertension: community fund 
organization, reminders, 
educational material and 
calendar, sessions for the 
optimization of the use of 
medicines, advice with 
experienced pharmacists, group 
educational meetings, obtention 
of medical records, identification 
of problems with medications 
and intervention on them, follow-
up with the pharmacist and 















































Kawalec, 201853 Antihypertensives NA 
Fixed-dose combination therapy. 
Aim: blood pressure lowering, 
increasing patients adherence 
Medication adherence, blood 
pressure lowering, persistence, 
health outcomes and adverse 
events 
Primary/health/soci












































Interventions aimed to modify 
medication adherence behaviour 
to chronic medications 
administered orally to treat 
diabetes, hypertension, or 
hyperlipidaemia: behavioural 
counselling, education and 
Informational materials, 
medication packaging that 
increased convenience by 








adherence           











Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 







































Coronary artery calcium 
screening: enable risk 
stratification, diagnosis of CAD 
and directs the treatment and 
management of CAD among 
asymptomatic individuals 
Behavioural modification, risk 
perception, and medication 












































Tsioufis, 2020138 Antihypertensives NA 
Single-pill combination therapy to 
treat hypertension. Aim: improve 
clinical outcomes and medication 
adherence 
Adherence and/or persistent, 
BP, cardiovascular outcomes, 








































Uhlig, 2013139 Antihypertensives NA 
Interventions to enhance 
management of hypertension: 
self-measured blood pressure 
with or without additional 
support 
Clinical outcomes (e.g. death 
and cardiovascular events), 
patient-reported outcomes 
(e.g. patient satisfaction or 
QOL), surrogate outcomes (e.g. 
measures of left ventricular 
hypertrophy), intermediate 
outcomes (e.g. BP; number, 
dose, or changes of 
antihypertensive medications; 
adherence to antihypertensive 
medication), health care 
utilization (including visits, 

















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 







































Mobile health technology to 











































Xu, 2018142 Antihypertensives NA 
Medication education, self-
monitoring of BP, reminders and 
regular follow-up visits to 












































Chong, 201196 Antidepressants NA 
 
 
Interventions to improve 
antidepressant medication 
adherence: categories include: 
Educational focus, behavioural 
focus,  Multifaceted interventions 
(more than a single component 
strategy (educational, 
behavioural or affective) 
targeting both the patient and 





















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 









































sulfonylurea drugs, oral 
nitrates 
Interventions to affect adherence 
to self-administered prescribed 
medications in short-term and in 






adherence feedback, technical 
reminder systems, monitoring 
the disease being managed, 
rewards, integrating depression 
treatment with hypertension 
management or type 2 diabetes 
care, home-based physician- 
directed, nurse-guided drug 
therapy, drug regimen 
Health outcomes' e.g.  
reductions in blood pressure, 


















































Hudson, 2019112 Antidepressants NA 
Collaborative care including 
following components: 
Multidisciplinary approach, 
telephone delivered case 
management, structured 
evidence-based case 
management plan, scheduled and 
proactive patient follow-up, 
enhanced inter-professional 
communication/support. Aim: 
enhance medication adherence 


























Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 







































































Not all medicines 
reported, but all  for CVD 
e.g. spironolactone, loop 
diuretics, digoxin 
Strategies to improve patient 








guidelines, fiscal, regulation, 
legislation, environmental/social 
planning, service provision 
Adherence, Physiological: BP 
control, mean DBP/SBP, lipids, 
glucose/HbA1c, INR, 
echocardiogram, health 
outcomes, health service 
utilisation, mortality, QOL, 
other lifestyle, 
smoking/alcohol, nutrition, 
physical activity, stress, 
adverse events, cost 




































































Medicare Part D cost-sharing 
provisions and drug coverage 
rules. Aim: improve access to 
essential medications through 
reduced cost-sharing with focus 
on under and over-use of specific 
drugs and classes 


























Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 


































































Community pharmacy based 
intervention for people affected 
by dementia to optimise 
prescribing of medication 
(including medicine 
reconciliation, assessing for 
potentially inappropriate drugs). 
Interventions included:                                        





medication safety check, 
telephone call with patients and 
caregivers post discharge, inter-
professional clinic, memory 
screening assessment, review of 
patients records, Donepezil 
outpatient consultation service 
Willingness to pay, dementia 
severity, anticholinergic drug 
scale scores, number of 
falls/deaths, risk of falls, 
caregiver burden, patient 
satisfaction, number of 
prescribed medicine/patient, 















































Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 






































(patient- targeted services) and 
healthcare professional-targeted 
services: PTS-counselling, 
providing educational materials, 
medical reminders, post-
discharge follow- up services and 
supporting rehabilitation 
transition care. HTS-medication 
reconciliation, communication 
with health-care providers 
Aim: improve CVD outcomes 
All-cause mortality, all-cause 
hospitalization, cardiac-related 


























































& peripheral vasodilators, 
cephalexin, amoxycillin 









Academic Detailing to modify 
drug prescription behaviour of 
Family Physicians in primary care 



















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 











































Interventions to change 
prescribing behaviour:  
educational outreach, academic 
detailing programs 
 
























































Interventions to optimise 
prescribing in care homes: staff 
education, multi-disciplinary 
team meetings, pharmacist 
medication reviews, 
computerised clinical decision 
support systems  
Improvement in appropriate 














to adhere to 
deprescribing 















Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 







































NSAIDs, combined oral 
contraceptive pill 
Regulatory risk communication: 
ensure medication safety 
Rate of prescribing. Secondary 
outcomes: rates of prescribing 
of substitute medicines, rates 
of prescribing of the target 
medicine in non-target 
population, change in 
intended/unintended health 
outcomes that were the focus 





































Wetzel, 201881 Opiates NA 
 
Intervention associated with 
postsurgical prescribing: clinician 
mediated, patient mediated, 
organizational, behavioural 
Discharge opioid prescriptions, 
quantity of opioids prescribed 














































Regulatory or educational 
strategies to improve appropriate 
use of sedative-hypnotics in 
insomnia treatment 
Changes in prescription and/or 
consumption of SH, switch to 
another non-recommended 
medication, changes in 
healthcare resource use, 






























Intervention name/s and aim Outcomes measured Setting/Context 
Relevant part of 

















































Clinical Practice Guidelines on 
prescribing practice in mental 
health. Aim: change in mental 
health prescribing practice 



















































































Yuan, 201985 Antihypertensives 







syndrome, drug related 
high risk of disease, 
outpatients taking 
multiple prescription 
drugs, bronchial asthma 
Community Pharmacist 
interventions to improve 
outcomes for people with 
hypertension: medication review, 
patient education, adherence 
assessment, health/lifestyle 
advice, physical assessment (e.g., 
BP), monitoring, prescribing, or 
adjusting and administering 
therapy 
Clinical outcomes of 
pharmaceutical services e.g.  
common end- points of systolic 
blood pressure, diastolic blood 
pressure and glycosylated 














adherence         
Progress review 
*Secondary aim or one of multiple aims; aNote that focus is on 'use' which includes initiating prescribing. Drugs of interest may be currently under- or over-used, bOne aspect of broad aim, 
cOne aspect of interventions. BP=Blood Pressure, CAD=Coronary Artery Disease, CPS=Community Pharmacist Services, CVD=Cardiovascular Disease, COX-2=Cyclooxygenase-2, DBP-Diastolic 
Blood Pressure, FDC=Fixed-Dose Combination, FRID=Fall Risk Increasing Drugs, HAART= Highly Active Antiretroviral Therapy, HBP=High Blood Pressure, HIV= Human Immunodeficiency Virus, 
HRT=Hormonal Replacement Therapy, HTS=Healthcare professional Targeted Services, INR=International Normalised Ratio, NA=Not Applicable, NR=Not Reported, NSAID=Non-Steroidal Anti-
Inflammatories,PTS=Patient Targeted Services, SBP=Systolic Blood Pressure, SH=Sedative Hypnotics, SR=Sustained Release, QOL=Quality of Life, 
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Table 15: 18 reviews synthesising studies conducting qualitative evidence synthesis 






Perspectives obtained Phenomenon of Interest Setting/Context 
Relevant part of 








miscellaneous PIMs Practitioner/Prescriber 
Prescribing                                                                                                                  
Experiences/views of an 
Intervention 
(Deprescribing: 
Perceptions related to 
stopping BZ in particular) 
Primary/health/social care 
Secondary health/social 
care (not hospital) 
Care home 




Decision to start 
agreed treatment 
plan 
















NR Patient adherence 
208 
 






Perspectives obtained Phenomenon of Interest Setting/Context 
Relevant part of 
care pathway  











care (not hospital) 
Patient home 
Patient adherence 
Decision to stop 
treatment: 
unsupported 































Perspectives obtained Phenomenon of Interest Setting/Context 
Relevant part of 
care pathway  
Kennedy, 201954 Opiates NA Practitioner/Prescriber Prescribing 
Primary/health/social care 
Secondary health/social 






Progress review                 
Maintaining 
treatment 
Toye, 2017137 Opiates NA Practitioner/Prescriber Prescribing 
Primary/health/social care 
Secondary health/social 






































Perspectives obtained Phenomenon of Interest Setting/Context 
Relevant part of 






lithium, atomoxetine,  
dexamphetamine, 
methylphenidat, 


















Decision to stop 
treatment: 
supported 











Perspectives obtained Phenomenon of Interest Setting/Context 
Relevant part of 
care pathway  
Sirdifield, 201779 
Benzodiazepines 




Experiences/views of an 
intervention 
(deprescribing) Primary/health/social care 
Accessing care 
Information and/or 
advice               
Patient adherence 
Decision to stop 
treatment: 
unsupported    










Perspectives obtained Phenomenon of Interest Setting/Context 
Relevant part of 














Experiences/views of an 
intervention 
(deprescribing) NR 
Decision to stop 
treatment: 
supported 
Sirdifield, 201378 Benzodiazepines NA Practitioner/Prescriber 
Prescribing 
Experiences/views of an 
intervention 
(deprescribing) Primary/health/social care 
Choosing a 
medication       











Perspectives obtained Phenomenon of Interest Setting/Context 
Relevant part of 
care pathway  









Decision to stop 
treatment: 
unsupported 












Decision to stop 
treatment: 
supported 











Perspectives obtained Phenomenon of Interest Setting/Context 
Relevant part of 
care pathway  



































Perspectives obtained Phenomenon of Interest Setting/Context 
Relevant part of 
care pathway  






care (not hospital) 
Hospital (outpatient) 
Patient home Patient adherence 
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Perspectives obtained Phenomenon of Interest Setting/Context 
Relevant part of 











for HIV, osteoporosis, 
anxiety, malaria 
prophylaxis, bipolar, 
back pain, ADHD, 
















Patient                              
Carer                                  
Family member 
Experiences/views of an 
intervention (adherence) 
Taking a medication 
Primary/health/social care 
Secondary health/social 









Ford, 201748 Antidepressants NA Practitioner/Prescriber 
Prescribing 
(Secondary focus) Primary/health/social care 


















Perspectives obtained Phenomenon of Interest Setting/Context 
Relevant part of 
care pathway  













Decision to stop 
treatment: 
supported 






* Data too thin for synthesis. Green highlighted text=High Overall Quality as appraised by AMSTAR-2, Turquoise highlighted text=Moderate Overall Quality as appraised by AMSTAR-2. 
ADHD=Attention-Deficit Hyperactivity Disorder, BZ=Benzodiazepine, HAART= Highly Active Antiretroviral Therapy, HIV= Human Immunodeficiency Virus, IBD=Irritable Bowel Disease, NA=Not 

















Synthesis of recommendations for the assessment 




Choosing a medication 
Prescribing guidelines 
Ernstzen, 
201746 Opiates NA 
Appraisal of available evidence-based CPGs for the 
management of chronic muscular skeletal pain  Primary/health/social care 
Identifying health or prescribing 
concern 
Initial assessment 
Information and/or advice 
Choosing a medication 
Prescribing guidelines 
Herzig, 2018111  Opiates NA 
Synthesis of acute pain management guidelines for 
management of acute, non-cancer pain  Hospital (inpatient) 
Choosing a medication 
Prescribing guidelines 




Summarises recommendations from evidence-based 
CPGs for management of chronic lower back pain 
Primary/health/social care 
Secondary health/social care (not 
hospital) 
Choosing a medication 
Prescribing guidelines 
Nuckols, 
2014129 Opiates NA 
Evaluation of quality and content of CPGs to: optimize 
patient care and use of opioids in the treatment of 
chronic pain:  
dosing limits, medications and formulations, titration 
of dose, switching from one opioid to another, drug, 
drug interactions, drug-disease interactions, risk 
mitigation strategies (opioid risk assessment tools, 
written treatment agreements, and urine drug 
testing) NR 
Choosing a medication 
Prescribing guidelines 
Decision to stop treatment: 
supported 
Decision/ability to adhere to 
deprescribing plan 
Zhang, 2020143 Opiates NA 
Review recommendations on: prescription of opioids 
at discharge, appropriate disposal of opioids, 
prevention of chronic postsurgical opioid use after 
abdominopelvic surgery Hospital (inpatient) 
Choosing a medication 
Prescribing guidelines 




1. General Medical Council. Good practice in prescribing and managing medicines and devices: 
General Medical Council; 2013. 
2. NHS. The NHS Long Term Plan: NHS; 2019. 
3. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment 
and reduction, including lipid modification [CG181]. Last updated: 27 September 2016: NICE; 2014. 
4. Ingersgaard MV, Helms Andersen T, Norgaard O, Grabowski D, Olesen K. Reasons for 
Nonadherence to Statins - A Systematic Review of Reviews. Patient Prefer Adherence 2020;14:675-
91. https://doi.org/10.2147/PPA.S245365 
5. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of 
systematic reviews. Frontiers in pharmacology 2013;4:91. https://doi.org/10.3389/fphar.2013.00091 
6. Kjeldsen SE. Hypertension and cardiovascular risk: General aspects. Pharmacol Res 
2018;129:95-9. https://doi.org/10.1016/j.phrs.2017.11.003 
7. Gupta A, Mackay J, Whitehouse A, Godec T, Collier T, Pocock S, et al. Long-term mortality 
after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the 
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a 
randomised factorial trial. The Lancet 2018;392:1127-37. 
https://doi.org/https://doi.org/10.1016/S0140-6736(18)31776-8 
8. Scholes S, Gebert S, NHS Digital. Health Survey for England 2018: Adults' Health.  Health and 
Social Care Information Centre; 2019. URL: https://files.digital.nhs.uk/E4/DAA235/HSE18-Adult-
Health-rep.pdf (accessed 1 March, 2021). 
9. NCD Risk Factor Collaboration. Long-term and recent trends in hypertension awareness, 
treatment, and control in 12 high-income countries: an analysis of 123 nationally representative 
surveys. Lancet 2019;394:639-51. https://doi.org/10.1016/s0140-6736(19)31145-6 
10. Suissa S, Brophy J, Azoulay L, Schuster T. Trends in Prescription of Antihypertensive 
Medications in UK Primary Care Practices, 1988-2018.  Clinical Practice Research Datalink; 2019. URL: 
https://cprd.com/protocol/trends-prescription-antihypertensive-medications-uk-primary-care-
practices-1988-2018 (accessed 1 March, 2021). 
11. Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Marešová V, et al. Risk Factors for 
Nonadherence to Antihypertensive Treatment. Hypertension 2017;69:1113-20. 
https://doi.org/10.1161/hypertensionaha.116.08729 
12. Taylor S, Annand F, Burkinshaw P, Greaves F, Kelleher M, Knight J, et al. Dependence and 




13. Dumas EO, Pollack GM. Opioid tolerance development: a 
pharmacokinetic/pharmacodynamic perspective. The AAPS journal 2008;10:537-51. 
https://doi.org/10.1208/s12248-008-9056-1 
14. Longo LP, Johnson B. Addiction: Part I. Benzodiazepines--side effects, abuse risk and 
alternatives. Am Fam Physician 2000;61:2121-8. 
15. Publishing HH. Sedative, Hypnotic or Anxiolytic Drug Use Disorder.  Harvard Medical School; 
2018. URL: https://www.health.harvard.edu/a_to_z/sedative-hypnotic-or-anxiolytic-drug-use-
disorder-a-to-z (accessed 1 March, 2021). 
16. NHS England and NHS Improvement South West. Opioid prescribing for chronic pain. n.d. 
URL: https://www.england.nhs.uk/south/info-professional/safe-use-of-controlled-drugs/opioids/ 
(accessed 1 March, 2021). 
17. Shanahan W. Opioids: understanding the current state in the UK.  Priory Group; n.d. URL: 
https://www.priorygroup.com/blog/opioids-understanding-the-current-state-in-the-uk (accessed 1 
March, 2021). 
18. Shaw E, Nunns M, Briscoe S, Melendez-Torres GJ, Garside R, Thompson Coon J. Optimal 
prescribing of drugs to prevent CVD and drugs that cause dependency: an evidence gap map 
(protocol). OSF; 2020. URL: https://osf.io/vktza/ (accessed 13 Jan, 2020). 
19. Snilstveit B, Vojtkova M, Bhavsar A, Stevenson J, Gaarder M. Evidence & Gap Maps: A tool 
for promoting evidence informed policy and strategic research agendas. J Clin Epidemiol 
2016;79:120-9. https://doi.org/10.1016/j.jclinepi.2016.05.015 
20. White H, Albers B, Gaarder M, Kornør H, Littell J, Marshall Z, et al. Guidance for producing a 
Campbell evidence and gap map. Campbell Systematic Reviews 2020;16:e1125. 
https://doi.org/10.1002/cl2.1125 
21. Petersen K, Feldt R, Mujtaba S, Mattsson M. Systematic mapping studies in software 
engineering. Paper presented at: 12th International Conference on Evaluation and Assessment in 
Software Engineering (EASE)26-27 June 2008. 
22. Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated 
methodologies. Health Info Libr J 2009;26:91-108. https://doi.org/10.1111/j.1471-
1842.2009.00848.x 
23. Collaboration for Environmental Evidence. The Collaboration for Environmental Evidence 
Synthesis Appraisal Tool (CEESAT). Version 2.1. (Last updated 27 October 2020).  CEE; 2018. URL: 
https://environmentalevidence.shinyapps.io/CEEDER/ (accessed 13 Jan, 2021). 
221 
 
24. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal 
tool for systematic reviews that include randomised or non-randomised studies of healthcare 
interventions, or both. BMJ 2017;358:j4008. https://doi.org/10.1136/bmj.j4008 
25. National Institute for Health and Care Excellence. Medicines optimisation: the safe and 
effective use of medicines to enable the best possible outcomes London: NICE; 2015. 
26. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and 
management NICE guideline [NG136] London: NICE; 2019. 
27. National Institute for Health and Care Excellence. Scenario: Benzodiazepine and z-drug 
withdrawal.  NICE; 2019. URL: https://cks.nice.org.uk/topics/benzodiazepine-z-drug-
withdrawal/management/benzodiazepine-z-drug-withdrawal/ (accessed 3 March, 2021). 
28. National Institute for Health and Care Excellence. Antidepressant treatment in adults.  NICE 
Pathways; 2021. URL: https://pathways.nice.org.uk/pathways/depression/antidepressant-
treatment-in-adults#content=view-node%3Anodes-stopping-or-reducing-antidepressants (accessed 
3 March, 2021). 
29. National Institute for Health and Care Excellence. Shared decision-making about medicines.  
NICE Pathways; 2021. URL: https://pathways.nice.org.uk/pathways/medicines-
optimisation#path=view%3A/pathways/medicines-optimisation/shared-decision-making-about-
medicines.xml&content=view-index (accessed 3 March, 2021). 
30. Oxford University Hospitals NHS Foundation Trust. Guidance for opioid reduction in primary 
care.  Oxford University Hospitals NHS Foundation Trust; 2017. URL: 
https://www.ouh.nhs.uk/services/referrals/pain/documents/gp-guidance-opioid-reduction.pdf 
(accessed 3 March, 2021). 
31. Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-White G, et al. Resisting medicines: 
a synthesis of qualitative studies of medicine taking. Soc Sci Med 2005;61:133-55. 
https://doi.org/10.1016/j.socscimed.2004.11.063 
32. Adler AJ, Martin N, Mariani J, Tajer CD, Owolabi OO, Free C, et al. Mobile phone text 
messaging to improve medication adherence in secondary prevention of cardiovascular disease. 
Cochrane Database Syst Rev 2017;4:CD011851. https://doi.org/10.1002/14651858.CD011851.pub2 
33. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising 
potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ 
Open 2014;4:e006544. https://doi.org/10.1136/bmjopen-2014-006544 
34. Awadalla R, Gnjidic D, Patanwala A, Sakiris M, Penm J. The Effectiveness of Stewardship 
Interventions to Reduce the Prescribing of Extended-Release Opioids for Acute Pain: A Systematic 
Review. Pain Med 2020;21:2401-11. https://doi.org/10.1093/pm/pnaa139 
222 
 
35. Baumgartner A, Drame K, Geutjens S, Airaksinen M. Does the Polypill Improve Patient 
Adherence Compared to Its Individual Formulations? A Systematic Review. Pharmaceutics 
2020;12:190. https://doi.org/10.3390/pharmaceutics12020190 
36. Beaudoin FL, Banerjee GN, Mello MJ. State-level and system-level opioid prescribing policies: 
The impact on provider practices and overdose deaths, a systematic review. J Opioid Manag 
2016;12:109-18. https://doi.org/10.5055/jom.2016.0322 
37. Becker SJ, Midoun MM. Effects of Direct-To-Consumer Advertising on Patient Prescription 
Requests and Physician Prescribing: A Systematic Review of Psychiatry-Relevant Studies. J Clin 
Psychiatry 2016;77:e1293-e300. https://doi.org/10.4088/JCP.15r10325 
38. Checchi KD, Huybrechts KF, Avorn J, Kesselheim AS. Electronic medication packaging devices 
and medication adherence: a systematic review. JAMA 2014;312:1237-47. 
https://doi.org/10.1001/jama.2014.10059 
39. Chhina HK, Bhole VM, Goldsmith C, Hall W, Kaczorowski J, Lacaille D. Effectiveness of 
academic detailing to optimize medication prescribing behaviour of family physicians. J Pharm 
Pharm Sci 2013;16:511-29. https://doi.org/10.18433/j3kk6c 
40. Conn VS, Ruppar TM, Chan KC, Dunbar-Jacob J, Pepper GA, De Geest S. Packaging 
interventions to increase medication adherence: systematic review and meta-analysis. Curr Med Res 
Opin 2015;31:145-60. https://doi.org/10.1185/03007995.2014.978939 
41. Conn VS, Ruppar TM, Enriquez M, Cooper P. Medication adherence interventions that target 
subjects with adherence problems: Systematic review and meta-analysis. Res Social Adm Pharm 
2016;12:218-46. https://doi.org/10.1016/j.sapharm.2015.06.001 
42. Conn VS, Ruppar TM, Enriquez M, Cooper PS, Chan KC. Healthcare provider targeted 
interventions to improve medication adherence: systematic review and meta-analysis. Int J Clin Pract 
2015;69:889-99. https://doi.org/10.1111/ijcp.12632 
43. Dagenais S, Tricco AC, Haldeman S. Synthesis of recommendations for the assessment and 
management of low back pain from recent clinical practice guidelines. Spine J 2010;10:514-29. 
https://doi.org/10.1016/j.spinee.2010.03.032 
44. Dann-Reed E, Poland F, Wright D. Systematic review to inform the development of a 
community pharmacy-based intervention for people affected by dementia. Int J Pharm Pract 
2020;28:233-45. https://doi.org/10.1111/ijpp.12586 
45. Du LP, Cheng ZW, Zhang YX, Li Y, Mei D. The impact of fixed-dose combination versus free-
equivalent combination therapies on adherence for hypertension: a meta-analysis. J Clin Hypertens 
(Greenwich) 2018;20:902-7. https://doi.org/10.1111/jch.13272 
223 
 
46. Ernstzen DV, Louw QA, Hillier SL. Clinical practice guidelines for the management of chronic 
musculoskeletal pain in primary healthcare: a systematic review. Implement Sci 2017;12:1. 
https://doi.org/10.1186/s13012-016-0533-0 
47. Fletcher BR, Hartmann-Boyce J, Hinton L, McManus RJ. The Effect of Self-Monitoring of 
Blood Pressure on Medication Adherence and Lifestyle Factors: A Systematic Review and Meta-
Analysis. Am J Hypertens 2015;28:1209-21. https://doi.org/10.1093/ajh/hpv008 
48. Ford E, Lee S, Shakespeare J, Ayers S. Diagnosis and management of perinatal depression 
and anxiety in general practice: a meta-synthesis of qualitative studies. Br J Gen Pract 2017;67:e538-
e46. https://doi.org/10.3399/bjgp17X691889 
49. Furlan AD, Carnide N, Irvin E, Van Eerd D, Munhall C, Kim J, et al. A systematic review of 
strategies to improve appropriate use of opioids and to reduce opioid use disorder and deaths from 
prescription opioids. Canadian Journal of Pain 2018;2:218-35. 
https://doi.org/10.1080/24740527.2018.1479842 
50. Gillaizeau F, Chan E, Trinquart L, Colombet I, Walton RT, Rege-Walther M, et al. 
Computerized advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev 
2013; 10.1002/14651858.CD002894.pub3:CD002894. 
https://doi.org/10.1002/14651858.CD002894.pub3 
51. Hopkins RE, Bui T, Magliano D, Arnold C, Dooley M. Prescriber Education Interventions to 
Optimize Opioid Prescribing in Acute Care: A Systematic Review. Pain Physician 2019;22:E551-E62. 
52. Jeffery RA, To MJ, Hayduk-Costa G, Cameron A, Taylor C, Van Zoost C, et al. Interventions to 
improve adherence to cardiovascular disease guidelines: a systematic review. BMC Fam Pract 
2015;16:147. https://doi.org/10.1186/s12875-015-0341-7 
53. Kawalec P, Holko P, Gawin M, Pilc A. Effectiveness of fixed-dose combination therapy in 
hypertension: systematic review and meta-analysis. Arch Med Sci 2018;14:1125-36. 
https://doi.org/10.5114/aoms.2018.77561 
54. Kennedy MC, Pallotti P, Dickinson R, Harley C. 'If you can't see a dilemma in this situation 
you should probably regard it as a warning': a metasynthesis and theoretical modelling of general 
practitioners' opioid prescription experiences in primary care. Br J Pain 2019;13:159-76. 
https://doi.org/10.1177/2049463718804572 
55. King S, Miani C, Exley J, Larkin J, Kirtley A, Payne RA. Impact of issuing longer- versus shorter-




56. Kinnear FJ, Wainwright E, Perry R, Lithander FE, Bayly G, Huntley A, et al. Enablers and 
barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative 
evidence synthesis. BMJ Open 2019;9:e030290. https://doi.org/10.1136/bmjopen-2019-030290 
57. Krack G. How to make value-based health insurance designs more effective? A systematic 
review and meta-analysis. Eur J Health Econ 2019;20:841-56. https://doi.org/10.1007/s10198-019-
01046-1 
58. Kunstler BE, Lennox A, Bragge P. Changing prescribing behaviours with educational 
outreach: an overview of evidence and practice. BMC Med Educ 2019;19:311. 
https://doi.org/10.1186/s12909-019-1735-3 
59. Legare F, Ratte S, Stacey D, Kryworuchko J, Gravel K, Graham ID, et al. Interventions for 
improving the adoption of shared decision making by healthcare professionals. Cochrane Database 
Syst Rev 2010; 10.1002/14651858.CD006732.pub2:CD006732. 
https://doi.org/10.1002/14651858.CD006732.pub2 
60. Maimaris W, Paty J, Perel P, Legido-Quigley H, Balabanova D, Nieuwlaat R, et al. The 
influence of health systems on hypertension awareness, treatment, and control: a systematic 
literature review. PLoS Med 2013;10:e1001490. https://doi.org/10.1371/journal.pmed.1001490 
61. Mamudu HM, Paul TK, Veeranki SP, Budoff M. The effects of coronary artery calcium 
screening on behavioral modification, risk perception, and medication adherence among 
asymptomatic adults: a systematic review. Atherosclerosis 2014;236:338-50. 
https://doi.org/10.1016/j.atherosclerosis.2014.07.022 
62. Marshall IJ, Wolfe CD, McKevitt C. Lay perspectives on hypertension and drug adherence: 
systematic review of qualitative research. BMJ 2012;345:e3953. https://doi.org/10.1136/bmj.e3953 
63. Mauri AI, Townsend TN, Haffajee RL. The Association of State Opioid Misuse Prevention 
Policies With Patient- and Provider-Related Outcomes: A Scoping Review. Milbank Q 2020;98:57-
105. https://doi.org/10.1111/1468-0009.12436 
64. Milosavljevic A, Aspden T, Harrison J. Community pharmacist-led interventions and their 
impact on patients' medication adherence and other health outcomes: a systematic review. Int J 
Pharm Pract 2018;26:387-97. https://doi.org/10.1111/ijpp.12462 
65. Morera-Fumero AL, Fernandez-Lopez L, Abreu-Gonzalez P. Melatonin and melatonin 
agonists as treatments for benzodiazepines and hypnotics withdrawal in patients with primary 
insomnia. A systematic review. Drug Alcohol Depend 2020;212:107994. 
https://doi.org/10.1016/j.drugalcdep.2020.107994 
66. Morrissey EC, Durand H, Nieuwlaat R, Navarro T, Haynes RB, Walsh JC, et al. Effectiveness 
and content analysis of interventions to enhance medication adherence and blood pressure control 
225 
 
in hypertension: A systematic review and meta-analysis. Psychol Health 2017;32:1195-232. 
https://doi.org/10.1080/08870446.2016.1273356 
67. Nguyen T, Nguyen HQ, Widyakusuma NN, Nguyen TH, Pham TT, Taxis K. Enhancing 
prescribing of guideline-recommended medications for ischaemic heart diseases: a systematic 
review and meta-analysis of interventions targeted at healthcare professionals. BMJ Open 
2018;8:e018271. https://doi.org/10.1136/bmjopen-2017-018271 
68. Nguyen T, Seiler N, Brown E, O'Donoghue B. The effect of Clinical Practice Guidelines on 
prescribing practice in mental health: A systematic review. Psychiatry Res 2020;284:112671. 
https://doi.org/10.1016/j.psychres.2019.112671 
69. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. 
Interventions for enhancing medication adherence. Cochrane Database Syst Rev 
2014;2014:CD000011. https://doi.org/10.1002/14651858.CD000011.pub4 
70. Ostini R, Jackson C, Hegney D, Tett SE. How is medication prescribing ceased? A systematic 
review. Med Care 2011;49:24-36. https://doi.org/10.1097/MLR.0b013e3181ef9a7e 
71. Pantoja T, Grimshaw JM, Colomer N, Castanon C, Leniz Martelli J. Manually-generated 
reminders delivered on paper: effects on professional practice and patient outcomes. Cochrane 
Database Syst Rev 2019;12:CD001174. https://doi.org/10.1002/14651858.CD001174.pub4 
72. Park YJ, Martin EG. Medicare Part D's Effects on Drug Utilization and Out-of-Pocket Costs: A 
Systematic Review. Health Serv Res 2017;52:1685-728. https://doi.org/10.1111/1475-6773.12534 
73. Polinski JM, Donohue JM, Kilabuk E, Shrank WH. Medicare Part D's effect on the under- and 
overuse of medications: a systematic review. J Am Geriatr Soc 2011;59:1922-33. 
https://doi.org/10.1111/j.1532-5415.2011.03537.x 
74. Posadzki P, Mastellos N, Ryan R, Gunn LH, Felix LM, Pappas Y, et al. Automated telephone 
communication systems for preventive healthcare and management of long-term conditions. 
Cochrane Database Syst Rev 2016;12:CD009921. https://doi.org/10.1002/14651858.CD009921.pub2 
75. Rash JA, Campbell DJ, Tonelli M, Campbell TS. A systematic review of interventions to 
improve adherence to statin medication: What do we know about what works? Prev Med 
2016;90:155-69. https://doi.org/10.1016/j.ypmed.2016.07.006 
76. Rubio-Valera M, Serrano-Blanco A, Magdalena-Belio J, Fernandez A, Garcia-Campayo J, Pujol 
MM, et al. Effectiveness of pharmacist care in the improvement of adherence to antidepressants: a 
systematic review and meta-analysis. Ann Pharmacother 2011;45:39-48. 
https://doi.org/10.1345/aph.1P429 
77. Shanbhag D, Graham ID, Harlos K, Haynes RB, Gabizon I, Connolly SJ, et al. Effectiveness of 
implementation interventions in improving physician adherence to guideline recommendations in 
226 
 
heart failure: a systematic review. BMJ Open 2018;8:e017765. https://doi.org/10.1136/bmjopen-
2017-017765 
78. Sirdifield C, Anthierens S, Creupelandt H, Chipchase SY, Christiaens T, Siriwardena AN. 
General practitioners' experiences and perceptions of benzodiazepine prescribing: systematic review 
and meta-synthesis. BMC Fam Pract 2013;14:191. https://doi.org/10.1186/1471-2296-14-191 
79. Sirdifield C, Chipchase SY, Owen S, Siriwardena AN. A Systematic Review and Meta-Synthesis 
of Patients' Experiences and Perceptions of Seeking and Using Benzodiazepines and Z-Drugs: 
Towards Safer Prescribing. Patient 2017;10:1-15. https://doi.org/10.1007/s40271-016-0182-z 
80. Weatherburn CJ, Guthrie B, Dreischulte T, Morales DR. Impact of medicines regulatory risk 
communications in the UK on prescribing and clinical outcomes: Systematic review, time series 
analysis and meta-analysis. Br J Clin Pharmacol 2020;86:698-710. https://doi.org/10.1111/bcp.14104 
81. Wetzel M, Hockenberry J, Raval MV. Interventions for Postsurgical Opioid Prescribing: A 
Systematic Review. JAMA Surg 2018;153:948-54. https://doi.org/10.1001/jamasurg.2018.2730 
82. Wilbur K, Elmubark A, Shabana S. Systematic Review of Standardized Patient Use in 
Continuing Medical Education. J Contin Educ Health Prof 2018;38:3-10. 
https://doi.org/10.1097/CEH.0000000000000190 
83. Wilson MN, Hayden JA, Rhodes E, Robinson A, Asbridge M. Effectiveness of Prescription 
Monitoring Programs in Reducing Opioid Prescribing, Dispensing, and Use Outcomes: A Systematic 
Review. Journal of Pain 2019;20:1383-93. https://doi.org/10.1016/j.jpain.2019.04.007 
84. Xiong S, Berkhouse H, Schooler M, Pu W, Sun A, Gong E, et al. Effectiveness of mHealth 
Interventions in Improving Medication Adherence Among People with Hypertension: a Systematic 
Review. Curr Hypertens Rep 2018;20:86. https://doi.org/10.1007/s11906-018-0886-7 
85. Yuan C, Ding Y, Zhou K, Huang Y, Xi X. Clinical outcomes of community pharmacy services: A 
systematic review and meta-analysis. Health Soc Care Community 2019;27:e567-e87. 
https://doi.org/10.1111/hsc.12794 
86. Brown JVE, Walton N, Meader N, Todd A, Webster LA, Steele R, et al. Pharmacy-based 
management for depression in adults. Cochrane Database Syst Rev 2019;12:CD013299. 
https://doi.org/10.1002/14651858.CD013299.pub2 
87. Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions 
for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev 2015; 
10.1002/14651858.CD009652.pub2:CD009652. https://doi.org/10.1002/14651858.CD009652.pub2 
88. Guzman-Tordecilla DN, Bernal Garcia A, Rodriguez I. Interventions to increase the 
pharmacological adherence on arterial hypertension in Latin America: a systematic review. Int J 
Public Health 2020;65:55-64. https://doi.org/10.1007/s00038-019-01317-x 
227 
 
89. Readdean KC, Heuer AJ, Scott Parrott J. Effect of pharmacist intervention on improving 
antidepressant medication adherence and depression symptomology: A systematic review and 
meta-analysis. Res Social Adm Pharm 2018;14:321-31. 
https://doi.org/10.1016/j.sapharm.2017.05.008 
90. Al AlShaikh S, Quinn T, Dunn W, Walters M, Dawson J. Multimodal Interventions to Enhance 
Adherence to Secondary Preventive Medication after Stroke: A Systematic Review and Meta-
Analyses. Cardiovasc Ther 2016;34:85-93. https://doi.org/10.1111/1755-5922.12176 
91. Al-Jumah KA, Qureshi NA. Impact of pharmacist interventions on patients' adherence to 
antidepressants and patient-reported outcomes: a systematic review. Patient Prefer Adherence 
2012;6:87-100. https://doi.org/10.2147/PPA.S27436 
92. Baandrup L, Ebdrup BH, Rasmussen JO, Lindschou J, Gluud C, Glenthoj BY. Pharmacological 
interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane 
Database Syst Rev 2018;3:CD011481. https://doi.org/10.1002/14651858.CD011481.pub2 
93. Bochkareva EV, Butina EK, Kim IV, Kontsevaya AV, Drapkina OM, Leon D, et al. Adherence to 
antihypertensive medication in Russia: a scoping review of studies on levels, determinants and 
intervention strategies published between 2000 and 2017. Arch Public Health 2019;77:43. 
https://doi.org/10.1186/s13690-019-0366-9 
94. Bourcier E, Korb-Savoldelli V, Hejblum G, Fernandez C, Hindlet P. A systematic review of 
regulatory and educational interventions to reduce the burden associated with the prescriptions of 
sedative-hypnotics in adults treated for sleep disorders. PLoS One 2018;13:e0191211. 
https://doi.org/10.1371/journal.pone.0191211 
95. Cheema E, Sutcliffe P, Singer DR. The impact of interventions by pharmacists in community 
pharmacies on control of hypertension: a systematic review and meta-analysis of randomized 
controlled trials. Br J Clin Pharmacol 2014;78:1238-47. https://doi.org/10.1111/bcp.12452 
96. Chong WW, Aslani P, Chen TF. Effectiveness of interventions to improve antidepressant 
medication adherence: a systematic review. Int J Clin Pract 2011;65:954-75. 
https://doi.org/10.1111/j.1742-1241.2011.02746.x 
97. Conn VS, Ruppar TM, Chase JA, Enriquez M, Cooper PS. Interventions to Improve Medication 
Adherence in Hypertensive Patients: Systematic Review and Meta-analysis. Curr Hypertens Rep 
2015;17:94. https://doi.org/10.1007/s11906-015-0606-5 
98. de Cates AN, Farr MR, Wright N, Jarvis MC, Rees K, Ebrahim S, et al. Fixed-dose combination 




99. De Simoni A, Hardeman W, Mant J, Farmer AJ, Kinmonth AL. Trials to improve blood 
pressure through adherence to antihypertensives in stroke/TIA: systematic review and meta-
analysis. J Am Heart Assoc 2013;2:e000251. https://doi.org/10.1161/JAHA.113.000251 
100. Deichmann RE, Morledge MD, Ulep R, Shaffer JP, Davies P, van Driel ML. A Metaanalysis of 
Interventions to Improve Adherence to Lipid-Lowering Medication. Ochsner J 2016;16:230-7. 
101. Dhar L, Dantas J, Ali M. A Systematic Review of Factors Influencing Medication Adherence to 
Hypertension Treatment in Developing Countries. Open Journal of Epidemiology 2017;07:211-50. 
https://doi.org/10.4236/ojepi.2017.73018 
102. Dills H, Shah K, Messinger-Rapport B, Bradford K, Syed Q. Deprescribing Medications for 
Chronic Diseases Management in Primary Care Settings: A Systematic Review of Randomized 
Controlled Trials. J Am Med Dir Assoc 2018;19:923-35 e2. 
https://doi.org/10.1016/j.jamda.2018.06.021 
103. Eccleston C, Fisher E, Thomas KH, Hearn L, Derry S, Stannard C, et al. Interventions for the 
reduction of prescribed opioid use in chronic non-cancer pain. Cochrane Database Syst Rev 
2017;11:CD010323. https://doi.org/10.1002/14651858.CD010323.pub3 
104. Frank JW, Lovejoy TI, Becker WC, Morasco BJ, Koenig CJ, Hoffecker L, et al. Patient Outcomes 
in Dose Reduction or Discontinuation of Long-Term Opioid Therapy: A Systematic Review. Ann Intern 
Med 2017;167:181-91. https://doi.org/10.7326/M17-0598 
105. Garcia-Perez L, Linertova R, Serrano-Perez P, Trujillo-Martin M, Rodriguez-Rodriguez L, 
Valcarcel-Nazco C, et al. Interventions to improve medication adherence in mental health: the 
update of a systematic review of cost-effectiveness. Int J Psychiatry Clin Pract 2020;24:416-27. 
https://doi.org/10.1080/13651501.2020.1782434 
106. Garcia-Perez L, Serrano-Aguilar P. Cost-effectiveness of interventions to enhance medication 
adherence in psychiatric patients: a systematic review. Curr Clin Pharmacol 2011;6:115-24. 
https://doi.org/10.2174/157488411796151147 
107. Gould RL, Coulson MC, Patel N, Highton-Williamson E, Howard RJ. Interventions for reducing 
benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry 
2014;204:98-107. https://doi.org/10.1192/bjp.bp.113.126003 
108. Griffiths EV, Willis J, Spark MJ. A systematic review of psychotropic drug prescribing for 
prisoners. Aust N Z J Psychiatry 2012;46:407-21. https://doi.org/10.1177/0004867411433893 
109. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose 




110. Hart LA, Phelan EA, Yi JY, Marcum ZA, Gray SL. Use of Fall Risk-Increasing Drugs Around a 
Fall-Related Injury in Older Adults: A Systematic Review. J Am Geriatr Soc 2020;68:1334-43. 
https://doi.org/10.1111/jgs.16369 
111. Herzig SJ, Calcaterra SL, Mosher HJ, Ronan MV, Groningen NV, Shek L, et al. Safe Opioid 
Prescribing for Acute Noncancer Pain in Hospitalized Adults: A Systematic Review of Existing 
Guidelines. J Hosp Med 2018;13:256-62. https://doi.org/10.12788/jhm.2979 
112. Hudson JL, Bower P, Kontopantelis E, Bee P, Archer J, Clarke R, et al. Impact of telephone 
delivered case-management on the effectiveness of collaborative care for depression and anti-
depressant use: A systematic review and meta-regression. PLoS One 2019;14:e0217948. 
https://doi.org/10.1371/journal.pone.0217948 
113. Kang JE, Han NY, Oh JM, Jin HK, Kim HA, Son IJ, et al. Pharmacist-involved care for patients 
with heart failure and acute coronary syndrome: a systematic review with qualitative and 
quantitative meta-analysis. J Clin Pharm Ther 2016;41:145-57. https://doi.org/10.1111/jcpt.12367 
114. Kassavou A, Sutton S. Automated telecommunication interventions to promote adherence 
to cardio-metabolic medications: meta-analysis of effectiveness and meta-regression of behaviour 
change techniques. Health Psychol Rev 2018;12:25-42. 
https://doi.org/10.1080/17437199.2017.1365617 
115. Kimmel HJ, Brice YN, Trikalinos TA, Sarkar IN, Ranney ML. Real-Time Emergency Department 
Electronic Notifications Regarding High-Risk Patients: A Systematic Review. Telemed J E Health 
2019;25:604-18. https://doi.org/10.1089/tmj.2018.0117 
116. Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Meta-analysis: impact 
of drug class on adherence to antihypertensives. Circulation 2011;123:1611-21. 
https://doi.org/10.1161/CIRCULATIONAHA.110.983874 
117. Laba TL, Bleasel J, Brien JA, Cass A, Howard K, Peiris D, et al. Strategies to improve adherence 
to medications for cardiovascular diseases in socioeconomically disadvantaged populations: a 
systematic review. Int J Cardiol 2013;167:2430-40. https://doi.org/10.1016/j.ijcard.2013.01.049 
118. Lawrence M, Pringle J, Kerr S, Booth J, Govan L, Roberts NJ. Multimodal secondary 
prevention behavioral interventions for TIA and stroke: a systematic review and meta-analysis. PLoS 
One 2015;10:e0120902. https://doi.org/10.1371/journal.pone.0120902 
119. Lynch T, Ryan C, Hughes CM, Presseau J, van Allen ZM, Bradley CP, et al. Brief interventions 
targeting long-term benzodiazepine and Z-drug use in primary care: a systematic review and meta-
analysis. Addiction 2020;115:1618-39. https://doi.org/10.1111/add.14981 
230 
 
120. Mallat SG, Tanios BY, Itani HS, Lotfi T, Akl EA. Free versus Fixed Combination 
Antihypertensive Therapy for Essential Arterial Hypertension: A Systematic Review and Meta-
Analysis. PLoS One 2016;11:e0161285. https://doi.org/10.1371/journal.pone.0161285 
121. Mann BS, Barnieh L, Tang K, Campbell DJ, Clement F, Hemmelgarn B, et al. Association 
between drug insurance cost sharing strategies and outcomes in patients with chronic diseases: a 
systematic review. PLoS One 2014;9:e89168. https://doi.org/10.1371/journal.pone.0089168 
122. Mathieson S, Maher CG, Ferreira GE, Hamilton M, Jansen J, McLachlan AJ, et al. 
Deprescribing Opioids in Chronic Non-cancer Pain: Systematic Review of Randomised Trials. Drugs 
2020;80:1563-76. https://doi.org/10.1007/s40265-020-01368-y 
123. Maund E, Dewar-Haggart R, Williams S, Bowers H, Geraghty AWA, Leydon G, et al. Barriers 
and facilitators to discontinuing antidepressant use: A systematic review and thematic synthesis. J 
Affect Disord 2019;245:38-62. https://doi.org/10.1016/j.jad.2018.10.107 
124. Maund E, Stuart B, Moore M, Dowrick C, Geraghty AWA, Dawson S, et al. Managing 
Antidepressant Discontinuation: A Systematic Review. Ann Fam Med 2019;17:52-60. 
https://doi.org/10.1370/afm.2336 
125. Mayer JM, Haldeman S, Tricco AC, Dagenais S. Management of chronic low back pain in 
active individuals. Curr Sports Med Rep 2010;9:60-6. 
https://doi.org/10.1249/JSR.0b013e3181caa9b6 
126. Moise N, Falzon L, Obi M, Ye S, Patel S, Gonzalez C, et al. Interventions to Increase 
Depression Treatment Initiation in Primary Care Patients: a Systematic Review. J Gen Intern Med 
2018;33:1978-89. https://doi.org/10.1007/s11606-018-4554-z 
127. Mokhar A, Topp J, Harter M, Schulz H, Kuhn S, Verthein U, et al. Patient-centered care 
interventions to reduce the inappropriate prescription and use of benzodiazepines and z-drugs: a 
systematic review. PeerJ 2018;6:e5535. https://doi.org/10.7717/peerj.5535 
128. Mugunthan K, McGuire T, Glasziou P. Minimal interventions to decrease long-term use of 
benzodiazepines in primary care: a systematic review and meta-analysis. Br J Gen Pract 
2011;61:e573-8. https://doi.org/10.3399/bjgp11X593857 
129. Nuckols TK, Anderson L, Popescu I, Diamant AL, Doyle B, Di Capua P, et al. Opioid 
prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med 
2014;160:38-47. https://doi.org/10.7326/0003-4819-160-1-201401070-00732 
130. Palmer MJ, Barnard S, Perel P, Free C. Mobile phone-based interventions for improving 
adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. 
Cochrane Database Syst Rev 2018;6:CD012675. https://doi.org/10.1002/14651858.CD012675.pub2 
231 
 
131. Pollmann AS, Murphy AL, Bergman JC, Gardner DM. Deprescribing benzodiazepines and Z-
drugs in community-dwelling adults: a scoping review. BMC Pharmacol Toxicol 2015;16:19. 
https://doi.org/10.1186/s40360-015-0019-8 
132. Rashid MA, Edwards D, Walter FM, Mant J. Medication taking in coronary artery disease: a 
systematic review and qualitative synthesis. Ann Fam Med 2014;12:224-32. 
https://doi.org/10.1370/afm.1620 
133. Reeves L, Robinson K, McClelland T, Adedoyin CA, Broeseker A, Adunlin G. Pharmacist 
Interventions in the Management of Blood Pressure Control and Adherence to Antihypertensive 
Medications: A Systematic Review of Randomized Controlled Trials. J Pharm Pract 2020; 
10.1177/0897190020903573:897190020903573. https://doi.org/10.1177/0897190020903573 
134. Sanders GD, Coeytaux R, Dolor RJ, Hasselblad V, Patel UD, Powers B, et al. AHRQ 
Comparative Effectiveness Reviews. In: Angiotensin-Converting Enzyme Inhibitors (ACEIs), 
Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential 
Hypertension: An UpdateRockville (MD): Agency for Healthcare Research and Quality (US); 2011. 
135. Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people 
facing health treatment or screening decisions. Cochrane Database Syst Rev 2017;4:CD001431. 
https://doi.org/10.1002/14651858.CD001431.pub5 
136. Tedesco D, Gori D, Desai KR, Asch S, Carroll IR, Curtin C, et al. Drug-Free Interventions to 
Reduce Pain or Opioid Consumption After Total Knee Arthroplasty: A Systematic Review and Meta-
analysis. JAMA Surg 2017;152:e172872. https://doi.org/10.1001/jamasurg.2017.2872 
137. Toye F, Seers K, Tierney S, Barker KL. A qualitative evidence synthesis to explore healthcare 
professionals' experience of prescribing opioids to adults with chronic non-malignant pain. BMC Fam 
Pract 2017;18:94. https://doi.org/10.1186/s12875-017-0663-8 
138. Tsioufis K, Kreutz R, Sykara G, van Vugt J, Hassan T. Impact of single-pill combination therapy 
on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent 
literature. Journal of Hypertension 2020;38:1016-28. 
https://doi.org/10.1097/Hjh.0000000000002381 
139. Uhlig K, Patel K, Ip S, Kitsios GD, Balk EM. Self-measured blood pressure monitoring in the 
management of hypertension: a systematic review and meta-analysis. Ann Intern Med 
2013;159:185-94. https://doi.org/10.7326/0003-4819-159-3-201308060-00008 
140. van Driel ML, Morledge MD, Ulep R, Shaffer JP, Davies P, Deichmann R. Interventions to 




141. Wong CK, O'Rielly CM, Teitge BD, Sutherland RL, Farquharson S, Ghosh M, et al. The 
Characteristics and Effectiveness of Interventions for Frequent Emergency Department Utilizing 
Patients With Chronic Noncancer Pain: A Systematic Review. Acad Emerg Med 2020;27:742-52. 
https://doi.org/10.1111/acem.13934 
142. Xu R, Xie X, Li S, Chen X, Wang S, Hu C, et al. Interventions to improve medication adherence 
among Chinese patients with hypertension: a systematic review and meta-analysis of randomized 
controlled trails. Int J Pharm Pract 2018;26:291-301. https://doi.org/10.1111/ijpp.12452 
143. Zhang DDQ, Dossa F, Arora A, Cusimano MC, Speller B, Little T, et al. Recommendations for 
the Prescription of Opioids at Discharge After Abdominopelvic Surgery: A Systematic Review. JAMA 
Surg 2020;155:420-9. https://doi.org/10.1001/jamasurg.2019.5875 
144. Zhang DDQ, Sussman J, Dossa F, Jivraj N, Ladha K, Brar S, et al. A Systematic Review of 
Behavioral Interventions to Decrease Opioid Prescribing After Surgery. Ann Surg 2020;271:266-78. 
https://doi.org/10.1097/SLA.0000000000003483 
145. Nussbaumer B, Morgan LC, Reichenpfader U, Greenblatt A, Hansen RA, Van Noord M, et al. 
Comparative efficacy and risk of harms of immediate- versus extended-release second-generation 
antidepressants: a systematic review with network meta-analysis. CNS Drugs 2014;28:699-712. 
https://doi.org/10.1007/s40263-014-0169-z 
146. Al Shemeili S. Exploring structures and processes of medicines management in elderly 
hospitalised patients in the United Arab Emirates [PhD]. OpenAIR@RGU: Robert Gordon University; 
2015. 
147. Cullinan S, O'Mahony D, Fleming A, Byrne S. A meta-synthesis of potentially inappropriate 
prescribing in older patients. Drugs Aging 2014;31:631-8. https://doi.org/10.1007/s40266-014-0190-
4 
148. Leslie RS. Adherence to medications to treat diabetes, hypertension, and 
hypercholesterolemia among Medicare Part D beneficiaries [PhD]. San Diego: University of 
California; 2016. 
149. Loganathan M, Singh S, Franklin BD, Bottle A, Majeed A. Interventions to optimise 
prescribing in care homes: systematic review. Age Ageing 2011;40:150-62. 
https://doi.org/10.1093/ageing/afq161 
150. Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of 
deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J 
Clin Pharmacol 2016;82:583-623. https://doi.org/10.1111/bcp.12975 
233 
 
151. Reeve E, Ong M, Wu A, Jansen J, Petrovic M, Gnjidic D. A systematic review of interventions 
to deprescribe benzodiazepines and other hypnotics among older people. Eur J Clin Pharmacol 
2017;73:927-35. https://doi.org/10.1007/s00228-017-2257-8 
152. Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P, et al. Identification and 
assessment of adherence-enhancing interventions in studies assessing medication adherence 
through electronically compiled drug dosing histories: a systematic literature review and meta-
analysis. Drugs 2013;73:545-62. https://doi.org/10.1007/s40265-013-0041-3 
153. Hoyle DJ, Bindoff IK, Clinnick LM, Peterson GM, Westbury JL. Clinical and Economic 
Outcomes of Interventions to Reduce Antipsychotic and Benzodiazepine Use Within Nursing Homes: 
A Systematic Review. Drugs Aging 2018;35:123-34. https://doi.org/10.1007/s40266-018-0518-6 
154. Huang Y, Wei X, Wu T, Chen R, Guo A. Collaborative care for patients with depression and 
diabetes mellitus: a systematic review and meta-analysis. BMC Psychiatry 2013;13:260. 
https://doi.org/10.1186/1471-244X-13-260 
155. Hukins D, Macleod U, Boland JW. Identifying potentially inappropriate prescribing in older 
people with dementia: a systematic review. Eur J Clin Pharmacol 2019;75:467-81. 
https://doi.org/10.1007/s00228-018-02612-x 
156. Khatib R, Schwalm JD, Yusuf S, Haynes RB, McKee M, Khan M, et al. Patient and healthcare 
provider barriers to hypertension awareness, treatment and follow up: a systematic review and 
meta-analysis of qualitative and quantitative studies. PLoS One 2014;9:e84238. 
https://doi.org/10.1371/journal.pone.0084238 
157. Low LF, Fletcher J, Goodenough B, Jeon YH, Etherton-Beer C, MacAndrew M, et al. A 
Systematic Review of Interventions to Change Staff Care Practices in Order to Improve Resident 
Outcomes in Nursing Homes. PLoS One 2015;10:e0140711. 
https://doi.org/10.1371/journal.pone.0140711 
158. Oori MJ, Mohammadi F, Norouzi K, Fallahi-Khoshknab M, Ebadi A. Conceptual Model of 
Medication Adherence in Older Adults with High Blood Pressure-An Integrative Review of the 
Literature. Curr Hypertens Rev 2019;15:85-92. 
https://doi.org/10.2174/1573402114666181022152313 
159. Rashid MA, Llanwarne N, Heyns N, Walter F, Mant J. What are the implications for practice 
that arise from studies of medication taking? A systematic review of qualitative research. PLoS One 
2018;13:e0195076. https://doi.org/10.1371/journal.pone.0195076 
160. Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of 




161. Centre for Reviews and Dissemination. Systematic Reviews: CRD's guidance for undertaking 
reviews in health care: University of York; 2008. 
162. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews 
and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535. 
https://doi.org/10.1136/bmj.b2535 
163. Thomas J, Graziosi S, Brunton J, Ghouze Z, O'Driscoll P, Bond M. EPPI-Reviewer: advanced 
software for systematic reviews, maps and evidence synthesis. EPPI-Centre Software. London: UCL 
Social Research Institute; 2020. 
164. Krnic Martinic M, Pieper D, Glatt A, Puljak L. Definition of a systematic review used in 
overviews of systematic reviews, meta-epidemiological studies and textbooks. BMC Med Res 
Methodol 2019;19:203. https://doi.org/10.1186/s12874-019-0855-0 
165. Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in reporting the 
synthesis of qualitative research: ENTREQ. BMC Med Res Methodol 2012;12:181. 
https://doi.org/10.1186/1471-2288-12-181 
166. Digital Solution Foundry, EPPI-Centre. EPPI Mapper, Version 1.2.5: EPPI-Centre, UCL Social 
Research Institute, University College London; 2020. 
 
